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ABSTRACT 
 
 
Mary K. Wojczynski: Characteristics of the Co-Morbidity of Irritable Bowel 
Syndrome: A Secondary Analysis of Existing Twin Data 
 
 
(Under the direction of Kari E. North, Ph.D.) 
 
 
 
Irritable bowel syndrome (IBS) is a chronic disorder whose 
manifestations typically fluctuate over time.  Prior epidemiologic studies 
estimate the one-year prevalence as 7-20%, depending on criteria used to 
define IBS.  Individuals with IBS demonstrate a high co-occurrence with 
common functional somatic syndromes and psychiatric disorders; however, 
the majority of these associations derive from non-population-based studies.  
We examined associations between IBS risk factors and Rome II-defined IBS 
in a U.S. population-based twin registry.  Data from 4,591 male and female 
twins were available for this analysis. Variables representing self-reported 
presence of IBS, major depressive disorder (MDD), chronic widespread pain 
(CWP), fatiguing illness (CFS-like illness), Medical Outcomes Study short 
form (SF-12) scores and other personal characteristics were obtained through 
questionnaire. Odds ratios (OR) and 95% confidence intervals (CI) were 
 iii
calculated as measures of association between IBS risk factors and IBS. The 
prevalence of lifetime IBS was 4.7% (95% CI: 4.1, 5.4).  Positive associations 
were observed between IBS and lifetime MDD (OR=2.0, 95% CI: 1.5, 2.7), 
lifetime CWP (OR=3.9, 95% CI: 2.7, 5.5), lifetime CFS-like illness (OR=4.7, 
95% CI: 3.0, 7.3), and female sex (OR=2.0, 95% CI: 1.4, 2.8).  Age, body 
size, and SF-12 scores demonstrated approximately null associations with 
IBS.   
We further examined the overlap of individuals with IBS and MDD 
since both disorders suggest a familial tendency and demonstrate a higher 
than expected co-occurrence.  Using the population-based Swedish Twin 
Registry, we examined the genetic and environmental architecture of the co-
occurrence of IBS and MDD among 31,407 twins who contributed information 
on medical data and personal characteristics via phone interview.  Both the 
case-control study and the co-twin control study design demonstrated an 
increased association between MDD and IBS (OR=2.7, 95% CI: 2.3, 3.2), and 
(OR=2.2, 95% CI, 1.5, 3.2), respectively.  Thus, genetic and environmental 
factors did not confound the association between MDD and IBS; rather one of 
these disorders may predispose individuals to the other disorder.  The 
positive associations observed between MDD and IBS suggest a possible 
hypothesis whereby one disorder is part of the causal disease mechanism of 
the other disorder, thereby leading to a high co-occurrence between MDD 
and IBS.  
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1 REVIEW OF THE LITERATURE 
1.1 SUMMARY 
This dissertation examines Rome II defined irritable bowel syndrome 
(1) and other disorders associated with IBS.  I describe the prevalence of 
Rome II defined IBS in a population-based sample, as well as further 
elucidating the covariates associated with Rome II IBS.  Additionally, because 
major depressive disorder (MDD) has a tendency to be associated with IBS, 
the lifetime co-occurrence of these two common disorders, IBS and MDD, is 
further analyzed using twin data to investigate the possible genetic and 
environmental effects involved in the co-occurrence of these two disorders.   
This chapter briefly reviews the background of IBS and then MDD.  
The review includes the definition of IBS, the epidemiology of IBS, the 
pathophysiology of IBS, and the genetic factors involved in IBS.  The review 
of MDD includes the definition of MDD, the epidemiology of MDD, the 
pathophysiology of MDD, and the genetic factors involved in MDD.  Finally, 
the review of the co-occurrence of IBS and MDD includes the epidemiology of 
the co-occurrence of IBS and MDD as well as the proposed mechanism for 
their co-occurrence. 
1.2 BACKGROUND AND SIGNIFICANCE 
1.2.1 Definition of Irritable Bowel Syndrome 
A. Clinical Definition 
Irritable bowel syndrome is a chronic disorder of the gastrointestinal 
(GI) tract.  It is characterized by exacerbations and remissions of abdominal 
pain and/or discomfort that leads to alterations in bowel habits (2-6).  IBS is a 
syndrome that falls under the classification of a functional gastrointestinal 
disorder.  The etiology of IBS is not known.  The abdominal pain and/or 
discomfort that individuals with IBS have is unexplained by other organic 
disease that is detectable with currently available diagnostic methods (3, 5).  
There is no diagnostic test nor biological indicator for IBS (4, 7).  Rather the 
diagnosis is based on symptom criteria and exclusion of structural disease (2, 
4).   
B. Consensus Criteria 
There are three similar, yet distinct sets of possible criteria to diagnose 
IBS.  These are the Manning criteria (1978), the Rome I criteria (1990), and 
the Rome II criteria (1999) (5), presented in Table 1.1.  Clinically, the Rome 
criteria (either I or II) are the most widely accepted research criteria for IBS.    
There are also red flags to the diagnosis, presented in Table 1.2.  If any red 
flags are present in the patient, the physician should look for a diagnosis 
alternate to IBS (8).   
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C. Disease Subgroups 
There are two distinct subgroups of individuals who have IBS, those 
who visit a physician for their symptoms and those who do not have such a 
physician visit (3, 4).  In a large percentage (40-60%) of those who seek 
medical advice or treatment for IBS, there is a close association of 
psychological distress or affective disorders with somatic symptoms (2).   
Only 10-30% of individuals with IBS seek health care for their 
symptoms (8).  IBS sufferers constitute 20%-50% of referrals to GI clinics (4, 
9).  Health-care seeking individuals with IBS are more likely to be female, 
have a lower socioeconomic status (SES), have greater levels of 
psychological morbidity (including anxiety and depression), and experience a 
reduced quality of life (5, 8).  Additionally consultation with a health care 
professional has been correlated with perceived seriousness of symptoms 
(10).     
To be diagnosed with IBS, two main conditions must be met: 1) no 
diagnostic organic disease can be detected and 2) the diagnostic criteria 
(Rome I or II) need to be fulfilled in order to have confidence in a positive IBS 
diagnosis (4, 5).  Although this is the common practice in diagnosing IBS, and 
the consensus opinion of expert gastroenterologists, it will continue to be 
controversial until the pathophysiology of IBS is better understood (11). 
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Once a diagnosis of IBS is obtained, it is further classified as either 
diarrhea-predominant, constipation-predominant, or pain/discomfort 
predominant IBS (3).  These designations help with the therapeutic approach 
employed for each patient, since therapy is directed towards alleviating the 
worst symptoms (4). 
D. Current Treatment 
Currently, there is no cure for IBS.  Treatment is aimed solely at 
alleviating symptoms and reducing disease related distress.  A good patient-
physician relationship is crucial for successful treatment of IBS symptoms.  A 
large percentage of patients (40-70%) will have symptom improvement with 
placebo alone (4).  Drug treatment should be targeted at alleviating the most 
bothersome symptoms (4, 12).  Current treatments based on symptomatology 
are: fiber for constipation; loperamide for diarrhea; smooth muscle relaxants 
for pain; psychotropic agents for treating depression, diarrhea, and pain; and 
psychological treatments (12). 
Newer therapies that have been introduced are 5-hydroxytryptamine3 
(5HT3) receptor antagonists and 5-hydroxytryptamine4 (5HT4) receptor 
agonists and antagonists (12).The 5HT4 agonist tegaserod has been shown to 
benefit those with constipation predominant IBS (7).  Significant symptom 
improvement has been shown with the use of specific antagonists of 5HT3 
receptors, which act peripherally at the enteric nervous system (13).   
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Alosetron, a 5HT3 antagonist has been shown to be effective in 
relieving pain and diarrhea in women with diarrhea-predominant IBS (14).  
One of the adverse effects of alosetron is that it has been shown to cause 
constipation in a dose-dependent manner (15).  Additionally, a more serious 
adverse event, ischemic colitis, was reported after administration of this drug 
(15, 16).  The combination of these two serious adverse events led to the 
voluntary removal of alosetron from the market by its manufacturer, 
GlaxoSmithKline (GSK), in November 2000 (15-17), only seven months after 
its initial approval (16).  Following this drug withdrawal, patient advocate 
groups sent letters to both the Food and Drug Administration (FDA) and GSK, 
stating how alosetron lessened IBS symptoms and improved their quality of 
life (16, 17).  The FDA and GSK met and created a risk management plan for 
alosetron that was submitted with a supplemental new drug application, 
approved by the FDA on June 7, 2002 (15-17).  Based on the risk 
management plan and the subsequent re-approval, alosetron is only available 
in the United States (US) to a select group of patients, and only from doctors 
enrolled in the alosetron prescribing program (17).  The only approved 
indication for alosetron is for women with severe diarrhea-predominant IBS 
who have symptoms for at least 6 months and who have failed conventional 
therapy (16, 17).   
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1.2.2 Epidemiology of Irritable Bowel Syndrome 
A. Public Health Burden 
IBS poses a substantial public health burden.  Many studies estimate 
that 9-22% of US adults have a lifetime history of IBS (8).  IBS is a common 
condition and can co-exist with organic disease (3).  Through the use of the 
International Classification of Disease (ICD) coding system, it is estimated 
that 15 million individuals in the United States are suffering from IBS (18). 
B. Public Health Significance 
As these numbers indicate, IBS is a substantial burden to the health 
care system.  It is estimated that IBS was responsible for 3.7 million physician 
office visits in 1998 (18).  In a community-based study in Minnesota, 
individuals with IBS incurred a substantial excess of physician charges when 
compared to control subjects of similar age and sex (9).  In terms of days lost 
from work, sufferers of IBS report missing more days of work due to their 
symptoms than any other disease/condition except the common cold (19, 20).  
The Minnesota study only included direct medical costs (9), thus if treatment 
and prescription costs are included, as well as days lost from work, the 
financial burden of IBS to the community would be even larger.  For the year 
1998, a conservative estimate of the total health care costs (direct and 
indirect) in the United States is $1.5 billion (18).  Health care utilization and 
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costs are not just an issue in the US.  In China, the diagnosis of IBS was 
significantly correlated with increased health care utilization (20). 
C. IBS Prevalence Estimates 
Most papers cite the one-year or current prevalence of IBS to be 
anywhere from 9% to 22% in the US as determined by community-based 
studies (5, 6, 8), with the majority having a prevalence between 10-15% (5, 9, 
21).  While this demonstrates that a substantial number of individuals have 
the disease, it also demonstrates the variability in its diagnostic definition (22).  
To obtain a more realistic estimate of the population prevalence of IBS, it is 
necessary to examine the prevalence for each specific set of criteria, the 
Manning criteria, Rome I criteria, and Rome II criteria (23-26).  The Manning 
criteria are the most inclusive, and therefore give the highest range in IBS 
prevalence.  In contrast, the Rome II criteria appear to be the most restrictive, 
with the lowest IBS prevalence.  The Rome I criteria are between the 
previously stated criteria.  As a research definition of IBS, the Rome II criteria 
are increasingly becoming the standard as the criteria are more specific (27).  
Table 1.3 summarizes the published literature on the population prevalence of 
IBS since 1995 (5, 9, 20, 23-25, 28-30). 
Additionally, since women usually have IBS at a rate of 2:1 compared 
to men (7), some studies have obtained estimates stratified by gender.  In 
these studies, the prevalence range for women, employing Rome II criteria, is 
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3.8-5.4% (26, 31).  When using Rome I criteria for women, the prevalence 
range is 10.7-18.1% (21, 25).  Among men, there is only one study with 
adequate methods that used the Rome II criteria, obtaining a prevalence of 
3.6% (31), and by Rome I criteria the prevalence range among men is from 
5.8% to 8.5% (21, 25).  Thus it appears as though the 2:1 female 
predominance is maintained for the Manning and Rome I IBS definitions, but 
may be slightly less when using the Rome II definition of IBS. 
 Studies have also demonstrated a difference based on geographic 
location.  Population-based studies with adequate methods and adequate 
sample size have been performed in Australia/New Zealand (5, 28, 29), and a 
recent one performed in 8 European countries (10).  Additional countries 
which had adequate studies performed were Spain (23), United States (9, 
24), Hong Kong (20, 30), Canada (21), and Bangladesh (25).  The prevalence 
ranges for these studies are presented in Table 1.4.  Studies that used the 
Manning criteria in Australia/New Zealand, Spain, and the US obtained similar 
prevalences, however the study of 8 European countries had a lower 
prevalence.  Rome I prevalence ranges varied from 4-12% across all 
geographic locations, while Rome II prevalence ranges were similar in 
Australia/New Zealand, 8 European countries, Hong Kong, and Spain, but the 
study performed in Canada was a distinct outlier.  This can be explained by 
the use of ‘modified’ Rome II criteria (21). 
 
 8
Based on this simple review of the literature on the population 
prevalence of IBS, it is clear that the definition used to obtain the prevalence 
estimate needs to be reported along with the prevalence.  Using this logic and 
the accompanying tables, it appears that the cited prevalence range of 9-22% 
has been derived using mainly the Manning criteria, and possibly the Rome I 
criteria.  The prevalence estimate of 10-15% is more than likely applicable to 
the diagnosis of IBS using the Rome I criteria.  Finally, since the majority of 
studies published in 2002 and later used the Rome II criteria, a population 
prevalence range of 4-7% by the Rome II criteria is probably the most 
accurate estimate based on our current knowledge. 
D. IBS Risk Factors 
Age.  Although age is not significantly associated with a diagnosis of 
IBS (5), half of IBS sufferers have symptoms that occur by age 35 (4).  
Additionally, patients younger than 45 years of age were more likely to be 
diagnosed with IBS than were those older than 45 years (7).  Based on the 
systematic review by Saito et al., the prevalence of IBS varies minimally with 
age (32).  Thus while age is important as a clinical descriptor of IBS, it is not a 
risk factor for IBS since there is no increase in risk associated with different 
age groups. 
Gender.  When examining gender as a risk factor for IBS, most studies 
have demonstrated a 2:1 female predominance of IBS in North American 
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population-based studies (7).  This is also substantiated by examining the 
gender-specific prevalence rates reported in the studies mentioned above (7, 
21, 25, 26, 31), which are representative of different areas of the world.   
Body mass index.  In studies examining body mass index (BMI) as a 
risk factor for IBS, results are conflicting.  In a US community-based study by 
Locke et al., no association was identified between IBS and BMI (33).  
Additionally, in a study of Swedish IBS patients by Simren et al., BMI was 
similar in patients and controls, and thus not associated with IBS (34).  In a 
clinic based study in Taipei, China, BMI was not significantly different among 
those with constipation-predominant IBS, diarrhea-predominant IBS, or 
controls; however BMI did have similar positive correlations with 
gastrointestinal transit times (35).  Despite these negative findings, a recent 
community-based study in Croatia demonstrated that an increase in BMI of 5 
kg/m2 increased the risk of IBS 36% (36).  Thus while evidence is leading 
towards BMI not being a risk factor for IBS, there is still controversy and more 
research needs to be done. 
Concurrent medical conditions.  All definitions of IBS (Manning, 
Rome I, or Rome II) have been shown to occur concurrently with many other 
medical conditions.  In a large European study, 21% of IBS sufferers also had 
gastroesophageal reflux disease (versus 7% among non-IBS sufferers), 13% 
had peptic ulcer (versus 6% among those without IBS), 13% had dyspepsia 
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(versus 4% among those without IBS), 25% had depression (versus 9% 
among those without IBS), and 13% had asthma (versus 7% among those 
without IBS) (10). 
Psychological disorders.  Psychological disorders are common co-
morbid conditions in most IBS patients who actively seek subspecialist 
medical care (7).  Blanchard et al. have shown through the use of a structured 
interview, the Anxiety Disorders Interview Schedule—Revised (ADIS-R), that 
IBS patients have greater psychopathology and are more anxious and 
depressed than either inflammatory bowel disease (IBD) patients or healthy 
controls (37).  In a study of 74 IBS patients seen at an outpatient clinic, the 
depression score on the Zung Depression Self-Rating Scale was significantly 
higher in patients with IBS compared to controls (38).   
In a study of psychiatric patients, the point prevalence of IBS was 29% 
in patients with major depression and 37% in generalized anxiety disorder 
patients as compared to 11% in control participants (39).    Furthermore, of 
patients seen in specialist clinics, IBS patients showed increased 
psychological morbidity (40-44).  Patients with IBS were shown to have higher 
anxiety and depression scores, as assessed using the hospital anxiety and 
depression scale, when compared to patients with no IBS (20).  More 
discussion of the epidemiology of IBS and MDD co-occurrence will be 
discussed on page 53. 
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Fibromyalgia.  Fibromyalgia also co-occurs with IBS at a substantial 
frequency.  Ranges of this co-occurrence are 32-66% (Rome criteria for IBS) 
(45-48).  Additionally, fibromyalgia and IBS share some epidemiologic 
features, such as a predominance of females (46, 48, 49) and associations 
with sleep disturbances, depression, anxiety (46), and muscle and abdominal 
pain (50), supporting a common pathophysiologic mechanism (46, 48, 51).  In 
addition, fibromyalgia patients have a clear dysregulation of their autonomic 
nervous system (pathology unknown) and also exhibit low serum levels of the 
serotonin precursor L-tryptophan (51), two possible etiologic hypotheses for 
IBS.  However, their diagnostic criteria overlap, which may be responsible for 
some of the demonstrated co-occurrence (46, 49, 52).  Additionally, a 
difference between these two disorders has been demonstrated.  IBS patients 
demonstrate visceral hypersensitivity, as measured by rectal balloon 
distention, and this characteristic is not shared with fibromyalgia patients, 
both those with and without co-occurring IBS (46).   
Hudson et al. studied 33 women with fibromyalgia and found that 39% 
had a current diagnosis of IBS, and 52% had a lifetime diagnosis of IBS (53).  
Additionally, of those with IBS and fibromyalgia, 47% had IBS for a year or 
more before the onset of fibromyalgia, 12% had IBS and fibromyalgia onset 
during the same year, and 41% had IBS onset a year or more after the 
diagnosis of fibromyalgia (53).  Thus these two disorders are associated over 
a patient’s lifecourse. 
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Chronic fatigue syndrome.  Chronic fatigue syndrome (CFS) is also 
associated with IBS (50, 52, 54).  CFS patients were more likely than controls 
to demonstrate symptoms of IBS according to the Manning criteria (50).  
Symptoms common to both disorders include muscle and abdominal pain 
(52), sleep, and concentration difficulties (50).  The rate of IBS among CFS 
patients ranges from 50-92% (50, 54).  Specifically, one study found that 73% 
of chronically fatigued adults met the Manning criteria over a 1-year 
retrospective time period (55).  These rates, while determined with differing 
IBS criteria, are well above the estimated population prevalence of IBS (54).  
Again, the etiology of CFS is unknown, and whether the apparent overlap 
results from shared underlying mechanisms or coexisting psychiatric 
disorders remains controversial (54).  In a twin study, fatigued twins were 4-
10 times more likely to be diagnosed with IBS compared to their unaffected 
co-twins, regardless of the definition of IBS (54). 
Asthma.  Asthma has also demonstrated an association with IBS (56-
59).  The study by Roussos et al. included two control groups: healthy 
controls and controls with other pulmonary disorders (56).  Results 
demonstrated that regardless of the control group, the IBS prevalence was 
significantly higher in asthmatics (56).  Similarly, Huerta et al. examined a 
cohort of asthmatics in the General Practice Research Database (GPRD) and 
also found a slight increased risk of IBS among asthmatics compared to the 
United Kingdom (UK) general population (58).  Yazar et al. examined cases 
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of IBS, using only one control group, and found that IBS patients had a higher 
prevalence of asthma than controls (57).  The study by Kennedy et al. 
examined bronchial hyper-responsiveness and demonstrated an independent 
association between IBS and bronchial hyper-responsiveness (59).  Thus it is 
apparent that IBS and asthma have a tendency to co-occur.  
Family history.  An increased likelihood of bowel symptoms among 
biologic relatives of IBS cases has been demonstrated (60).  Using logistic 
regression in a twin analysis, it has been shown that having a mother with IBS 
and having a father with IBS are independent predictors of irritable bowel 
status (p<0.001), and both are stronger predictors than having a twin with IBS 
(61).  Further discussion of the familial clustering of IBS will be covered in 
greater detail on page 19. 
E. Quality of Life 
Patients with IBS report a reduced quality of life, as measured using 
the Medical Outcomes Study 36-item short form health survey (SF-36) (62-
65) or the shorter Medical Outcomes Study 12-item short form health survey, 
version 2 (SF-12v2) (66).  There is also a tendency for a lower SF-36 score 
based on severity of IBS, with the lowest scores for patients with the most 
severe IBS (62, 67).  Additionally, this relationship was also observed when 
compared with gastroesophageal reflux disease controls, asthma controls, or 
migraine controls (65).  In a population-based, nested, case-control study, the 
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SF-36 was used to initially demonstrate that health-related quality of life is 
impaired in community subjects, consisting of both health-care consulters and 
non-consulters, with IBS (68).  After further analyses in this study, it was 
demonstrated that the apparent association could be explained by the 
Symptom Checklist-90 somatization score (68).  Taken together, these 
studies demonstrate that quality of life is impaired among individuals with IBS. 
1.2.3 Pathophysiology of Irritable Bowel Syndrome 
A. Possible Etiologies 
  Since the etiology of IBS is largely unknown, there are several 
mechanisms proposed to produce the symptoms of IBS.  These include, but 
are not limited to, altered motility, visceral hypersensitivity, abnormal brain-gut 
interaction, autonomic dysfunction, immune activation (69), intestinal luminal 
irritants, psychological distress and psychiatric disease, post-infectious or 
post-inflammatory phenomenon, abnormal motor function (gastrointestinal 
motility), and abnormal visceral perception (32).  Additionally, investigators 
have postulated that disturbances in intestinal motility result in symptoms of 
abdominal pain, bloating, and disturbed defecation (7).  In 92% of IBS 
patients, regardless of their IBS type, there is a common symptom of bloating, 
indicating that there may be a unifying theory of IBS that is not yet known 
(69). 
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A dysfunction of the brain-gut axis, linking the central nervous system, 
autonomic nervous system, enteric nervous system, and related humoral and 
immunological processes may be involved in the disturbances of motility and 
visceral sensitivity associated with IBS (70, 71).  The visceral sensitivity 
associated with IBS means that patients with IBS sense pain or discomfort 
with less distension of the colon than do control patients (7).  Burr et al. have 
shown that severe pain intensity and pain that is not postprandial are both 
associated with significantly lower average vagal activity and higher average 
sympathetic nervous system/parasympathetic nervous system balance (70).  
The dysfunction of the brain-gut axis may trigger a number of inappropriate 
reflexes which alter gastrointestinal motility, secretion and absorption, thus 
causing the wide variety of symptoms often associated with IBS (71). 
The small intestinal bacterial overgrowth (SIBO) theory comes from the 
observation that in normal, non-IBS individuals, the bacteria that ferments 
undigested food are located in the colon; however it has been demonstrated 
that in IBS patients, due to low food motility, undigested food does not 
proceed to the colon.  Thus the colonic bacteria migrates to the undigested 
food in the distal small intestine, thereby colonizing the small intestine, 
producing gas and fermentation of undigested food (69).  Recently the SIBO 
theory of IBS (69) explains postprandial bloating and distension, altered 
motility (1), visceral hypersensitivity (72), abnormal brain-gut interaction (73), 
autonomic dysfunction (74), and immune activation (69).  Postprandial 
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bloating is common in most IBS sufferers, yet the prior IBS pathophysiologic 
theories of abnormal motility, visceral hypersensitivity, altered brain-gut 
interaction, autonomic dysfunction, and immune activation do not account for 
this predominant symptom (69).  Support for the SIBO theory of IBS comes 
from the reduction of both gastrointestinal and extraintestinal symptoms when 
eradication of SIBO is achieved (69).    
B. Serotonin Involvement in IBS Etiology 
Serotonin (5-HT), a neurotransmitter, may be involved in irritable bowel 
syndrome (8).  Of the serotonin in the body, it is estimated that 95% is 
present and functioning in the gastrointestinal tract (75).  Of the serotonin 
found in the GI tract, it has been estimated that 90% is in enterochromaffin 
cells and 10% is found in enteric neurons (75).  Serotonin is released from the 
bowel when enteric nerves are stimulated (75).  Serotonin modulates 
sensorimotor functions in the digestive tract (76).   
Seven subclasses of 5-HT receptors are defined.  These receptors are 
differentiated on the basis of structure, molecular mechanism, and function 
(76).  The type 3 receptor (5-HT3) is known to partially mediate the 
postprandial colonic motor response (77) that is often associated with 
cramping, urgency, and diarrhea in patients with IBS (78, 79).  The type 2B 
receptor (5-HT2B) has been shown to mediate the excitatory effects of 5-HT in 
the human colon (80).  The 5-HT2B receptors have been localized on both the 
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colon smooth muscle and on the nerves of the myenteric plexus.  Thus, 5-HT 
may be exerting its effects on smooth muscle directly, or in combination with 
increasing the release of excitatory neurotransmitters (80).   
Serotonin is a known modulator of sensorimotor functioning in the 
digestive tract, as is demonstrated by the response to specific serotonin 
receptor agonist and antagonist drugs.  It is thought that 5-HT may stimulate 
intestinal secretion and peristalsis in addition to the usual visceral pain 
receptors via 5-HT3 and 5-HT4 pathways (8).  Two drugs, alosetron and 
tegaserod, are used for the treatment of IBS at target these receptors.  
Alosetron is a 5-HT3 receptor antagonist that is more effective than placebo at 
relieving global IBS symptoms in female IBS patients with diarrhea (7, 15).  
Antagonists of 5-HT3 receptors act peripherally at the enteric nervous system 
to decrease motility and visceral sensitivity (15) and significantly improves 
IBS symptoms (13).  Alosetron slows colonic transit and decreases discomfort 
during distension of the colon (7).  However alosetron has some serious side-
effects associated with its usage, as previously discussed. 
 Tegaserod, a 5-HT4 receptor agonist, was more effective than placebo 
in randomized clinical trials at relieving global IBS symptoms in female IBS 
patients with constipation (7).  Tegaserod stimulates the peristaltic reflex, 
increases intestinal and colonic transit, reduces the firing rate of rectal 
afferent nerves, and reduces visceral sensitivity (7).     
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Reuptake of serotonin in the intestine is under control of the serotonin 
transporter protein (SLC6A4) (16, 81).  Polymorphisms in SLC6A4 may affect 
responses to serotonergic medications (15) by affecting the efficiency of the 
serotonin transporter in removing 5-HT from the synapse.  The study by 
Camilleri, et al., showed that the homogeneous long polymorphism (L/L) of 
the SLC6A4 promoter in IBS patients was associated with a longer transit 
time through the colon in response to alosetron compared to heterozygous 
patients (76).  Thus there may be a genetic susceptibility to IBS treatment 
response, and in this case specifically to alosetron (16, 76).  
1.2.4 Role of Genetics in Irritable Bowel Syndrome Etiology 
A. Family Studies in IBS 
Substantial evidence for the clustering of IBS in families is documented 
in the literature and presented in Table 1.5.  These studies comprised a mix 
of population and clinical cohorts, with the majority of recent studies 
examining population-based samples.  Methodologically, the Locke (60) and 
Kalantar (82) studies used formal family methods whereas the others 
demonstrated a family history of IBS using family history as a covariate.  
Additionally, only the latter studies presented in the table used research 
criteria specific for IBS.   
In the Locke et al. (60) study, applying the Rome I criteria for IBS,  the 
odds of IBS were twice as great (odds ratio (OR) 2.3, 95% confidence interval 
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(CI) 1.3-3.9) in first degree relatives with abdominal symptoms in comparison 
to first degree relatives without abdominal symptoms, adjusted for age, sex, 
and psychosomatic symptom checklist score (60).  Evidence for the familial 
aggregation of IBS is additionally supported by Kalantar et al., where among 
those with a positive family history of IBS, the odds of IBS were twice as great 
for those with persistent or fluctuating IBS versus those with no IBS (83).  The 
other family study completed by Kalantar et al. also demonstrated a familial 
component to IBS (82) with the odds of IBS nearly three times higher among 
those with a first-degree relative with IBS than with an affected in-law (OR 
2.7, 95% CI 1.19-6.25), adjusted for age and sex (82).  When this model was 
further adjusted for somatization score, the OR was attenuated and no longer 
significant.  Thus while these results support a familial component to IBS, it is 
possible that the aggregation may be due to another disorder (82, 84).  As 
these studies demonstrate, there is substantial evidence to support a familial 
component to IBS. 
Limitations.  There are limitations to these studies that may affect the 
validity of their conclusions.  One of the limitations is the possibility of 
reporting bias, as individuals with IBS may preferentially remember relatives 
that had abdominal problems.  Additionally, the assessment of family history 
may not be very rigorous, as demonstrated in the Locke et al. (60) study.  The 
question asked broadly about relatives with abdominal symptoms, used no 
time frame for those symptoms, and  cited only a fair reliability (κ=0.48) for 
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this question (60).  Also, the definition of IBS used in these studies was either 
Manning, Rome I, or abdominal pain, and the results may not reflect the 
prevalences that would be observed using Rome II criteria, which are more 
restrictive than the other criteria.  It has also been suggested that the 
demonstrated aggregation may be due to another disorder, possibly 
somatization (82).  Finally, the demonstrated aggregation could be attributed 
to a common childhood environment or even to a possible gene-environment 
interaction (82), neither of which are possible to ascertain using family study 
methodologies. 
B. Adoption Studies 
There are no adoption studies for IBS.  If adoption studies were 
performed for IBS, the results would help to distinguish genetic effects from 
shared environmental effects on the etiology of IBS. 
C. Twin Studies 
General Method.  Twin studies often examine the relative importance 
of genetic and environmental influences for behavioral characteristics and 
diseases.  The use of twin studies in research is attractive because it uses the 
natural biological phenomenon of twinning in order to differentiate 
environmental and genetic factors in disease etiology.  Using principles of 
biology and genetics, the twin phenomenon implies that monozygotic (MZ) 
twins are, for most purposes, genetically identical, whereas dizygotic (DZ) 
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twins share the same amount of genes as would two normal siblings.  That is 
dizygotic twins share on average half of their genes, identical by descent, and 
monozygotic twins share all their genes, thus being genetically identical.  To 
use this phenomenon of twinning in research, one compares the similarity of 
monozygotic twin pairs for a trait or a disorder with the similarity of dizygotic 
twin pairs, and thereby can detect environmental and genetic effects, and 
most importantly, has the ability to quantify the magnitude of these effects 
(85-87).  This is especially attractive when examining co-occurring disorders 
because twin studies control, to a substantial extent, genetic and 
environmental factors, thus helping to elucidate the complex interactions of 
biological, psychological, and environmental factors involved in co-morbid 
conditions (54, 87). 
Classic twin modeling partitions the variation in liability to a disorder by 
means of decomposition of variance (88).  This is done using structured 
equation modeling (SEM), as performed by various software programs such 
as Mx (89).    This analysis uses path diagrams and matrix algebra to 
determine the decomposition of variances and covariances, and in doing so is 
able to determine what percent of the demonstrated association is due to 
additive genetic effects (a2) (also known as heritability), common 
environmental effects (c2), and unique environmental effects (e2) (87, 88), 
which also encapsulates measurement error.  This analysis is heavily 
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dependent on knowing the pairwise zygosity of the twins as well as their 
affection status. 
Results of Twin Studies in IBS.  Four twin studies examining the 
genetic liability to IBS are described in Table 1.6.  All three twin studies were 
population-based samples of twin pairs.  Methodologically all but the third 
study employed classic twin methods, examining monozygotic (MZ) and 
dizygotic (DZ) concordance rates, whereas the third study employed a co-twin 
control design.  A drawback of these studies is the lack of use of a consensus 
definition of IBS, either Manning, Rome I, or Rome II.  The Svedberg et al. 
(90) study employed a diagnostic algorithm to define IBS that is similar to the 
Rome criteria, however use of a consensus definition would help 
comparability and consistency of IBS definition across different studies.   
The study by Morris-Yates et al. demonstrated a higher concordance 
of IBS in MZ twins than in DZ twins (33.3% versus 13.3%, respectively) (91).  
Similar results were reported in the twin study by Levy et al., where the MZ 
twin concordance was 17.2% and DZ twin concordance was 8.4% for IBS 
(61).  While the concordances are considerably higher in identical (MZ) twins, 
there is not a perfect concordance of 100%, suggesting moderate to high 
environmental influences (86).  Morris-Yates et al. alluded to this in their 
analysis where 58% of the difference in liability to functional bowel disorders 
(FBD) was attributed to genetic control (91), and not 100% as perfect MZ 
 23
concordance would demonstrate.  One problem with this study is that the 
assessed phenotype of FBD includes a mix of individuals with IBS, functional 
abdominal bloating, functional constipation, functional diarrhea, and functional 
abdominal pain.  Thus the results may not be true of the individual disorders 
that fall under the realm of FBD.  Together, these results are suggestive of 
both genetic and environmental contributions to the etiology of IBS. 
In contrast, the classic twin study by Mohammed et al. (92) 
demonstrated similar IBS concordance rates between MZ and DZ twin pairs 
(28% and 27%, respectively).  Additionally, the best-fitting classic twin model 
did not contain a variable for heritability, but only variables for common and 
unique environmental influences.  Thus this study demonstrated that genetic 
factors have little or no influence over IBS.  The main difference between this 
twin study and the previous studies was the use of the most recent, more 
restrictive Rome II IBS criteria. 
The third twin study by Svedberg et al. performed a case-control and 
co-twin analysis.  The case-control analysis demonstrated associations 
between IBS and eating disorders (OR 2.4; 95% CI 1.1-5.1), urological 
problems (OR 3.3; 95% CI 1.3-8.2), poor self-rated health (OR 1.8; 95% CI 
1.0-3.2), eating allergies (OR 9.0; 95% CI 1.4-60.1), and rheumatoid arthritis 
(OR 3.2; 95% CI 1.1-9.4) (90).  The co-twin analysis examined 58 disease 
discordant MZ twin pairs and only the association between urologic problems 
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and IBS remained (OR 4.0; 95% CI 1.0-16.8), suggesting a common etiology 
not attributable to genetic effects (90).  The associations between IBS and 
eating disorders, eating allergies, and rheumatoid arthritis decreased in the 
co-twin analysis, suggesting genetic as well as family environmental effects 
on these associations (90). 
In summary, three of these twin studies are supportive of both genetic 
and environmental components to IBS; however several problems were 
noted.  First, a consensus definition of IBS was not employed, and one study 
used the broader term of functional bowel disorders and applied the results to 
IBS.  Thus a better defined phenotype may add to this existing knowledge.  
Another criticism of twin studies is the inability to separate similarity due to 
common environment (from conception onward) from similarity due to genetic 
influences (86).  Despite these limitations, there were strengths.  These 
studies all used population-based twin registries and twin study 
methodologies.  Taking the results of twin and family studies together, there is 
accumulating evidence suggestive of genetic and environmental contributions 
to IBS. 
D. Linkage Studies 
General Method.  Linkage analysis is used to determine the 
chromosomal location of genes that affect a given disorder.  It is based in 
classical genetics and relies on the violation of Mendel’s second law; the law 
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of independent assortment.  Independent assortment dictates that loci on a 
chromosome are able to separate from each other during meiosis and thus be 
transmitted to successive generations independently.  The violation of 
independent assortment means that when two loci on the same chromosome 
are in close proximity, the alleles at these loci tend to sort together 
(“cosegregate”) within a pedigree (93), thus violating the independence 
between many loci.  Additionally, the degree of cosegregation is loosely 
dependent upon the genetic distance between the two loci (93).  Thus we 
assume that the genotype at the marker locus represents the genotype at the 
surrounding sequence, which may harbor the functional variant associated 
with disease etiology.  Significant evidence for linkage to a phenotypic trait is 
determined either by consistent transmission of a phenotype or disease from 
parent to offspring, proportion of alleles shared between affected and 
unaffected siblings, or the relationship between allele sharing and means or 
differences in phenotypic values for pairs of relatives.  Traditional linkage 
analysis is performed using family pedigrees and thus any demonstrated 
linkage is family specific and needs to be replicated in different pedigrees, 
unless there is considerable linkage disequilibrium (93, 94).   
Results in IBS.  To date, no linkage studies of IBS have been 
performed.   
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E. Candidate Gene Studies 
 General Methods.  Candidate gene studies, or association studies, 
are used to identify possible causal variants in candidate genes.  A variety of 
samples, including case-control, case only, and family data, are used to find 
disease pre-disposing alleles (94).  In population based case-control 
association studies, the most commonly implemented design, the statistical 
comparison is the marker allele frequency between cases (diseased or 
affected) and controls (non-diseased or non-affected) (86).  This methodology 
thus identifies alleles or combinations of alleles that occur more often than 
predicted by chance among individuals with a particular phenotype (cases) 
than among non-cases (86, 93).  Of considerable importance in the design of 
association studies is control selection, as controls should be chosen to 
represent the population from which cases are derived (93), and thus 
represent the same underlying population.  This is important because allelic 
frequencies for deoxyribonucleic acid (DNA) markers have been shown to 
vary among different ethnic groups (86, 93).  Additionally, the controls are 
used to estimate the prevalence of the marker alleles in the source population 
(93), and if the case and control populations are not from the same source 
population, the prevalence of the marker alleles in cases is not being 
compared to the correct prevalence of marker alleles in controls, thus the 
possibility of incorrect association.  In addition to needing special care for 
control selection, association studies are subject to the same biases as 
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traditional case-control studies (low power, selection bias, misclassification, 
and confounding) (93). 
Until such time that full genome association studies are affordable for 
non-industry investigation, the majority of population-based research will likely 
use a candidate gene approach.  The selection of candidate genes should be 
made based on a biologically plausible hypothesis; such that the gene 
product is involved in the phenotype of interest.  Information on the function of 
candidate genes and the identification of important polymorphisms and 
validated single nucleotide polymorphisms (SNPs) within these genes can be 
obtained at various on-line resources. 
 Results in IBS.  Table 1.7 summarizes the published candidate gene 
studies for IBS.   These studies were performed in clinic-based samples, and 
suffer from issues of health-care seeking influence, poor marker coverage of 
the gene, and low power.  To date, the serotonin and transforming growth 
factor β1 (TGFB1) polymorphisms that were investigated were not successful 
in demonstrating an association with IBS.  The association between the 
polymorphism in Interleukin 10 and IBS, while not statistically significant, is of 
further interest because the study was slightly underpowered to detect such a 
small result.  Also of further interest is the polymorphism in the study by 
Camilleri, et al., because the L/L homozygote demonstrated delayed colonic 
emptying (76), regardless of the fact that the study was underpowered.  
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Despite being the most severely underpowered study, the results of Pata et 
al. suggested that the S/S and L/S genotypes of the SLC6A4 gene-linked 
polymorphic region [5-HTTLPR] may predispose individuals to certain 
subtypes of IBS (81).  Thus while none of these studies have shown genetic 
polymorphisms associated with IBS, there are other polymorphisms in these 
genes that can be investigated, as well as performing studies on these same 
polymorphisms using larger sample sizes in order to obtain adequate power 
to detect a smaller effect.   
1.2.5 Definition of Major Depressive Disorder 
A. Clinical Definition 
Major depressive disorder (MDD) is a medical illness that is 
characterized by abnormalities of affect and mood, appetite, sleep 
disturbances, inappropriate feelings of guilt and worthlessness, and agitation 
(95).  Additionally, concentration and forgetfulness; sleep problems; irritability; 
worry about physical health; depression; depressive ideas and worry are 
symptom areas that have particular relevance for depressive disorders (96).  
Patten found there to be an increased risk of developing major depression 
with almost any long-term medical condition: 4% of those with one or more 
medical conditions, compared with 2.8% of those without medical conditions 
(97). 
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B. Diagnosis 
Similar to IBS, there is no biological test for a diagnosis of MDD.  A 
diagnosis of MDD is made by interpreting practice guidelines that are outlined 
in the American Psychiatric Association’s Diagnostic and Statistical Manual, 
4th edition (DSM-IV) (95).  Although the diagnosis relies on the subjective 
judgment of the physician, most physicians agree on the use and application 
of the guidelines.  However interpretation may lead to practice differences 
among physicians, as a patients’ previous history as well as demonstrated 
behaviors during the current visit are used in determining a diagnosis of MDD.   
A temporal criterion in the guidelines state that those affected by MDD 
must have experienced at least five or more symptoms during the same 2-
week period.  At least one of the symptoms must be either a depressed (or 
irritable) mood or loss of interest or pleasure.  Other symptoms include: 
changes in weight or failure to make necessary weight gains; sleep problems; 
psychomotor agitation or retardation; fatigue or loss of energy; feelings of 
worthlessness or abnormal amounts of guilt; diminished ability to think or 
concentrate, or indecisiveness; and thoughts of death, including repeated 
suicidal ideation or plans for suicide, as well as suicidal attempts (98).  These 
guidelines are a combination of clinical and historical consensus of experts in 
psychiatry about the most important signs and symptoms of depressive 
illness (95). 
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C. Recurrence 
MDD is usually not a one time occurrence (99), with recurrence 
probabilities over 50%.  In most individuals, MDD is episodic with multiple 
recurrences over the course of an individual’s lifetime (100).  A 15-year 
observational study of individuals with MDD at the beginning of follow-up and 
subsequently treated determined that after recovery the cumulative proportion 
of recurrence of any affective disorder at 15-years was 85% (Kaplan-Meier) 
(101).  Specifically, the 15-year recurrence for MDD was 78% (101).  
Similarly, after 5 years of recovery, the cumulative probability of MDD 
recurrence was 60% (102).  Thus MDD follows a waxing and waning of 
symptoms over the course of an individual’s lifetime.  Additionally, risk factors 
for recurrence of an affective disorder were being female, having an 
increased number of prior episodes, never marrying, and having a longer 
duration of episode before seeking treatment (101). 
1.2.6 Epidemiology of Major Depressive Disorder 
A. Public Health Significance/Burden of Illness 
Depression affects 51 million individuals worldwide and is responsible 
for more than 1 in every 10 years of life lived with disability (103).  The most 
common psychiatric disorder is MDD (95).  In any one year, 10.3% of the US 
adult population is affected by depression (104).  In the US the annual cost of 
depression has been estimated to be between $43.7 billion and $52.9 billion, 
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including costs due to health care, suicide, and workplace losses.  Overall 
medical costs for a depressed individual are twice as high as a non-
depressed individual.  Depressed individuals utilize health care services 3 
times more frequently and visit the emergency room 7 times more often.  The 
diagnosis of depression may be missed in one third to one half of all patients 
(105). 
Major depression is associated with increased symptom burden and 
decreased functioning and quality of life (106).    Major depression is 
widespread and often chronic.  Associated with depression are social and 
financial costs in the form of impaired relationships, lost productivity, and lost 
wages (105).  Depression has a tremendous impact on all aspects of an 
individual’s life (105).  Depressed patients are more unlikely to comply with 
therapy than non-depressed patients, placing them at risk for poor health 
outcomes (105). 
Major depression is a substantial public health burden as it is a 
common disorder associated with a high morbidity (107), high mortality (108, 
109), and in the past it was largely untreated (107), with the percent of 
individuals receiving treatment increasing more recently.  The meta-analysis 
of community-based studies by Cuijpers et al. determined that the combined 
relative risk (RR) of dying was 1.81 (95% CI 1.58-2.07) for depressed 
individuals compared to non-depressed individuals (109).  Additionally, the 
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relative risk was significantly elevated for those individuals with subclinical 
depression (RR 1.65 (95% CI 1.39-1.96)) (109).  The main drawback of this 
study was that information about chronic illnesses and other important 
confounders was not available for analysis (109).  In Sweden, the 
standardized mortality ratios for patients with major depression were 2.0 (95% 
CI 2.0-2.1) for men and women for all causes combined (108).  The main 
limitation of this study was that it only used patients with a hospital admission 
and thus the ratio may be higher than expected due to a possible selection of 
more severely depressed individuals (108). 
B. Diagnostic Instruments 
There are many different instruments that researchers use to diagnose 
and define depression, as well as to quantify its severity in clinical and 
epidemiological studies.  These include the structured clinical interview for 
DSM-IV (SCID) (110), the composite international diagnostic interview (CIDI) 
(111), the structured psychopathological interview and rating of the social 
consequences of psychic disturbances for epidemiology (SPIKE) (112), the 
inventory for depressive symptomatology (IDS) (113), the research diagnostic 
criteria (RDC) (114), the schedule of affective disorders and schizophrenia 
(SADS) (115-117), the inventory to diagnose depression (IDD) (118, 119), the 
diagnostic interview schedule (DIS) (120), the short depression interview 
(SDI) (121), and the diagnostic inventory for depression (DID) (122), to name 
a few.  Some of these are structured or semi-structured instruments, whereas 
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others are self-report instruments that were developed.  All of these 
instruments are validated and have certain advantages and disadvantages 
associated with them.  One of the problems in psychiatric research is 
comparing results of studies that use different instruments, as they may not 
necessarily obtain the same population of depressed patients based on the 
instrument used to operationalize a research definition of depression. 
C. MDD Prevalence 
Table 1.8 summarizes studies examining MDD prevalence.  
Prevalence rates vary by the time period for which prevalence is defined.  
Current prevalence rates vary between 1% and 6%, while six-month 
prevalence rates vary between ~2% and 5%.  Lifetime and one-year 
prevalence rates are more variable, with one-year prevalence rates varying 
between ~2% and 12%, and lifetime prevalence rates ranging from 1.5% to 
19%. 
As these rates demonstrate, there is much variability in their ranges.  
Reasons for this are the way in which MDD is defined, and also cultural or 
environmental differences.  First, while most of these studies used either the 
DIS or the CIDI to define MDD by using the responses to obtain Diagnostic 
and Statistical Manual (DSM) MDD diagnoses, differing versions of the DSM 
were used in different studies.  Thus, variability in the estimates is introduced 
through these definitional differences.   
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Another possible cause of the demonstrated variability may be cultural 
or environmental differences.  This is demonstrated in the studies used in the 
reviews by Bland et al. (123) and Weissman et al. (124).  The included 
studies of these reviews were performed in the US, Puerto Rico, France, Italy, 
Lebanon, Korea, Taiwan, and New Zealand; and the lifetime prevalence rates 
were all standardized to the US population.  Thus, by standardizing these 
rates, more similar lifetime prevalences should have been demonstrated if no 
cultural/environmental influences have an effect on MDD.  However this was 
not the case and therefore cultural or environmental influences have an effect 
on MDD prevalence and MDD susceptibility.  Despite these limitations, the 
majority of studies in Table 1.8 estimate the range of the lifetime prevalence 
of MDD to be between 10-20%, with some additional outliers. 
D. MDD Risk Factors 
The major risk factors for major depression are being female (95, 107, 
120, 125-127), having stressful life events (95, 127), experiencing adverse 
childhood experiences (95, 127), demonstrating certain personality traits (95, 
127), being born after World War II (107, 120, 125, 126), being 
separated/divorced or in an unhappy marriage (107, 126), having asthma or 
heart disease (126), and having a family history of major depression (107, 
127).  Based on these risk factors, it follows that cohort effects may also be 
influencing MDD (107, 120).  Such an example is individuals born after World 
War II.  Additionally, individuals born in the same birth cohort endure the 
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same social and political life stresses.  With major life stresses, such as war, 
affecting a birth cohort, additional effects may also been seen in MDD 
occurrence. 
Age.  Depression can affect both adults and children.  Evidence of an 
increased rate in younger individuals has been demonstrated, with the 
average age of first onset in young adulthood (107, 123).  The National 
Comorbidity Study—Replication (NCS-R) was consistent with results from 
previous studies that demonstrated that major depressive disorder has an 
early onset (111).   
Gender.  Of the 10 to 14 million individuals who are depressed in any 
given year (105), women aged 18 to 45 years comprise the largest group 
(128).  Women have consistently demonstrated a higher risk of MDD than 
men, and in most studies the ratio of prevalence rates in women to men has 
been between 1.5 and 2.5:1 (95, 127).  For example, the National 
Comorbidity Study estimated a lifetime prevalence of MDD in US women to 
be 21.3%, and 12.7% in US men (129).  Additionally, data from the National 
Survey of Psychiatric Morbidity, completed in Britain, found that women suffer 
from higher rates of depression than men until menopause and then the rate 
of depression in women becomes similar to men (96).   
Stressful life events.  In the community study by Patten et al., 
experiencing one or more recent life events was associated with the 12-
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month prevalence of major depression (OR 2.01, 95% CI 1.08-3.72) (125).  
Additionally Kessler et al. demonstrated that the exposure to stressful life 
events is higher among individuals with a history of depression (127).  In the 
developmental model of major depression described by Kendler et al., 
stressful life events in the last year had a correlation of 0.35 with an episode 
of major depression in the last year (130). 
Marital factors.  In an Australian community sample, the 30-day 
prevalence of major depression was less in those currently married (OR 1.0) 
than in those never married (OR 1.77, 95% CI 1.19-2.63) or those separated, 
widowed, or divorced (OR 2.81, 95% CI 1.53-4.82) (126).  Weissman et al. 
observed the lowest major depression rates among married women and 
women that get along with their spouse, and the highest rates of major 
depression among women in unhappy marriages (107).  In fact, unhappy 
marriage increased the risk of major depression about 25-fold in both men 
and women (107).  Additionally, in the developmental model by Kendler et al., 
marital problems or difficulties in the last year and history of divorce were 
correlated with an episode of major depression in the last year (130). 
Family history.  A two-to-threefold increased risk for major depression 
has been demonstrated if there is a family history of the disorder (95, 105, 
107, 125).  The Zurich cohort reported that of participants receiving a 
diagnosis of depression, 54-73% reported a family history of depression 
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among first degree relatives (112).  Recently, results from family studies are 
consistently showing that major depression is familial (107).  Additionally, 
children of depressed parents are more than 3 times as likely to experience 
depression than are children of non-depressed parents (105).   
1.2.7 Pathophysiology of Major Depressive Disorder 
Depression is a symptom of many medical conditions, including stroke, 
Cushing’s disease, hypothyroidism, multiple sclerosis, Huntington’s disease, 
and Parkinson’s disease (95).  In addition, it is commonly comorbid with 
numerous psychiatric disorders such as attention-deficit/hyperactivity 
disorder, bulimia nervosa, dysthymic disorder, generalized anxiety disorder, 
obsessive-compulsive disorder, panic disorder, post-traumatic stress 
disorder, premenstrual syndrome, and social phobia (131); however its 
etiology is not fully understood. 
A. Biologic Abnormalities in MDD/Possible Etiologies 
Some of the biological bases of MDD are dysregulations of circadian 
rhythms, cognitive processing, and both appetite and psychomotor 
functioning, which may be an influence of the co-occurring medical conditions 
(95).  Major depression patients usually experience abnormalities in mood, 
sleep, sexual behavior, and appetite (132-134).  These disturbed functions 
are regulated by serotonin and norepinephrine (132-135).  Additionally, 
monoamine oxidase (MAO) is one of the major enzymes responsible for the 
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degradation of neurotransmitters such as serotonin, norepinephrine, and 
dopamine (136).  Significant symptom improvement in mood and anxiety 
disorders can occur by the administration of substances that inhibit MAO 
activity (136) or by pharmaceuticals that increase serotonin activity by 
decreasing its reuptake, known as selective serotonin reuptake inhibitors 
(SSRIs) (137).   
The exact causes of depression are still being investigated (138); but 
likely both genetic and environmental factors contribute to its pathogenesis 
(139).  A plethora of information about the biology of depression comes from 
results of antidepressant drug studies (140, 141).  Biologic causes include 
changes in the chemistry of the brain or fluctuations in the body’s secretion of 
hormones (139).  Individuals with depression may have abnormally low levels 
of certain brain chemicals and slowed cellular activity in areas of the brain 
that control mood, appetite, sleep, and other functions (138).  Additionally, 
increases or decreases in the production of specific hormones may interfere 
with the brain’s natural chemistry and lead to depression (138, 140).   
B. Role of Neurotransmitters 
Biologically, the brain communicates with the body through the work of 
neurotransmitters (138-140).  Neurotransmitters carry the brains messages 
across synapses from one neuron to another (138, 139).  Each 
neurotransmitter has a distinctive structure, which allows for recognition of its 
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receptors structure (similar to a lock and key).  If the receptor is not the 
specific receptor corresponding to that neurotransmitter, its message is not 
relayed across the synapse (139).  Once the neurotransmitter has bonded to 
its receptor and delivered the message, the neurotransmitter pulls away from 
the receptor and returns to the synapse, where the brain is able to remove the 
neurotransmitter (138, 139). 
C. Neurotransmitters Implicated in MDD 
  Of the many known neurotransmitters in the brain, associations 
between depression and the activity of three main neurotransmitters: 
norepinephrine, serotonin, and dopamine are demonstrated in the literature 
(139).  These neurotransmitters are active in the brain areas that control 
activities shown to malfunction during depression (135, 139).  In MDD a 
dysfunction of neural function in both pre- and post-synaptic serotonergic 
systems is demonstrated (137).  In addition to the neurotransmitters having a 
role in depression, it is also thought that their receptors may be involved in 
causing depression (139).   
Norepinephrine (NE).  Norepinephrine plays a role in modulating 
mood, sleep, appetite, and neuroendocrine functions which are often 
abnormal in MDD (142, 143).  The norepinephrine transporter (NET) is a main 
target of antidepressant action and is dysregulated in major depression (134, 
144).  NET is responsible for terminating the action of NE in the synapse 
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(144).  Blockade of NET by tricyclic antidepressants results in prolongation of 
the action of NE in the synapse (140), as antidepressant treatment causes 
decreased NE turnover (145).  Lee et al. demonstrated that levels of NETs on 
brain noradrenergic neurons appear to be regulated in such a way as to 
maintain normal concentrations of NE in the noradrenergic synapse (146).  
Thus malfunction of the NET may be involved in the etiology of MDD (142). 
Data from a study using postmortem brain tissue demonstrated a 
reduced expression of the NET on noradrenergic neurons of the locus 
coeruleus in individuals with major depression, using a radioisotope binding 
technique (144).  Additionally, increased levels of NE and its metabolites were 
reported in cerebrospinal fluid, plasma, and urine of depressed patients over 
normal controls (147-149).  Therefore, these studies demonstrate that NE and 
the NET are dysregulated in individuals with major depression. 
Serotonin (5-HT).  Substantial evidence supports a role for 
dysfunction of brain serotonergic (5-HT) systems in the pathogenesis of major 
depression (115), including the serotonin type 5 receptors, serotonin type 2 
receptors, serotonin type 3 receptors, serotonin type 1 receptors, and the 
serotonin transporter.  The relative abundance of serotonin type 6 receptor (5-
HT6) in the limbic area of the brain and the high affinity of some 
antidepressants for the 5-HT6 receptors suggest that this receptor might be 
involved in the pathogenesis of mood disorders (150).  Serotonin type 2 
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receptor (5-HT2) density and function are disturbed in the depressed patient 
and return to normal values only following effective treatment (140).  A 
decrease in the functional activity of the 5-HT2A receptor is associated with the 
symptoms of depression (140).  It was initially thought that the main function 
of 5-HT was as a peripheral hormone due to the relatively high concentration 
in the gastrointestinal (GI) tract and in blood (140), however there is 
increasing evidence suggesting that the peripheral serotonin receptor is 
identical to the serotonin type 3 (5-HT3) receptor in the brain (140), thus there 
is a link between the serotonin in the brain and the serotonin in the GI tract 
which may explain the brain-gut dysfunction demonstrated in IBS.   
Although the precise mechanism of action of most antidepressants is 
incompletely understood, there is evidence to suggest that serotonin 
receptors, particularly 5-HT1A and 5-HT2, play a role in the action of 
antidepressants (140).  Stimulation of 5-HT1A pre-synaptic receptors results in 
a decrease in the excitation of serotonergic neurons (135, 151, 152), thus a 
possible cause of depression.  Depressed patients have decreased 5-HT2 
receptors in the brain in comparison to control participants (153).  Irrespective 
of the presumed specificity of antidepressants on the various 
neurotransmitters in the brain, in general antidepressants modulate the 
activity of a number of different transmitters whose functions are inter-related 
(140).  There is some evidence to suggest that serotonergic function is 
abnormal in some groups of depressives, yet it is not certain if such changes 
 42
are a result or a cause of the mood states associated with major depressive 
disorder (137, 140). 
D. Serotonin Hypothesis of MDD 
The ‘serotonin hypothesis’ of MDD is the most widely accepted 
hypothesis of the neural basis of MDD (137).  Serotonin is synthesized in the 
body from the essential amino acid L-tryptophan, provided to the body by 
protein-rich food (152).  Figure 1.1 diagrams the metabolic pathways of 
tryptophan (152).  In individuals with MDD, a decrease in the concentration of 
serotonin and an increase in the concentration of kynurenine has been noted.  
This implies that there is a relative deficiency of brain serotonergic activity in 
depression (151, 154), attributable to either less serotonin release or to fewer 
serotonin receptors or impaired serotonin receptor-mediated signal 
transduction (135).  As Staley et al. have summarized, support for the 
serotonin hypothesis comes from studies that have measured 5-HT function 
in various ways: from cerebrospinal fluid (CSF) 5-Hydroxyindoleacetic acid (5-
HIAA) levels (155, 156), plasma precursors (140, 156), and blood platelet 
function (141, 156). 
Additional evidence for this hypothesis comes from studies of the 
serotonin transporter and other serotonin receptor subtypes.  The 5-HT 
transporter (SERT) is located on the pre-synaptic membrane and controls the 
amount of 5-HT in the synapse (141).  The SERT is responsible for the 
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reuptake of 5-HT from the extracellular space back into the neuron (157), 
which thereby inactivates serotonin (151).  The 5-HT that the SERT 
transports back into the presynaptic neuron is then stored in vesicles until it is 
either re-released into the synapse or it is degraded (151).  Arango et al. 
document that MDD sufferers have fewer platelet SERT sites (157).  
Moreover, individuals with MDD have less SERT binding compared to 
nondepressed individuals, with the difference in SERT binding more 
pronounced in men (33%) than in women (19%) (157), which may explain 
part of the gender difference observed in MDD. 
Adequate control of the serotonin network depends on appropriate 
balance of presynaptic 5-HT storage and release as well as on 5-HT reuptake 
from the synaptic cleft by 5-HT transporters (152).  The release of serotonin 
from the neuron is necessary to activate its postsynaptic receptors which 
activate the corresponding second messenger systems or stimulate target 
organs (152).  A schematic of a serotonin neuron is portrayed in Figure 1.2.  
Recently, Linner et al. demonstrated that noradrenaline may regulate 
serotonergic neurotransmission at both the serotonin neuron and the nerve-
terminal (158).  At the serotonin neuron, regulation by noradrenaline is 
accomplished by stimulatory α1-adrenoceptors, whereas at the nerve-
terminal, regulation of serotonin transmission is inhibited by noradrenergic α2-
adrenoceptors (158).  Thus while the biologic mechanism of MDD is evolving, 
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the current state of knowledge is implicating serotonin as a major contributor 
to the biologic basis of MDD. 
1.2.8 Role of Genetics in Major Depressive Disorder Etiology 
The complex etiology of MDD is studied with family, adoption, and twin 
studies.  Additionally, MDD has been the subject of linkage studies and 
association studies, mainly searching for gene regions linked to MDD and 
candidate genes that are associated with neurotransmitters that are MDD 
drug targets or hypothesized to be involved in the etiology of MDD.  These 
studies are summarized below.  
A. Family Studies 
Table 1.9 summarizes family studies examining the familiality of MDD 
with adequate methods, as outlined in the meta-analysis by Sullivan et al. 
(159).  These studies used a mix of population- and clinic-based samples, 
thus allowing the comparison of possible treatment-seeking effects on the 
estimates.  The phenotype of MDD is well-defined in these studies, as MDD 
was distinctly separated from bipolar disorder.  All probands were recruited 
systematically, and their diagnoses were made blind to recruitment status.  
Additionally, the relatives were diagnosed without knowledge of the affection 
status of other relatives, and through a direct interview, where possible. 
Sullivan et al. combined the first five studies in Table 1.9 into a meta-
analysis, and the appropriate homogeneous combined odds ratio for proband 
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versus first-degree relative status was 2.84 (95% CI 2.31-3.49) (159), 
supporting the notion of the familiality of MDD.  Since publication of that meta-
analysis, additional population-based family studies of MDD probands were 
performed.  This is in contrast to prior studies which used mainly hospital or 
clinic samples for probands, which was a limitation of the meta-analysis by 
Sullivan et al. (159).   
The population-based studies also demonstrate familiality of MDD in 
the following manners: children of depressed probands having a higher risk of 
MDD (160-162); the rate of MDD in relatives of adolescent probands being 
elevated (163); and relatives of chronic MDD probands exhibiting higher rates 
of MDD than either relatives of episodic MDD probands or relatives of 
probands with no history of mood disorders (164).  Thus both the results of 
the meta-analysis and the results of subsequent population-based family 
studies support the hypothesis of the familiality of MDD. 
B. Adoption Studies 
Table 1.10 summarizes the three MDD adoption studies.  These 
studies are not as methodologically rigorous as the aforementioned family 
studies; however a discussion is warranted.  The study by von Knorring et al. 
(165) did not support a genetic influence to the liability of MDD, however the 
definition of the MDD probands was not rigorous, employing health insurance, 
sick leave, and claims data.  This is in methodologic contrast to the additional 
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adoption studies, one which used direct interview (166), and the other 
employed discharge diagnoses and death records (167) to define MDD 
probands, both more rigorous methodologies.  The study by Cadoret et al. 
(166) had limited statistical power as well as limited information on the 
biological parents of the adoptees, and when the data was analyzed by 
gender, the results were non-significant (166).  However Sullivan et al. 
analyzed the relationship combining genders and found a significant trend-
level relationship (OR 2.54; 95% CI 1.0-6.47) (159).  The adoption study by 
Wender et al. (167) provided the best evidence for a genetic effect regardless 
of the fact that the MDD information came from an indirect source as opposed 
to direct interviews (OR 7.25, 95% CI: 1.21-43.20) (159), however the width of 
the confidence interval demonstrates the lack of precision due to a small 
sample size.  Thus it appears as though the majority of these adoption 
studies support the genetic influence to MDD (159). 
C. Twin Studies 
Table 1.11 summarizes the twin studies performed for MDD.  These 
studies fulfilled the criteria stated of family studies, with the additional criteria 
that zygosity was determined accurately for all twins, both those with and 
without MDD, as fully stated in the meta-analysis by Sullivan et al. (159).  
These studies used both community-based and clinic-based samples of 
twins, and employed traditional twin methodologies, MZ and DZ concordance 
rates, as well as twin modeling.  All of these studies used DSM-III-R criteria 
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for MDD based on interviews, and the majority were community-based 
samples.  Sullivan et al. (159) combined the first six studies in Table 1.11 into 
a meta-analysis.  By inspecting the difference in concordance rates between 
MZ and DZ twins within these studies, MZ twin concordance rates are usually 
1.5-2 times greater than DZ twin concordance rates, implying a genetic 
influence to MDD (86). 
Methodologically twin studies are able to partition the variance in 
liability to MDD into three components: additive genetic effects (quantitatively 
known as heritability), common environmental effects (shared family/twin 
environment), and unique environmental effects (individual environment) 
(159).  The meta-analysis by Sullivan et al. obtained a combined estimate of 
heritability of 0.37 (95% CI 0.33-0.42) (159) and the combined estimate for 
the unique environmental effects was 0.63 (95% CI 0.58-0.67) (159).  The 
model used to obtain these estimates determined that the common 
environment did not significantly contribute to the variance in liability to MDD.  
Since the publication of this meta-analysis, two additional twin studies were 
performed satisfying the inclusion criteria of the meta-analysis.  In these two 
studies, the estimated heritability was between 0.34 and 0.40 (168, 169) and 
the remainder of the variance in liability to MDD was due to unique 
environmental effects of the individual, similar to the results of the meta-
analysis.  Additionally, the meta-analysis determined the heritability in clinical 
studies to be 0.43 (95% CI 0.21-0.58) (159) and 0.37 (95% CI 0.28-0.42) in 
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community-based samples (159), which are not markedly different from each 
other.   
D. Linkage Studies 
Table 1.12 summarizes linkage studies performed for MDD.  These 
studies were defined by families with MDD or recurrent, early-onset MDD 
(RE-MDD) and most were genome-scans.  Additionally, the majority used 
standardized instruments to obtain valid MDD diagnoses.  An issue with many 
of these studies is the use of RE-MDD to identify the probands, which may be 
a genetically distinct subtype of MDD.  
The majority of studies did not find significant evidence for linkage to 
MDD; however some found evidence for linkage that was gender dependent.  
Among women chromosome 2 demonstrated significant linkage for RE-MDD 
(170, 171), whereas men demonstrated linkage to chromosome 12 for MDD 
(172).  Two recent studies report significant linkage of RE-MDD to 
chromosome 11 (multi-point LOD 4.2, p<0.001 for marker D11S1984; and 
LOD 2.51, p<0.001 for marker D11S2002) (173) and to chromosome 15 (LOD 
3.73, p=0.023, flanked by markers D15S652 and D15S816) (174), 
independent of gender.  These results do not overlap with the regions 
implicated previously for specific gender.  Reasons for this discrepancy may 
be that a ‘clearer’ signal may have been available when examining each 
gender independently.  Additionally, different markers and families were used 
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in these studies, and thus replication in different families is needed.  Lastly, 
the lack of overlapping regions may be due to none of these regions being the 
disease locus, but rather being susceptibility loci (173).  Further it is possible 
that since MDD is a complex disease that these regions may all be important 
in the etiology of MDD.  Regardless, these studies demonstrate regions of the 
genome having an effect on MDD, with RE-MDD deemed to be the most 
genetic subtype of MDD. 
E. Candidate Gene Studies  
Table 1.13 displays information on candidate gene association studies 
of MDD.  Most of these studies did not examine the same gene, however 
many studies have examined SLC6A4 and various serotonin receptors.  
These candidate genes are involved in the biochemical neurotransmission 
pathways hypothesized to cause depression, or are the site of antidepressant 
drug activity (175).  These studies used both in- and out-patients diagnosed 
with MDD through use of interviews and case notes to obtain DSM-IV MDD 
diagnoses.   
The following genes demonstrated positive associations with MDD: 
SLC6A4(I/D) (176-178), SLC6A4(VNTR, allele9) (177, 179), SLC6A4(VNTR, 
allele12) (180), SLC6A4(VNTR, allele2) (181), PLA2 (182), TPH1 (183), 
DRD4 (184), HTR1B (185), CYP2C9*3 (186), HTR2C (115), MAOA (116, 
187), CRHR2 (188), TPH2 (189), GABRA3 (190), TH (191, 192), HTR2A 
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(193), and GNAL (194).  The majority of progress is in the serotonin system, 
although most findings have no replication and suffer from inadequate power.  
A meta-analysis for the SLC6A4 (I/D) polymorphism demonstrated a non-
significant summary effect of the polymorphism on the risk of MDD (OR 1.08, 
95% CI 0.96-1.22, p=0.198) (195).  The meta-analysis further pooled results 
of prior studies for the SLC6A4 (VNTR) polymorphisms.  Overall, none of the 
alleles (9, 10, or 12) showed an increased risk for MDD (195), results in Table 
1.14.  The results of the meta-analysis should be considered preliminary, as it 
combined results from various regions of the world and used differing 
diagnostic instruments for the diagnosis of MDD.  Thus future studies should 
be larger, aim to replicate initial positive findings in the same geographic 
region, use similar diagnostic instruments and criteria for MDD, and 
investigate other genes with hypothesized involvement in the pathophysiology 
of MDD. 
Limitations.  A problem with many of these studies is control 
selection.  Many controls were not screened for psychiatric disorders.  
Additionally, all these studies are underpowered to detect small effects (OR of 
1.2-1.3).  The type II error rate is also large due to multiple comparisons.  
Spurious associations are also a concern when the cases and controls are 
not matched properly (86).  Misclassification of the genotype (exposure) is 
possible due to laboratory errors (196), although these are becoming less.  
Disease misclassification may have an effect due to disease heterogeneity, 
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phenocopies, and age-related penetrance (93).  Specifically for MDD, relying 
on DSM criteria for disease classification causes problems because the 
diagnosis is based on fulfillment of these criteria and not on biology or 
biological tests (154), and this may dilute a true effect by causing 
heterogeneity by including as diseased individuals that may have a different 
causal pathway for their disease.  Lastly, ethnicity may have an affect on the 
results for some of the polymorphisms, as allele frequencies vary between 
different populations/ethnicities (94).  However the majority of these studies 
were completed in one ethnicity and thus within study population stratification 
is minimized, but between studies there is evidence of population stratification 
as differing results were demonstrated in different populations.  This is clearly 
demonstrated for SLC6A4 (VNTR) where significant results were found 
among English/Scottish (179), and Han Chinese (180), but non-significant 
results were demonstrated among Germans (197), Japanese (198, 199), 
French (200), Spanish (201), and Danish (202).  
1.2.9 Lifetime Co-morbid IBS and MDD 
A. Definition of ‘Lifetime Co-morbid’ 
For this study, the phrase ‘lifetime co-morbid’ means that an individual 
has had both disorders at some point in their lifetime, not necessarily at the 
same time.  This is due to the chronicity as well as the waxing and waning of 
 52
both IBS and MDD symptoms, and the fact that the causality between IBS 
and MDD is not known. 
B. Epidemiology of Co-morbid IBS and MDD 
Psychological disorders are common co-morbid conditions in most IBS 
patients who actively seek subspecialist medical care (7).  Patients with major 
depression and any IBS were more likely to have a personal or family history 
of bowel disease, but not more likely to be treated for their gastrointestinal 
problems (39).  Among elderly, slow colonic transit in constipated individuals 
has been associated with increased psychological symptoms (203). 
There have been a number of studies which captured information 
regarding psychiatric disorders in IBS patients and vice versa.  In these 
studies, there is some consensus among the findings, but also a few 
inconsistent findings, as summarized below.  The largest consensus is that 
there is an overlap of MDD and IBS, where approximately 50% of the 
sufferers of either disorder have the other disorder as well. 
In two studies of IBS patients, one using a structured interview (37) 
and one using a self-rating scale for depression (38), it was found that IBS 
patients have psychopathology that is diagnosed more often and are more 
anxious and depressed than either inflammatory bowel disease (IBD) patients 
or healthy controls (37).  In addition, depression scores were significantly 
higher among patients with IBS compared to controls (38).   
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Mayer et al. have summarized studies of IBS patients seeking care at 
GI clinics and found that in studies with an adequate sample size and a 
standardized psychiatric interview, 50-60% of IBS patients also have 
psychiatric disorders (204).  The most commonly observed psychiatric 
disorders found in these IBS patients are major depression, panic disorder, 
social phobia, generalized anxiety disorder, post-traumatic stress disorder, 
and somatization disorder (205).  There is some evidence that depression is 
more common in patients suffering from chronic IBS symptoms, and anxiety 
may be more prominent early in the course of IBS (204, 205).  Of IBS patients 
seeking specialist care, 54-94% met Diagnostic and Statistical Manual, third 
edition revised (DSM-III-R) criteria for a primary (Axis I) psychological 
disorder (206), but only 18% of IBS patients in a population-based study met 
Diagnostic and Statistical Manual, third edition (DSM-III) criteria for a primary 
psychiatric disorder (207).  Of psychiatric disorders, major depression has 
been shown to precede IBS or partial IBS in 50% of subjects, and to follow 
IBS in 45.8% of subjects with the remaining 4.2% having IBS and psychiatric 
disorders diagnosed at approximately the same time (39).   
Additionally, in a study of psychiatric patients, the point prevalence of 
IBS was 29% in patients with major depression and 37% in generalized 
anxiety disorder patients as compared to 11% in the controls (39).  In a recent 
population study in New Zealand, the association between MDD and IBS was 
not substantiated (29).  This was the first study to define IBS using Rome II 
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criteria, which may have had an effect on the association since these are the 
most restrictive IBS criteria.  However, the authors concluded that the high 
rates of psychiatric disorders in IBS patients reported in prior studies using 
referral centers probably reflects referral bias (29).   
In population-based samples, subjects who reported two GI symptoms 
had significantly higher lifetime prevalence rates for depression, panic 
disorder, and agoraphobia than those who reported no GI symptoms (204).  
In a community study, lifetime psychiatric disorders are significantly more 
common in individuals meeting diagnostic criteria for IBS (63%) than in those 
without IBS (24.8%) (205).  Additionally, the association of IBS and 
psychiatric disorders appeared to be independent of treatment seeking status 
(205).  Similarly, in the IBS review by Camilleri et al., more psychiatric 
disease was observed in the general population of IBS sufferers implying that 
the increase in psychiatric disease among IBS sufferers was not due to health 
care seeking bias (208).     
C. Limitations of Prior Research 
These studies are problematic and more research on the co-
occurrence of MDD and IBS is needed.  The majority of studies on co-
occurrence have not been population-based, rather only considering patients 
which have sought treatment.  Thus they may not be representative of all 
individuals with IBS and MDD and may suffer from referral bias as well as 
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treatment-seeking bias.  Also, the diagnostic criteria used to define IBS were 
not specified in many of the studies, although it could be assumed to be either 
Rome I or Manning based on the date of the studies.  In one study, neither of 
these criteria were used, but rather criteria that were referred to as ‘Drossman 
criteria’ (39).  Therefore, using the more recent Rome II criteria and a 
population based sample could make the results more generalizable to the 
population of individuals with IBS, both those that do and do not seek 
treatment. 
1.2.10 Role of Genetics in Lifetime Co-morbid IBS and MDD 
A. Familial Overlap of IBS and MDD 
There have been 5 studies examining the familiality of IBS, as 
discussed in detail on page 19.  Similarly, there are at least 11 family studies 
of MDD, discussed previously on page 45.  From these studies, there is 
support of a familial (environmental or genetic) component to both of these 
disorders independently.  Additionally, it has been shown that patients with 
major depression and any IBS were more likely to have a personal or family 
history of bowel disease but not more likely to be treated for their 
gastrointestinal problems (39).   
The familial overlap of IBS and major depression was demonstrated in 
a study conducted by Sullivan et al. (209).  This study showed that patients 
with both IBS and major depression had a similar, higher prevalence of 
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relatives with psychiatric illness than controls, attributable to a higher 
prevalence of anxiety and depressive disorder in the relatives (209).  
Additionally, Hudson et al. remarked that relatives of individuals with IBS 
display a higher prevalence of major affective disorder than relatives of 
control subjects (210). 
In a small family study by Woodman et al., IBS probands (defined with 
Manning criteria) had a greater frequency of lifetime psychiatric disorders 
than control probands, and this was also demonstrated when major 
depression was separated out from other psychiatric disorders (211).  This 
study also demonstrated familiality of IBS and MDD because relatives of IBS 
probands demonstrated more lifetime depression than relatives of control 
probands.  A drawback of this study, aside from its small size, is that it is not 
population based and thus it is not known if the psychiatric disorders in IBS 
probands contributed to their treatment seeking (211). 
B. Treatment Response Subgroups 
The prevailing thought in research on co-occurrence is that response 
to pharmacologic treatments may identify groups of disorders with a common 
pathophysiology (210).  Support for this hypothesis is from patients 
demonstrating an improvement in their co-occurring disorders with several 
different classes of antidepressant drugs which are chemically unrelated.  The 
disorders may share a specific biologic abnormality, either known or 
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unknown, in common with major depression, and thus the various classes of 
antidepressant drugs may benefit the disorders via their effect on the 
particular biologic abnormality in common (212). 
Specifically with regard to IBS and major depression, patients with IBS, 
regardless of the presence of psychiatric symptoms, respond to three 
chemically different classes of antidepressant medications.  These are 
tricyclic antidepressants, monoamine oxidase inhibitors, and selective 
serotonin reuptake inhibitors (8, 14, 210).   
C. Serotonin to Treat IBS and MDD 
Indirectly, the therapeutic use of serotonin to treat both MDD and IBS 
independently suggests the possibility of a common etiology, and further a 
possible common genetic or environmental etiology.  Recently, investigation 
into the role of serotonin in the gut of IBS sufferers has begun (8), as 
discussed previously on page 17.  Additionally, serotonin is also involved in 
treating major depression, as one of the major classes of drugs used for 
treatment is selective serotonin reuptake inhibitors (SSRIs).  Thus, serotonin 
abnormalities may represent a common pathophysiology between IBS and 
various disorders often found to be co-morbid with IBS, such as depression, 
anxiety disorders, fibromyalgia, migraine, drug abuse, and eating disorders 
(53, 54, 131). 
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The function of the serotonin transporter protein (SLC6A4) is to 
remove 5-HT from the synaptic cleft and determine the magnitude and 
duration of postsynaptic receptor-mediated signaling, thus playing a pivotal 
role in the fine-tuning of 5-HT neurotransmission (213).  Serotonin transporter 
functions are dysregulated in depression (142).   
A polymorphism in the promoter for the synthesis of the serotonin 
transporter gene, SLC6A4, is known to influence the response to serotonergic 
medications in depression.  Recently, genetic polymorphisms (long, short, 
and heterozygous) at the SLC6A4 promoter have been shown to influence 
response to a 5-HT3 antagonist in diarrhea-predominant IBS (76).  SLC6A4 
polymorphisms were associated with colonic transit response, specifically, 
there was a greater response to 5-HT3 antagonists in those with long 
homozygous versus heterozygous polymorphisms (76).  Thus SLC6A4 has 
demonstrated biological importance in both IBS and MDD.   
D. Summary 
Through this review of the literature, commonalities between IBS and 
MDD exist and have been highlighted.  For IBS, family, twin, and population 
based studies demonstrate that both genes and environment are important in 
its etiology.  Likewise in MDD the relevance of genes and environment to its 
etiology is demonstrated in family, adoption, twin, and population based 
studies.  Additionally, IBS and MDD have a demonstrated tendency to affect 
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the same individual over the course of their lifetime.  Further, a commonality 
in their possible etiologies, namely the influence of the neurotransmitter 
serotonin, suggests that the demonstrated co-occurrence may not be 
spurious but possibly due to a common deficiency or dysfunction.  Thus 
common genetic and/or environmental effects may explain the demonstrated 
covariation between IBS and MDD.   
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1.3 TABLES 
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Table 1.1: Manning, Rome I, and Rome II Diagnostic Criteria for Irritable Bowel Syndrome. 
 
Manning Criteria (27) Rome I Criteria (8) Rome II Criteria (8) 
Two or more of the following 
symptoms 
At least 3 months of continuous or 
recurrent symptoms of abdominal pain 
that is: 
12 or more weeks of continuous or 
recurrent abdominal pain or discomfort 
     Pain eased after bowel movement      Relieved by defecation  
              And/or 
Plus at least 2 of the following: 
     Looser stools at onset of pain      Associated with a change in stool 
     consistency  
              And/or 
     Relieved by defecation 
               And/or 
     More frequent bowel movements at 
onset of pain 
     Associated with a change in frequency
     of stool 
     Associated with change in frequency 
     of stool 
               And/or          
     Abdominal distension Plus 2 or more of the following greater 
than 25% of the time: 
     Associated with a change in form 
     (appearance) of stool 
     Mucus per rectum      Altered stool frequency (more than 3 
per day or less than 3 per week) 
 
     Feeling of incomplete emptying      Altered stool form (lumpy, hard or 
watery, loose) 
 
      Altered stool passage (straining, 
urgency, or incomplete evacuation) 
 
      Passage of mucus  
      Bloating or feeling of abdominal 
distension  
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Table 1.2: Red flags in diagnosing Irritable Bowel Syndrome. 
 
Anemia 
Family history of colon cancer or inflammatory bowel disease 
Fever 
Heme-positive stools 
New or recent onset in patient older than 50 years of age 
Nocturnal symptoms 
Palpable abdominal or rectal mass 
Persistent diarrhea or severe constipation 
Recent antibiotic use 
Rectal bleeding 
Weight loss 
 
 
Table 1.3: IBS prevalence stratified by diagnostic criteria. 
 
Criteria Prevalence Range Reference 
Manning 10.3-20.4% (5, 9, 23, 24, 28, 29) 
Rome I 8.5-12% (23-25, 28) 
Rome II 3.3-7% (5, 23, 26, 29-31) 
  
 
Table 1.4: International population-based IBS prevalence ranges. 
 
Country Sample 
Size(s) 
Manning 
Range 
Rome I 
Range 
Rome II 
Range 
Australia/New 
Zealand (5, 28, 29) 
730; 2910; 
890 
12.7%-
13.6% 
4.4%-12% 4.3%-6.9% 
Bangladesh (25) 2426  8.5%  
Canada (21) 1149  13.5% 12.1%* 
Europe (UK, France, 
Germany, Italy, 
Holland, Belgium, 
Spain, Switzerland) 
(10) 
 6.5% 4.2% 2.9% 
Hong Kong (20, 30) 1649; 1000  4.1% 6.6% 
Spain (23) 2000 10.3% 12.1% 3.3% 
United States (9, 24) 3022; 643 18-20.4% 8.5%  
   *modified Rome II criteria 
  
Table 1.5: Family Studies of IBS*. 
 
Authors Setting Sample size IBS definition Method of 
family 
member 
assessment 
Adjustment 
variables 
Results 
Oster, J 
(214) 
School 
children 
18,162 over 8 
years of follow-up 
635 children 
examined each 
year for 5 or more 
consecutive years 
185 had 
abdominal pain 
for 3 or more 
consecutive years 
Abdominal pain Questionnaire 
sent to parents 
of case and 
control children 
 Children with pain came 
from families where 
parents were prone to 
pain 
 
OR 2.29 (95% CI 1.69-
2.89) 
      
      
 
Whorwell, 
PJ, et al. 
(84) 
IBS 
outpatients 
100 IBS patients 
100 matched 
controls 
Abdominal pain, 
abdominal 
distension, and 
abnormal bowel 
habit in 
association with 
normal 
hematology, 
serum 
biochemistry, 
rectal history, and 
colonoscopy or 
contrast radiology 
 
No direct 
assessment 
 
Participants 
asked if there 
was a family 
history of IBS 
Age, gender, social 
class 
Familial incidence of IBS 
is 33% 
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Table 1.5 (Continued): Family Studies of IBS*. 
 
Authors Setting Sample size IBS definition Method of 
family 
member 
assessment 
Adjustment 
variables 
Results 
Locke, GR, 
et al. (60) 
Population-
based 
cohort in 
Olmsted 
County, MN 
643 (76 with IBS) 
First degree 
relatives 
     With 
abdominal  
     Symptoms, 
148 
     Without 
abdominal 
     Symptoms, 
475 
Spouse 
     Present 
abdominal  
     Symptoms, 
132 
     Absent 
abdominal 
     Symptoms, 
475 
Rome I Self-report 
questionnaire 
asked about GI 
symptoms of 
spouse and 1st 
degree 
relatives history 
of abdominal 
pain or bowel 
problems 
Age, gender, 
psychosomatic 
symptoms 
IBS prevalence 12% 
 
When abdominal 
symptoms were present 
in first degree relative the 
odds of IBS were twice 
as great (OR 2.3; 95%CI 
1.3-3.9), adjusted for age, 
sex, and psychosomatic 
symptom checklist score 
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Table 1.5 (Continued): Family Studies of IBS*. 
 
Authors Setting Sample size IBS definition Method of 
family 
member 
assessment 
Adjustment 
variables 
Results 
Kalantar, 
JS, et al. 
(82) 
IBS patients 
and IBS 
people in 
educational 
classes 
(Olmsted 
County, 
MN) 
181 IBS patients 
153 relatives of 
patients 
98 spouse 
relatives 
97 children 
Manning or Rome 
I 
(Manning used for 
analysis since all 
Rome I also 
fulfilled Manning) 
Participants 
asked for name 
and address of 
relatives and 
then relatives 
sent Bowel 
Disease 
Questionnaire 
Age, gender 
OR attenuated 
when additional 
control from 
somatization score 
IBS prevalence of 17% in 
patients’ relatives 
 
IBS prevalence of 7% in 
spouses’ relatives 
 
OR 2.72 (1.19-6.25) 
       
Kalantar, 
JS, et al. 
(83) 
Longitudinal 
population-
based study 
in Olmsted 
County, MN 
523 total 
404 controls 
119 IBS 
Rome I Participant 
questionnaire 
asked specific 
questions 
about 1st 
degree 
relatives 
abdominal 
aches, pains, 
or bowel 
problems 
Age, gender, 
somatic symptom 
score 
IBS prevalence 11-12% 
 
Positive family history of 
IBS in 23% of subjects 
 
Increased odds of 
persistent IBS among 
those with a family 
member with symptoms, 
OR 2.51 (95% CI 1.28-
4.90) 
 
Increased odds of 
fluctuating IBS among 
those with a family 
member with symptoms, 
OR 2.38 (95% CI 1.30-
4.37) 
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*IBS= irritable bowel syndrome; OR= odds ratio; 95% CI= 95% confidence interval; GI=gastrointestinal 
 
67
   
Table 1.6: Twin studies of IBS*. 
  Authors Setting Sample size IBS
definition 
Adjustment 
variables 
Results 
Morris-Yates, A, et 
al. (91) 
Volunteer twins in 
Australian twin registry 
462 twin pairs (924 
twins) 
Functional 
bowel disorder 
(greater than 1 
symptom) 
Gender MZ IBS concordance 33.3% 
 
DZ IBS concordance 13.3% 
 
Genetic liability to FBD 
estimated at 58% 
 
A2=0.754 
C2=0.657 
Levy, RL, et al. (61) Population-based 
registry of twins in the 
Commonwealth of 
Virginia 
6060 twin pairs 
(10,699 twins) 
281 pairs had 1 or 
both twins with IBS 
Self-report of 
IBS diagnosis 
Father with IBS, 
Mother with IBS, 
co-twin with IBS 
IBS prevalence 2.6% 
 
MZ IBS concordance 17.2% 
 
DZ IBS concordance 8.4% 
 
Having either a mother or 
father with IBS is greater risk 
of IBS than having a twin 
with IBS 
Svedberg, P, et al. 
(90) 
Population-based 
registry of twins in 
Sweden 
850 twin pairs (58 
twin pairs discordant 
for IBS, 72 unrelated 
IBS cases) 
Diagnostic 
algorithm that 
combined 
abdominal 
problems at 
least 7 days a 
month with 1 
additional IBS 
symptom 
Case-control 
study: Age, 
gender 
Case-control study 
demonstrated associations 
between 5 disorders and 
IBS 
 
Co-twin analysis determined 
that three of these disorders 
may be due to common 
genetic effects between IBS 
and the disorder 
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Table 1.6 (Continued): Twin studies of IBS*. 
  Authors Setting Sample size IBS
definition 
Adjustment 
variables 
Results 
Mohammed, I, et al. 
(92) 
Population-based 
registry of twins in the 
United Kingdom 
1870 twin pairs (888 
MZ twin pairs and 
982 same sex DZ 
twin pairs) 
Self-report 
mailed 
questionnaire; 
past-year 
Rome II IBS 
Matched for age, 
drug therapy, 
excess alcohol, 
psychosomatic 
score, and 
handedness 
MZ IBS concordance: 28% 
 
DZ IBS concordance: 27% 
 
Twin modeling revealed 
genetic factors of little or no 
influence on IBS 
*MZ= monozygotic twin; DZ= dizygotic twin; IBS=irritable bowel syndrome; FBD= functional bowel disorder; a2=additive genetic effect; 
c2=common environmental effect
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Table 1.7: Genetic Association Studies for IBS*. 
 
Gene 
(Polymorphism) 
Population Study Size Results Reference 
TGFB1 promoter 
(C-509T) 
IBD/ 
Crohn’s 
Disease 
Association 141 IBD 
88 Healthy 
controls 
NS Schulte, 
CMS, et al. 
(215) 
SLC6A4 (VNTR 
and 5-HTTLPR) 
IBS (Rome 
I) 
Association 54 IBS 
91 Healthy 
controls 
NS Pata, C, et al. 
(81) 
SLC6A4 (SERT-
P) 
Diarrhea-
predominan
t IBS  
(Rome I) 
Treatment 
response  
30 IBS 
patients  
(23 with 
genotyping) 
L/L 
influence 
delayed 
colonic 
emptying 
Camilleri, M, 
et al. (76) 
IL10 (-1082) Out-patient 
clinic,  
Rome I IBS 
Association 230 IBS  
450 Healthy 
controls 
1.17 
(0.93, 
1.49) 
Gonsalkorale
, WM, et al. 
(216) 
TGFB1 (869 and 
915) 
Out-patient 
clinic,  
Rome I IBS 
Association 134 IBS 
127 Healthy 
controls 
NS Gonsalkorale
, WM, et al. 
(216) 
*NS=not significant at p=0.05; IBD= inflammatory bowel disease; IBS= irritable bowel 
syndrome 
 
Table 1.8: International population-based studies of the prevalence of MDD*. 
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Prevalence
Location     MDD definition Sample
Size 
 Current 6-Month 1-year Lifetime Reference
New Haven, CT DIS?DSM-III    
    
      
      
       
       
       
     
5,038 Men: 1.7
Women: 4.1 
 
Men: 2.1 
Women: 4.9 
 
Men: 3.8 
Women: 8.2 
 
Weissman, MM 
(120) 
USA (Epidemiologic 
Catchment Area) 
DIS?DSM-III 18,572 2.2 3.0** 5.2** Bland, RC (123)
Weissman, MM 
(124) 
Edmonton, Canada DIS?DSM-III 3.2 5.2** 9.6** Bland, RC (123)
Weissman, MM 
(124) 
Puerto Rico DIS?DSM-III 3.0 3.0** 4.3** Bland, RC (123)
Weissman, MM 
(124) 
Paris, France DIS   4.5** 16.4** Bland, RC (123) 
Weissman, MM 
(124) 
Florence, Italy DIS   5.2 12.4** Bland, RC (123) 
Weissman, MM 
(124) 
Beirut, Lebanon DIS 19.0** Bland, RC (123)
Weissman, MM 
(124) 
Seoul, Korea DIS 2.3** 2.9** Bland, RC (123)
Weissman, MM 
(124) 
Taiwan DIS 0.8** 1.5** Bland, RC (123)
Weissman, MM 
(124) 
New Zealand DIS 
~38,000 
combined 
5.3 5.8** 11.6** Bland, RC (123)
Weissman, MM 
(124) 
 
Table 1.8 (Continued): International population-based studies of the prevalence of MDD*. 
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Prevalence
Location     MDD definition Sample
Size 
 Current 6-Month 1-year Lifetime Reference
USA (National 
Comorbidity Study) 
CIDI        10.3 17.1 Bland, RC (123)
Ontario, Canada CIDI, DSM-III-R        
     
       
       
       
         
4.1
Men: 2.8 
Women: 5.4 
 
Bland, RC (123)
Britain (National 
Survey of Psychiatric 
Morbidity) 
Clinical Interview 
Schedule?ICD-
10 
10,108 Age 16-54 
Men: 1.7 
Women: 
2.7 
 
Age 55-64 
Men: 2.0 
Women: 
1.1 
Bebbington, PE
(96) 
USA (National 
Comorbidity Survey) 
CIDI?DSM-III-R 1,769 5.8 12.4 15.3 Kessler, RC
(217) 
USA (National 
Comorbidity Survey-
Replication) 
CIDI?DSM-IV 9,090 6.6 16.2 Kessler, RC
(111) 
Australia (Australian 
National Survey of 
Mental Health and 
Well-Being) 
CIDI 10,641 3.2 Wilhelm, K (126)
Canada CIDI 501 10.4 Patten, SB (125)
* DIS=Diagnostic Interview Schedule; DSM-III=Diagnostic and Statistical Manual, third edition; CIDI=Composite International Diagnostic 
Interview; DSM-III-R=Diagnostic and Statistical Manual, third edition, revised; ICD-10=International Classification of Diseases, tenth 
edition; DSM-IV=Diagnostic and Statistical Manual, fourth edition 
 
** Rates standardized to the US population, ages 18-65 
 
Table 1.9: Family Studies of Major Depressive Disorder*. 
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Author Population Sample size MDD definition Results
Tsuang MT, et al. 
(218) 
Admissions to University 
of Iowa Psychiatric 
Hospital between 1934 
and 1944 
Probands: 
200 
Schizophrenics 
100 Manics 
225 Depressives 
Relatives: 
1578 Total first 
degree relatives 
467 First degree 
relatives of 
depressives 
Iowa Structured 
Psychiatric 
Interview Form 
(personal interview) 
MDD prevalence: 
8.8% among first degree relatives of MDD 
probands 
4.6% among control probands 
 
Morbidity risk of MDD: 
12.0 ± 1.76 among first degree relatives 
of MDD probands 
7.3 ± 1.40 among control probands 
 
Gershon ES, et al. 
(219) 
Patients admitted for 
treatment of affective 
disorders at the National 
Institute of Mental Health 
 
Controls were admitted to 
medical institutes of 
National Institute of 
Health (psychiatrically 
normal) 
172 Probands 
(30 MDD 
probands, 43 
Control probands) 
 
1254 relatives of 
probands and 
controls 
Schedule of 
Affective Disorders 
and Schizophrenia-
Lifetime Version 
(SADS-L) and 
Research 
Diagnostic Criteria 
(RDC) 
Lifetime prevalence of major affective 
disorder: 
20% in relatives of MDD proband 
7% in normal controls 
 
Morbidity risk of major affective disorder: 
74% when both parents affected 
27% when only one parent affected 
 
In controls, prevalence of major affective 
disorder in relatives lower than in proband 
relatives 
 
Table 1.9 (Continued): Family Studies of Major Depressive Disorder*. 
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Author Population Sample size MDD definition Results
Weissman MM, et 
al. (220) 
Community sample in 
New Haven, CT 
 
Depressed probands 
received treatment at 
Yale outpatient between 
1968 and 1977 
335 Probands (163 
MDD probands) 
82 Normal controls 
2003 First degree 
relatives 
Modified SADS-L 
and RDC 
Age-adjusted rate of MDD in first degree 
relative: 
17.2-18.4/100 among mild and severe 
MDD probands 
5.9/100 among normal controls 
 
Odds ratios of MDD: 
2.48 for severe MDD vs normal controls 
2.71 for mild MDD vs normal controls 
 
MDD aggregated in relatives of probands 
with mild and severe MDD 
Maier W, et al. (221) Psychiatric inpatients at 
hospital of University of 
Mainz, Germany 
 
Controls were people in 
Mainz with at least one 
accessible first degree 
relative 
525 Probands (184 
MDD probands) 
109 General 
population control 
probands 
514 Interviewed 
relatives of MDD 
probands 
320 Interviewed 
general population 
control relatives 
SADS-L, RDC, and 
some medical 
records 
Prevalence of MDD: 
11.7% in relatives of MDD probands 
7.2% in normal controls 
9.0% in alcoholic controls 
 
Lifetime morbidity risk of MDD: 
21.6% in MDD proband relatives 
10.6% in control relatives 
12.0% in alcoholic control relatives 
 
Table 1.9 (Continued): Family Studies of Major Depressive Disorder*. 
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Author Population Sample size MDD definition Results
Weissman MM, et 
al. (222) 
Cases: specialty clinics at 
Yale University; the 
Connecticut Mental 
Health Center, New 
Haven (Anxiety Research 
Clinic and the Depression 
Research Unit); and the 
New Haven site of the 
Epidemiologic Catchment 
Area (ECA) study 
 
Controls: ECA study 
controls 
193 Probands (148 
MDD, 45 control) 
1047 Adult 
relatives 
SADS-L and RDC Aggregation of early-onset MDD, 21%, in 
relatives of probands with early-onset 
MDD 
 
Probands with early-onset MDD had 5 
fold increased risk of early-onset MDD 
(OR 5.29, 95% CI 2.7-10.4) 
 
Early-onset MDD is not familialy 
associated with late-onset MDD 
Sullivan PF, et al. 
(159) 
Meta-analysis  5 previously
reported studies 
 OR for proband 2.84 (95% CI 2.31-3.49) 
Weissman MM, et 
al. (160) 
Probands’ parents from 
the Yale Family Study of 
Major Depression 
220 children from 
91 families: 125 
children of 56 
depressed 
probands and 95 
children of 35 
normal probands 
SADS-L and RDC 
 
Children: K-SADS-
E 
Children of depressed probands reported 
more depression (RR 1.6, p<0.05) 
 
Children of depressed probands had a 
lower mean age of  onset of depression 
(12.7 years) than children of normal 
probands (16.8 years), p<0.001 
 
Table 1.9 (Continued): Family Studies of Major Depressive Disorder*. 
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Author Population Sample size MDD definition Results
Hammen C, et al. 
(161) 
Australian birth cohort of 
children born between 
1981 and 1984 at the 
Mater Misericordiae 
Mother’s Hospital in 
Brisbane, Queensland 
816 mothers and 
their 15-year old 
adolescent children 
Mothers: SCID 
 
Children: K-SADS-
E 
Children of mothers with major 
depression by age 10 were significantly 
more likely to have experienced major 
depression (χ2=14.05, p<0.001, 20% 
depressed mothers and 10% non-
depressed mothers) 
 
Children of mothers with only one major 
depressive episode had significantly 
higher rates of diagnosed depression 
(19% vs 10%; χ2=6.83, p<0.001) 
Lieb R, et al. (162) Early Development 
Stages of 
Psychopathology Study 
(EDSP); 14-24 years at 
baseline; community; 
Germany 
2427 respondents 
who completed the 
whole study period 
and for whom 
diagnostic 
information about 
psychopathology in 
both parents was 
available 
Offspring: M-
CIDI/DSM-IV 
 
Parental History: 
M-CIDI family 
history module 
Offspring of either 1 or 2 depressed 
parents reported higher rates of 
depression (26.1% and 28.5% versus 
12.3%) 
 
Parental major depression increases 
offspring risk of depression 
 
Table 1.9 (Continued): Family Studies of Major Depressive Disorder*. 
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Author Population Sample size MDD definition Results
Klein DN, et al. (164) Oregon Adolescent 
Depression Project family 
study; community sample 
of adolescents 
30 probands with 
lifetime history of 
dysthymic disorder 
65 probands with 
history of chronic 
MDD 
313 probands with 
history of episodic 
MDD 
392 probands with 
no lifetime history 
of any mood 
disorders 
 
2750 First-degree 
relatives 
Adolescents: 
Schedule for 
Affective Disorders 
and Schizophrenia 
for School-Age 
Children, with 
additional items to 
derive DSM-III-R 
diagnoses 
 
Relatives: SCID, 
non-patient 
version; family 
history by the 
Family Informant 
Schedule and 
Criteria, modified 
for DSM-IV 
diagnoses 
Relatives of chronic MDD probands had a 
higher rate of MDD than either relatives of 
episodic MDD probands or relatives of 
probands with no history of mood 
disorders (HR=1.41, 95% CI=1.07-1.87, 
p<0.02; HR=2.08, 95% CI=1.56-2.76, 
p<0.001, respectively) 
 
Attenuation of rate of MDD when 
comparing relatives of episodic MDD 
probands to probands with no history of 
mood disorders (HR=1.47, 95% CI=1.21-
1.79, p<0.001) 
 
Similar relationships existed when 
examing the rate of recurrent MDD 
 
Rate of chronic MDD was greater in the 
relatives of chronic MDD probands than in 
the relatives of probands with no history 
of mood disorders (HR=2.30, 95% 
CI=1.26-4.20, p<0.01) 
 
Higher rates of episodic MDD were found 
among relatives of chronic MDD probands 
(HR=1.91, 95% CI=1.38-2.65, p<0.001) 
and among relatives of epidsodic MDD 
probands (HR=1.46, 95% CI=1.17-1.81, 
p<0.001), compared with relatives of 
probands with no history of mood 
disorders 
 
Table 1.9 (Continued): Family Studies of Major Depressive Disorder*. 
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Author Population Sample size MDD definition Results
Klein DN, et al. (163) Oregon Adolescent 
Depression Project family 
study; community sample 
of adolescents 
268 adolescents 
with MDD 
110 adolescents 
with a history of 
non-mood 
disorders but no 
history of MDD 
291 adolescents 
with no history of 
psychopathology 
through age 18 
2202 first-degree 
relatives 
Adolescents: 
Schedule for 
Affective Disorders 
and Schizophrenia 
for School-Age 
Children, with 
additional items to 
derive DSM-III-R 
diagnoses 
 
Relatives: SCID, 
non-patient 
version; family 
history by the 
Family Informant 
Schedule and 
Criteria, modified 
for DSM-IV 
diagnoses 
Rate of MDD was significantly elevated in 
the relatives of adolescent probands with 
a history of MDD (HR=1.77; 95% CI 1.46-
2.31) 
 
Rate of MDD in relatives did not differ as 
a function of sex of the proband 
 * MDD= major depressive disorder; SADS-L=schedule of affective disorders and schizophrenia-lifetime version; RDC=research 
diagnostic criteria; OR=odds ratio; 95% CI= 95% confidence interval; RR= risk ratio; M-CIDI=maternal-composite international diagnostic 
interview; DSM-IV= Diagnostic and Statistical Manual, fourth edition; HR=hazard ratio; SCID=structured clinical interview for DSM-IV; 
DSM-III-R= Diagnostic and Statistical Manual, third edition, revised 
 
 
Table 1.10: Adoption Studies of Major Depressive Disorder*. 
 
Author Population Sample size MDD definition Results 
Von Knorring AL, et 
al. (165) 
Stockholm Adoption 
Study (adoptive and 
biologic mothers and 
fathers of adoptees 
with affective 
disorders and 
histories of 
substance abuse) 
115 adoptees with 
disorder 
115 control adoptees 
biologic and 
adoptive mothers 
and fathers 
 
Health insurance: F-
card psychiatric 
illness, defined by 
being on the National 
Health Insurance 
Board sick list at 
least 2 weeks with 
psychiatric diagnosis 
(ICD-8, codes 290-
309) and treated as 
outpatients or 
inpatients in a 
psychiatric 
department or 
mental hospital 
Risk of affective disorder: 
6.1% in biologic mothers 
2.5% in biologic fathers 
3.0% in both adoptive mothers and fathers 
 
No evidence of familial aggregation of 
parents and adoptees with same diagnosis 
among biologic relatives 
 
Concordance for psychiatric treatment 
among adoptive fathers and their children 
 
Psychiatric patients had a 5-fold excess of 
adoptive fathers with psychiatric illness 
compared to fathers of matched controls 
 
Biologic mothers of female patients had a 
3-fold increase in psychiatric illness 
compared to mothers of matched controls 
Wender PH, et al. 
(167) 
Denmark adoptees 
Cases: adoptees with 
affective disorders 
 
Controls: 
demographically 
matched adoptees 
without known mental 
illness 
71 cases (27 with 
MDD) 
71 controls 
Cases: discharge 
diagnoses from 
psychiatric facility 
(taken from 
Psychiatric Register 
and the Register of 
the Bispebjerg 
Hospital) 
 
Relatives: DSM-III as 
taken from death and 
psychiatric records 
Biologic relatives had greater frequency of 
same affective disorders as the index case 
(p=0.03) 
 
No difference in frequency of MDD among 
index and control among adoptive relatives 
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Table 1.10 (Continued): Adoption Studies of Major Depressive Disorder*. 
 
Author Population Sample size MDD definition Results 
Cadoret RJ, et al. 
(166) 
Adoptees from two 
agencies in Iowa: 
Iowa Children’s and 
Family Services and 
Lutheran Social 
Services (both in Des 
Moines, IA) 
443 adoptees (48 
with MDD) 
DSM-III major 
depression (SADS-L, 
DIS, or earlier 
interview based on 
Feighner criteria) 
Exposure to environmental factors before 
age 18 of the adoptees predisposed them 
to depression 
 
Correlation of MDD with a biologic 
background of affective disorders: 
Men: 15% of those with MDD had a 
biologic relative with affective disorder 
7% of those with MDD did not have a 
biologic relative with affective disorder 
Women: 28.6% of those with MDD have a 
biologic relative with an affective disorder 
13.9% of those without MDD did not have 
a biologic relative with an affective 
disorder 79
*ICD-8=International Classification of Diseases, 8th edition; MDD=major depressive disorder; DSM-III= Diagnostic and Statistical Manual, 
third edition; SADS-L=schedule of affective disorders and schizophrenia-lifetime version; DIS=diagnostic interview schedule 
 
 
Table 1.11: Twin Studies of Major Depressive Disorder*. 
 
Author Population Sample size MDD definition Results 
McGuffin P, et al. 
(223) 
Probands ascertained 
via Maudsley Hospital 
Twin Register 
(London, England) 
177 MDD probands 
and their co-twins 
Diagnosis on twin 
registry 
DSM-III-R 
Present State Exam 
(PSE) 
MDD concordance: 
MZ 46% (n=68) 
DZ 20% (n=109) 
 
Heritability of MDD: 
Between 48-75% based on varying 
baseline prevalence of MDD 
Kendler KS, et al. 
(224) 
Psychiatric 
hospitalization from 
Swedish Psychiatric 
Twin Registry 
1002 twin probands DSM-III-R MDD concordance: 
MZ men: 50% 
DZ men: 33% 
MZ women: 32% 
DZ women: 20% (159) 
 
Lyons MJ, et al. (225) Male twins 
Vietnam Era Twin 
Registry 
3372 twin pairs (1874 
MZ pairs and 1498 
DZ pairs) 
Standardized 
telephone interview, 
DIS version III 
Revised 
 
DSM-III-R 
9.2% MDD prevalence 
 
MDD concordance: 
MZ 22.5% 
DZ 14.0% 
 
36% heritability of MDD 
 
64% of variance in liability due to 
unique environment 
Kendler KS, et al. 
(224) 
General population 
Swedish Twin 
Registry 
800 twin pairs DSM-III-R MDD concordance: 
MZ men: 40% 
DZ men: 33% 
MZ women: 67% 
DZ women: 32% (159) 
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Table 1.11 (Continued): Twin Studies of Major Depressive Disorder*. 
 
Author Population Sample size MDD definition Results 
Bierut LJ, et al. (226) Australian community 
based twin sample 
2662 twin pairs 
(women=3494, 
men=1830) 
Semi-structured 
assessment for the 
Genetics of 
Alcoholism (semi-
structured lay 
interview designed to 
assess psychiatric 
symptoms) 
 
DSM-III-R 
DSM-IV 
Severe DSM-IV MDD 
DSM-III-R 
Lifetime MDD prevalence: 
Men: 24% 
Women: 31% 
 
MDD concordance: 
MZ men: 34% 
DZ men: 30% 
MZ women: 50% 
DZ women: 37% 
 
MDD heritability: 
Men: 24% 
Women: 44% 
 
DSM-IV 
Lifetime MDD prevalence: 
Men: 16% 
Women: 22% 
 
MDD concordance: 
MZ men: 20% 
DZ men: 23% 
MZ women: 38% 
DZ women: 25% 
 
MDD heritability: 
Men: 18% 
Women: 36% 
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Table 1.11 (Continued): Twin Studies of Major Depressive Disorder*. 
 
Author Population Sample size MDD definition Results 
Kendler KS and 
Prescott CA (227) 
 
Erratum (228) 
Virginia Twin Registry 3790 complete twin 
pairs 
Telephone interview 
Lifetime history MDD 
DSM-III R (SCID-
based) 
MDD concordance: 
MZ men: 41% 
DZ men: 34% 
MZ women: 47% 
DZ women: 43% 
 
Male-male twin pairs: 
OR MZ: 3.29 
OR DZ: 1.86 
 
MDD heritability: 38% 
Unique environment: 62% 
 
Female-female twin pairs: 
OR MZ: 3.02 
OR DZ: 1.59 
 
MDD heritability: 39% 
Unique environment: 61% 
 
All types of twin pairs: 
MDD heritability:  
39% (95% CI: 30-47%) 
Unique environment: 61% 
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Table 1.11 (Continued): Twin Studies of Major Depressive Disorder*. 
 
Author Population Sample size MDD definition Results 
Sullivan PF, et al. 
(159) 
Meta-analysis; clinic 
and community 
samples 
21,000 twin pairs DSM-III-R Overall: 
Best model was genetic and unique 
environment 
Heritability: 37% (95% CI 33-42%) 
 
Unique environment, 63% (95% CI 
58-67%) 
 
Community studies 
Heritability: 37% (95% CI 28-42%) 
 
Clinic studies 
Heritability: 43% (95% CI 21-58%) 
Fu Q, et al. (168)  Vietnam Era Twin 
Registry 
3360 male-male twin 
pairs 
Computerized 
telephone version of 
the DIS, version 3, 
revised (DSM-III-R) 
Lifetime prevalence of DSM-III-R 
MDD was 9.2% 
 
Heritability of lifetime major 
depression was 40% 
Kendler KS and 
Aggen SH (169) 
Virginia Twin Registry 858 female-female 
twin pairs 
Structured psychiatric 
interview based on 
the SCID (DSM-III-R) 
 
Heritability estimates of MDD 
between 0.34 and 0.41 for the four 
time periods of interviews 
 
83
   
*MDD=major depressive disorder; PSE=present state exam; DSM-III-R=Diagnostic and Statistical Manual, third edition, revised; 
MZ=monozygotic; DZ=dizygotic; DIS=diagnostic interview schedule; DSM-IV=Diagnostic and Statistical Manual, fourth edition; 
SCID=structured clinical interview for DSM-IV; OR=odds ratio; 95% CI= 95% confidence interval 
 
 
Table 1.12: Linkage Studies in Major Depression*. 
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Gene 
(Polymorphism) 
Population Size Results Reference
27 markers on 
Chromosomes 16, 18, 
21, and 4p 
Swedish 
Recurrent MDD 
5 families 
defined by 
recurrent MDD 
proband—60 
individuals; 19 
recurrent MDD 
No significant linkage found Balciuniene J, et al. 1998 
(229) 
     
451 Kb region of 2q33-34 
between markers 
D2S2321 and D2S2208 
Proband defined as 
recurrent early-onset 
MDD (SADS-L) 
81 families (all 
affected relative 
pairs)—407 first 
degree 
relatives, 835 
extended 
relatives 
Men—Not significant 
Women—Similar LOD 
scores as sex-dependent 
reported below 
 
Multi-point Linkage 
Major Mood Disorder 
     D2S2321 LOD 4.592 
     D2S2208 LOD 4.753 
Major or Minor Mood 
Disorder 
     D2S2321 LOD 6.331 
     D2S2208 LOD 6.866 
Recurrent Early Onset Major 
Depression 
     D2S2321 LOD 3.108 
     D2S2208 LOD 3.167 
Recurrent Major Depression 
     D2S2321 LOD 3.229 
     D2S2208 LOD 3.314 
 
Zubenko GS, et al.  2002 
(171) 
 
Table 1.12 (Continued): Linkage Studies in Major Depression*. 
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Gene 
(Polymorphism) 
Population Size Results Reference
Genomewide scan with 
628 microsatelite 
markers 
Mormon population of 
Utah 
 
Pedigrees ascertained for 
MDD 
110 Utah 
pedigrees 
1890 individuals 
Men MDD 
D12S1300 LOD 4.6, 
p=0.00003 
D12S1706 LOD 6.1, 
p=0.0000007 
Abkevich V, et al.  2003 (172) 
    
    
     
 
38 SSTRPs covering 12 
chromosomal regions 
with genes involved in 
neuroendocrine 
regulation or 
serotonergic 
neurotransmission 
US 
Recurrent, early-onset 
(≤25 yo) major 
depression 
 
SADS-L 
34 families in 
total 
 
16 families 
(initial), n=148 
 
18 additional 
families, n=97 
 
Using pairwise linkage 
analysis, none of the 
markers were significant for 
major depression 
Neiswanger K, et al.  1998 
(117) 
D2S2944, 124-bp allele US 
Recurrent, early-onset 
(≤25 yo) major 
depression (SADS-L) 
 
Controls: SCID 
 
100 RE-MDD 
100 controls 
Men: no significant effect on 
RE-MDD 
 
Women: evidence of linkage 
and linkage disequilibrium of 
allele with RE-MDD (χ2=5.23, 
p=0.02) 
Zubenko GS, et al. 2002 (170) 
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Gene 
(Polymorphism) 
Population Size Results Reference
Genome-wide linkage 
using 392 highly 
informative 
polymorphisms spaced 
9cM apart on average 
US 
Recurrent, early-onset 
(≤25 yo) major 
depression (SADS-L) 
 
Controls: SCID 
 
81 families 
identified by 
proband with 
recurrent early 
onset major 
depressive 
disorder (407 1st 
degree relatives 
and 835 
extended 
relatives) 
2 regions demonstrated 
significant linkage for RE-
MDD and R-MDD: 11pter-
p15, marker D11S1984, 
multipoint LOD 4.20, 
p<0.0001; and 11q13-14, 
marker D11S2002, multipoint 
LOD 2.51, p<0.0001 
 
 
Zubenko GS, et al. 2003 (173) 
 
Early-onset <=25 years 
     
     
Genome scan using 389 
microsatellite markers 
(mean spacing of 9.3 cM) 
Six sites across the US 
involved in the Genetics 
of Recurrent Early-Onset 
Depression (GenRED) 
project 
 
Opportunistic 
recruitment/ascertainment 
 
Interviews—DIGS and 
FIGS 
 
DSM IV 
297 families 
including 685 
informative 
affected relative 
pairs 
Chromosome 15q25.3-26.2 
had a significant peak, 
LOD=3.73, p=0.23 
 
This peak mapped to the 
103.4 cM of the decode map, 
flanked by the D15S652 and 
D15S816 markers 
Holmans P, et al. 2004 (174) 
 
Early-onset was before age 31 
for probands or age 41 for 
other affected relatives 
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Gene 
(Polymorphism) 
Population Size Results Reference
Alpha2 adrenergic 
receptors 
Univerisity of Iowa 
Psychiatric Hospital or the 
Veterans Administration 
Hospital in Iowa City 
 
Feighner criteria 
17 pedigrees, 7 
with pure 
depressive 
disease and 10 
with depression 
spectrum 
disease 
 
involved 161 
individuals, 49 
with unipolar 
depression 
All analyses had LOD scores 
less than -2, indicating 
linkage exclusion for these 
candidate genes 
Wang Z, et al. 1992 (230)  
     
* MDD=Major Depressive Disorder; SADS-L=Schedule of Affective Disorders and Schizophrenia—Lifetime version; LOD=Log Odds; 
SSTRPs=Single Sequence Tandem Repeat Polymorphisms; SCID=Structured Clinical Interview for Diagnostic and Statistical Manual, 3rd 
edition 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
SLC6A4 (VNTR 
and I/D) 
 Meta-analysis VNTR: 
299 
 
I/D: 
275 
VNTR: 772 
 
I/D: 739 
No significant associations of 
VNTR and unipolar patients 
 
Significant association with 
promoter allele 2 and risk of 
unipolar disorder (OR 1.23, 
95% CI 1.01-1.52, χ2=4.10, 
p=0.042) 
Furlong RA, et al. 1998 
(181) 
      
  
  
     
      
   
 
SLC6A4 (VNTR) Han
Chinese 
MDD patients 33 362 Allele 12 associated with 
MDD (p=0.0107) 
 
12/12 homozygous genotype 
associated with MDD 
(p=0.0137) 
Liu N, et al. 1999 (180) 
SLC6A4 (VNTR) UK DSM-IV
 
Lithium clinic 
out-patients 
86 187 NS Collier DA, et al. 1996 
(175) 
 
No assessment of control 
mental health 
  
SLC6A4(VNTR) Japanese RDC 42 137 NS Kunugi H, et al. 1996 
(199) 
 
SLC6A4 (VNTR) Germany DSM-IV
SADS-L 
 
Recurrent MDD 
patients 
49 218 NS Stober G, et al. 1996 
(197) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
SLC6A4 (VNTR) English 
and 
Scottish 
DSM-IV 
SADS-L 
 
MDD in- and 
out-patients 
 
Controls 
SADS-L for 
mental health 
39  123
controls 
(not 
screened 
psych 
disorders) 
 
71 controls 
screened 
with SADS-
L 
Two control groups had 
similar frequencies of alleles, 
and thus were pooled into 
one control group 
 
Significant genotype 
distribution difference 
between MDE patients and 
controls (χ2=10.05, p<0.004 
(Bonferroni corrected), OR 
6.95 (1.8-27.2))—patients 
had higher frequency of being 
homo or heterozygous for the 
9 repeat allele 
 
Significant allele frequency 
difference between MDE 
patients and controls 
(χ2=9.87, p<0.02 (Bonferroni 
corrected), OR 6.51 (1.7-
24.9))—unipolar patients had 
a higher frequency of 9 
repeat allele than controls 
Ogilvie AD, et al. 1995 
(179) 
SLC6A4 (VNTR 
and I/D) 
France and 
Germany 
DSM-IV 
SADS-L 
 
MDD out-
patients 
36 294 NS Hoehe MR, et al. 1998 
(200) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
SLC6A4 Postmorte
m suicides 
DSM-III-R by 
psychological 
autopsy 
82 138 NS allele frequency 
distribution 
 
Genotype frequency varied, 
those with MDD had higher 
rate of heterozygotes (χ2=9.6, 
p=0.008) 
 
Mann JJ, et al. 2000 
(176) 
     
  
 
  
SLC6A4 (VNTR 
and I/D) 
UK DSM-IV
SCAN interview 
 
MDD in- and 
out-patients 
80 
(lifetim
e 
MDD) 
121 VNTR: genotype and allele 
frequencies not different 
cases and controls; however 
there is a difference when 
examining those not taking 
lithium and controls, p=0.041 
for allele 9 presence 
 
I/D:  no allele frequency 
difference statistically 
significant; those taking 
lithium had a sig decrease in 
frequency of the deleted 
allele compared to controls 
(χ2=6.71, p=0.010) 
Rees M, et al. 1997 (177) 
 
Controls not screened for 
psych disorders 
SLC6A4 (VNTR 
and I/D) 
UK SADS-L, case
note 
 125 
 
MDD in- and 
out-patients 
174 NS Furlong RA, et al. 1998 
(181) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
SLC6A4 (VNTR 
and I/D) 
Japanese   DSM-IV 
 
MDD in- and 
out-patients 
 
Controls were 
medical 
students and 
hospital staff 
49 212 VNTR: NS  
 
I/D: NS  
Kunugi H, et al. 1997 
(198) 
 
Controls did not undergo 
psych evaluation 
      
    
     
 
     
 
SLC6A4 (VNTR 
and 5-HTTLPR) 
Spanish Personal
interview 
 
MDD out-
patients 
74 84 VNTR: NS 
 
5-HTTLPR: NS 
 
Overall distribution of 
haplotypes differed 
significantly with the 10 
repeat allele having increased 
risk for disease  (χ2=7.298, 
p=0.0069, OR=2.53, 95% CI 
1.21-5.34) 
 
Gutierrez B, et al. 1998 
(201) 
 
SCL6A4 (VNTR 
and 44-BP Ins/Del)  
 
Denmark MDD in-
patients 
 
92 108 NS Mellerup E, et al. 2001 
(202) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
SLC6A4 (I/D) Polish    SCID 
 
MDD in-
patients 
94 213 Everyone: statistically
significant difference in allele 
and genotype frequencies 
between unipolar cases and 
controls (p=0.001; χ2=11.760, 
p=0.003, respectively) 
 
Males: statistically significant 
difference in allele frequency 
between cases and controls 
(p=0.031) (unipolar had 
higher frequency of short 
allele), but not in genotype 
frequency (χ2=5.283, 
p=0.071) 
 
Females: NS 
Hauser J, et al. 2003 
(178) 
 
Controls not 
psychiatrically screened 
      
 
      
      
      
 
SLC6A4 (I/D) Italy OPCRIT and/or
SADS-L 
 67 
 
MDD in-
patients 
 
0 NS Serretti A, et al. 1999 
(231) 
HTR2A (T102C) 
HTR2A 
(His452Tyr) 
SLC6A4 
Germany DSM-IV 137 121 NS
 
Minov C, et al. 2001 (232)
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
HTR2A (T102C) Spanish SCID 
 
MDD out-
patients 
159 162 No overall differences in 
genotype or allele 
frequencies between cases 
and controls 
 
Differences existed when 
MDD separated into seasonal 
and non-seasonal for the 
genotype (χ2=10.63, p=0.004) 
Arias B, et al. 2001 (193) 
HTR2A (T102C) European 
(ECPAD) 
 
 142 142 NS Oswald P, et al. 2003 
(233) 
HTR1B (G861C) SCID  208 183
inpatients 
without 
MDD 
 
96 healthy 
Significant differences in 
genotype and allele 
frequencies between those 
patients with MDD and those 
without MDD (χ2=6.83, 
p=0.033; χ2=5.81, p=0.016, 
respectively) 
 
MDD associated with HTR1B 
G861C locus, OR=0.46, 95% 
CI=0.31-0.68, χ2=14.93, 
p=0.001, independent of race 
 
MDD associated with HTR1B 
G861C locus, OR=1.64, 95% 
CI=1.16-2.31, χ2=7.81, 
p=0.005, independent of sex 
Huang Y, et al. 2003 
(185) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
HTR5A (-19G/C 
and 12A/T) 
Spanish    SCID 181 157 NS
 
Arias B, et al. 2001 (234) 
       
       
  
      
      
     
HTR6 (C267T) China DSM-IV 77 147 NS Hong CJ, et al. 1999 
(150) 
HTR2C (cys23ser) European
(ECPAD) 
European 
Collaborative 
Project on 
Affective 
Disorders 
(ECPAD) 
 
513 
Recurr
ent 
901 MDD associated with ser23 
allele carrier status (χ2=7.34, 
p=0.006) 
Lerer B, et al. 2001 (115) 
TPH1 
HTR2A 
HTR2C 
SLC6A4 
DRD4 
DAT1 
COMT 
Ashkenazi 
and non-
Ashkenazi 
Jews 
SADS-L or 
SCID 
102 172 NS Frisch A, et al. 1999 (235)
 
DRD2 (-
141CIns/Del) 
 
UK 
caucasians 
 
MDD patients 128 262 NS Furlong RA, et al. 1998 
(236) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
DRD2 
(Ser311/Cys311) 
DRD3 (Ser9/Gly9) 
DRD4 
DAT1 
Japanese   DSM-III-R  
 
Hospital 
employee and 
their friends as 
controls 
49 100 DRD2, DRD3, and DAT1 not 
significant 
 
DRD4: Frequency of 4 and 5 
repeat allele significantly 
different between patients (4-
allele χ2=6.49, p=0.011; 5-
allele χ2=4.18, p=0.041) and 
controls, but frequency of 2 
repeat allele not significant 
 
4-allele less frequent in MDD 
patients 
5-allele more frequent in 
MDD patients 
 
4-allele homozygotes 
significantly less frequent in 
MDD (58.2%) than controls 
(80%), χ2=7.26, p=0.007 
 
4/5-allele heterozygotes 
significantly more frequent in 
MDD (18.4%) than controls 
(7%), χ2=4.43, p=0.035  
Manki H, et al. 1996 (184)
DRD2 
DRD3  
European 
(ECPAD) 
 DRD2: 
133 
DRD3: 
136 
DRD2: 133 
 
DRD3: 136 
NS 
 
Massat I, et al. 2002 
(237) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
DRD4 Italy MDD in-
patients 
 126 471 Exon 1 and 3 polymorphisms 
did not differ in allele or 
genotype distribution 
 
Trend observed toward 
excess of DRD4*2/4 
(χ2=8.34, df=1, p=0.004 
OR=2.09; 95% CI= 1.27-3.43) 
Serretti A, et al. 1999 
(238) 
 
Power low but higher 
than 60%  
      
  
       
   
    
 
DRD4 
TH 
Croatia SADS-L,
clinical 
interviews, 
hospital case 
notes 
41 71 NS Oruc L, et al. 1997 (239) 
TH 
(tetranucleotide 
repeat 
polymorphism 
(TH4) in intron 1 
and the 5’ TaqI 
RFLP 
polymorphism) 
Belgian SADS-LA 35 (at
least 2 
MDE) 
50 TH4 polymorphism: NS 
 
5’TaqI polymorphism: 
significant genotype 
frequency differences 
between cases and controls 
(χ2=9.99, p=0.002, after 
correcting for multiple 
comparisons, p=0.006) 
  
the 2-2 genotype was 
significantly more often 
observed in unipolar patients 
Souery D, et al. 1996 
(192) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
TH 
(tetranucleotide 
repeat) 
UK   MDD out-
patients 
 126 242 TH tetranucleotide repeat:  
No significant differences in 
allele or genotype 
frequencies (χ2=4.33, df=4, 
p=0.36; χ2=17.69, df=14, 
p=0.22, respectively) 
 
PstI polymorphism: 
Cambridge sample 
demonstrated a significant 
difference in allele frequency 
between cases and controls 
(χ2=3.946, df=1, p=0.047); no 
such difference for Edinburgh 
samples 
 
No difference in genotype 
frequencies between cases 
and controls in either 
Cambridge or Edinburgh 
 
Significant test of association 
(p<0.05), estimated OR 0.72 
(95% CI 0.54-0.97) for allele 
B vs allele A, and 0.55 (95% 
CI 0.25-0.993) for genotype 
BB vs genotype AA 
Furlong RA, et al. 1999 
(191) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
MAOA (MAOA-
LPR) 
Germany DSM-IV 
 
Controls from 
blood donor 
center 
74 
recurre
nt 
229 NS Syagailo YV, et al. 2001 
(240) 
MAOA  Germany     
       
  
In-patients 146
patient
s (42 
MDE 
and 
104 
recurre
nt 
MDD) 
 
101 Significant genotype
frequency differences among 
women with recurrent MDD 
and controls (χ2=4.767, 
p=0.029) 
 
Trend of the longer allele 
being more frequent in 
controls (p=0.053) 
Schulze TG, et al. 2000 
(116) 
MAOA (T941G) Germany MDD out-
patients 
108 276 NS Tadic A, et al. 2003 (136) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
MAOA (MAOA-
LPR) 
Germany DSM-IV 
 
Controls from 
blood donor 
center 
74 
recurre
nt 
229 NS Syagailo YV, et al. 2001 
(240) 
TPH1 ( 218 A?C, 
-1067 G?A, and -
347 T?G) 
Chinese  
     
  
     
      
     
DSM-IV
 
MDD out-
patients 
91 139 No significant difference in 
genotype or allele frequency 
between cases and controls 
for -1067 G?A or -347 T?G 
 
Significant genotype 
frequency difference between 
cases and controls for 218 
A?C polymorphism 
(χ2=6.915, p=0.032) 
 
Tan EC, et al. 2003 (183) 
 
TPH1 (A281C) UK MDD out-
patients 
125 437 NS Furlong RA, et al. 1998 
(241) 
 
80% power to detect 
gene with a RR of 1.5-2.0 
  
CLOCK (T3111C) European
Americans 
 
DSM-IV/SCID 143 195 NS
 
Desan PH, et al. 2000 
(242) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
TPH2 (10 SNPs in 
the region) 
Germany MDD in-
patients 
300 265 Significant allele frequency 
difference for SNP rs1386494 
(A/G poly), cases had higher 
G frequency than controls 
(χ2=10.51, p=0.0012; 
OR=0.60; Bonferroni 
corrected p=0.012) 
 
Marginally significant allele 
frequency difference for SNP 
rs1843809 (G/T poly) 
(χ2=3.85, p=0.0496; 
OR=1.38; Bonferroni 
correction was not significant) 
 
Three haplotypes significantly 
differed between cases and 
controls, p<0.00001; one 
more frequent in controls and 
two only present in cases 
Zill P, et al. 2004 (189) 
      
   
     
      
  
 
NET (T-182C) Korea 
 
DSM-IV 
 
112 136 NS Ryu SH, et al. 2004 (243) 
  
NET (T-182C and 
G1287A) 
 
Germany MDD patients 193 136 NS
 
Zill P, et al. 2002 (134) 
NET (G1287A) Canada Recurrent MDD 105 
DSM-IV 
74 NS Owen D, et al. 1999 (142) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
CYP2C9 (*1, *2, 
*3) 
Spanish  DSM-IV 70
MDD 
89 
Schizophre
nic 
 
138 healthy 
No differences in CYP2C9*1 
or *2 allele 
 
CYP2C9*3 allele frequency 
higher in MDD patients than 
in healthy controls (p<0.01) or 
schizophrenia controls 
(p<0.01) 
 
OR CYP2C9*3 allele: 
     2.76 (1.51-5.05) in MDD 
              vs healthy controls 
     3.30 (1.5-6.13) in MDD vs  
schizophrenia 
controls 
 
Lerena A, et al. 2003 
(186) 
CRHR2 
(CRHR2s03, 
CRHR2s04, 
CRHR2s181, 
CRHR2s183, 
CRHR2s185) 
Belgian   MDD in-
patients 
89 89 age-,
gender-, 
and 
ethnicity-
matched 
controls 
Significant genotype 
frequency between cases and 
controls for CRHR2s183 
(p=0.03) 
 
Significant allele frequency 
difference between cases and 
controls for CRHR2s183, with 
the A allele being more 
common in cases than 
controls (12% vs 6%, p=0.04) 
 
Other markers not significant 
Villafuerte SM, et al. 2002 
(188) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
CCK (STR) Japanese MDD in- and 
out-patients 
82 253 NS Hattori E, et al. 2002 
(244) 
      
    
      
 
      
  
     
 
GABRA3 (CA-
repeat)  
Germany MDD in-
patients 
201 151 Males: NS
 
Females:  
No significant genotype 
differences between cases 
and controls for alleles 1 and 
4 (χ2=9.66, df=6, p=0.13; 
χ2=7.75, df=1, p=0.08, 
respectively) 
 
Significant allele distribution 
difference between cases and 
controls for alleles 1 and 4 
(χ2=13.21, df=3, p≤0.0001; 
χ2=12.66, df=1, p≤0.0001, 
respectively) 
 
Henkel V, et al. 2004 
(190) 
ACE I/D Germany MDD in-
patients 
 
63 169 NS Pauls J, et al. 2000 (245) 
ACE I/D UK MDD in-
patients 
 
169 313 NS Furlong RA, et al. 2000 
(246) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
ACE (I/D) Japan DSM-III-R 
Clinical 
interview and 
medical 
records 
 
MDD in-
patients 
34 579 NS Arinami T, et al. 1996 
(247) 
      
   
      
 
GNAL Germany ICD-10
DSM-IV 
176 145 No significant differences in 
allele or genotype 
frequencies for either 
polymorphism between cases 
and controls 
 
Intron 3: allele, p=0.339 
            Genotype, χ2=1.813, 
                               p=0.404 
Intron 10: allele, p=0.352 
            Genotype, χ2=1.069,  
                              p=0.586 
 
Gender effect in intron 3: 
females stat sig higher g-
allele frequencies than males, 
p=0.0036; genotype, 
χ2=9.069, p=0.011 
 
Zill P, et al. 2002 (194) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
PLA2 Belgium, 
Bulgaria, 
Croatia, 
Germany, 
Greece, 
Italy 
(BIOMED 1 
and 
BIOMED 2) 
DSM-IV 
DSM-III-R 
RDC 
328 630 After controlling for population 
group and gender, allele 7 
had a stat sig association 
among unipolar depressives 
with more than three MDEs, 
OR 1.40, 95% CI 1.09-1.81, 
p=0.01 compared to controls 
Papadimitriou GN, et al. 
2003 (182) 
      
  
      
   
   
 
DDC (1-bp 
deletion and 4-bp 
deletion) 
Germany DSM-IV
SADS-L, family 
history, 
OPCRIT, 
medical 
records 
 
MDD in-
patients 
 
183 234 NS Jahnes E, et al. 2002 
(248) 
CTLA4 (A49G) 
 
Korean 
 
DSM-IV  
 
77 149 NS Jun TY, et al. 2001 (249) 
 
WFS1 (His611Arg) UK RDC
SADS-L, case 
note review  
 
MDD in- and 
out-patients 
163 316 NS Furlong RA, et al. 1999 
(250) 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
10 cM systematic 
survey of human 
genome using 
SSTRPs 
US  Recurrent,
early-onset 
(≤25 yo) major 
depression 
(SADS-L) 
 
Controls: SCID-
I-NP and SCID-
II 
100 
RE-
MDD 
100 healthy 
controls, 
matched by 
age, sex, 
race, and 
ethnicity 
Significant allele differences 
in 19 SSTRPs, 9 specific for 
women, 7 specific for men, 
and 3 sex-independent 
 
Female specific 
D1S1677            
             (χ2=5.78, p=0.016) 
 
D2S2944      
116 bp   (χ2=5.64, p=0.018) 
124 bp   (χ2=13.06, p=0.0003) 
 
D5S1462      
217 bp   (χ2=7.79, p=0.005) 
229 bp   (χ2=8.41, p=0.004) 
 
D13S317      
175 bp   (χ2=6.82, p=0.009) 
195 bp   (χ2=6.82, p=0.009) 
 
ACTC            
233 bp   (χ2=5.18, p=0.023) 
237 bp   (χ2=7.79, p=0.005) 
241 bp   (χ2=5.60, p=0.018)  
 
Zubenko GS, et al. 2002 
(251) 
 
Sex-specificity of 
susceptibility loci for RE-
MDD 
 
Both protective and 
increased risk is 
associated with these 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
10 cM systematic 
survey of human 
genome using 
SSTRPs 
US  Recurrent,
early-onset 
(≤25 yo) major 
depression 
(SADS-L) 
 
Controls: SCID-
I-NP and SCID-
II 
100 
RE-
MDD 
100 healthy 
controls, 
matched by 
age, sex, 
race, and 
ethnicity 
Female specific (continued) 
D18S858            
               (χ2=7.68, p=0.006) 
 
D20S478            
               (χ2=11.05, p=0.001) 
 
GATA31E08  
238 bp    (χ2=8.00, p=0.005) 
246 bp    (χ2=4.57, p=0.033) 
 
DXS6800       
197 bp    (χ2=5.63, p=0.018) 
205 bp    (χ2=5.94, p=0.015) 
 
 
Zubenko GS, et al. 2002 
(251) 
 
Sex-specificity of 
susceptibility loci for RE-
MDD 
 
Both protective and 
increased risk is 
associated with these 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
10 cM systematic 
survey of human 
genome using 
SSTRPs 
US  Recurrent,
early-onset 
(≤25 yo) major 
depression 
(SADS-L) 
 
Controls: SCID-
I-NP and SCID-
II 
100 
RE-
MDD 
100 healthy 
controls, 
matched by 
age, sex, 
race, and 
ethnicity 
Significant allele differences 
in 19 SSTRPs, 9 specific for 
women, 7 specific for men, 
and 3 sex-independent 
 
Male specific 
D6S1056            
                 (χ2=4.71, p=0.030) 
D10S1248          
                 (χ2=8.56, p=0.003) 
D10S189            
                 (χ2=7.23, p=0.007) 
D15S643       
207 bp      (χ2=6.11, p=0.013) 
211 bp      (χ2=9.07, p=0.003) 
223 bp      (χ2=5.84, p=0.016) 
 
D16S3253 
                 (χ2=9.51, p=0.002) 
D19S178            
                 (exact p, p=0.035) 
D21S2055     
117 bp      (χ2=6.66, p=0.010) 
129 bp      (χ2=6.08, p=0.014) 
153 bp      (χ2=4.39, p=0.036) 
 
 
Zubenko GS, et al. 2002 
(251) 
 
Sex-specificity of 
susceptibility loci for RE-
MDD 
 
Both protective and 
increased risk is 
associated with these 
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Gene 
(Polymorphism) 
Ethnicity Diagnostic
criteria 
/instrument 
Cases Controls Results (gene/allele
frequencies) 
Reference 
10 cM systematic 
survey of human 
genome using 
SSTRPs 
US  Recurrent,
early-onset 
(≤25 yo) major 
depression 
(SADS-L) 
 
Controls: SCID-
I-NP and SCID-
II 
100 
RE-
MDD 
100 healthy 
controls, 
matched by 
age, sex, 
race, and 
ethnicity 
Significant allele differences 
in 19 SSTRPs, 9 specific for 
women, 7 specific for men, 
and 3 sex-independent 
 
Sex-independent 
D12S398        
132 bp    (χ2=9.01, p=0.003) 
140 bp    (χ2=7.09, p=0.008) 
 
D15S822 
258 bp    (χ2=9.34, p=0.002) 
294 bp    (χ2=5.85, p=0.016) 
 
D17S1293  
262 bp    (χ2=7.11, p=0.008) 
274 bp    (χ2=5.31, p=0.021) 
286 bp    (χ2=4.63, p=0.031) 
Zubenko GS, et al. 2002 
(251) 
 
Sex-specificity of 
susceptibility loci for RE-
MDD 
 
Both protective and 
increased risk is 
associated with these 
*SLC6A4=Serotonin Transporter Protein; VNTR=Variable Number of Tandem Repeats; I/D=Insertion/Deletion; OR=Odds Ratio; 95% 
CI=95% Confidence Interval; MDD=Major Depressive Disorder; DSM-IV=Diagnostic and Statistical Manual, 4th edition; SADS-L=Schedule 
of Affective Disorders and Schizophrenia—Lifetime version; MDE=Major Depressive Episode; RDC=Research Diagnostic Criteria; DSM-
III-R=Diagnostic and Statistical Manual, 3rd edition revised; 5-HTTLPR=serotonin transporter long polymorphic repeat; 
OPCRIT=Operational Criteria Checklist; HTR2A=Serotonin Transporter Type 2A receptor; NS=not significant; SCID=Structured Clinical 
Interview for Diagnostic and Statistical Manual; ECPAD=European Collaborative Project on Affective Disorders; HTR1B=Serotonin 
Transporter Type 1B receptor; HTR5A=Serotonin Transporter Type 5A receptor; HTR6=Serotonin Transporter Type 6 receptor; 
HTR2C=Serotonin Transporter Type 2C receptor; TPH1=Tryptophan Hydroxylase; DRD4=Dopamine Receptor D4; DAT1=Dopamine 
Transporter Gene; COMT=Catechol-O-Methyl Transferase; DRD2=Dopamine Receptor D2; DRD3=Dopamine Receptor D3; TH=Tyrosine 
Hydroxylase; RFLP=Restriction Fragment Length Polymorphism; MAOA=Monoamine Oxidase A; TPH2=Tryptophan Hydroxylase 2; SNP= 
Single Nucleotide Polymorphism; CLOCK=Circadian Locomotor Output Cycles Kaput; CYP2C9=Cytochrome P450 2C9; NET= 
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Norepinephrine Transporter; CRHR2=Corticotropin-Releasing Hormone Receptor 2; CCK(STR)=Cholecystokinin (Short Tandem Repeat); 
GABRA3=Gamma-Aminobutyric Acid Receptor, alpha-3; ACE=Acetylcholine; GNAL=Guanine Nucleotide-binding Protein, alpha-activating 
activity polypeptide, olfactory type; ICD-10=International Classification of Disease, 10th edition; PLA2=Phospholipase A2; 
BIOMED1=European Collaborative Biomedical Research Project 1; BIOMED2=European Collaborative Biomedical Research Project 2; 
DDC=Dopa Decarboxylase; CTLA4=Cytotoxic T Lymphocyte-associated 4; WFS1=Wolfram syndrome (WFS) gene; SSTRP=Single 
Sequence Tandem Repeat Polymorphism; SCID-I-NP= Structured Clinical Interview for DSM-III, Axis I disorders, Non-patient; SCID-
II=Structured Clinical Interview for DSM-III, Axis II Disorders; RE-MDD=Recurrent Major Depressive Disorder 
Table 1.14: SLC6A4 (VNTR) results from Anguelova et al. (195)*. 
 
 OR 95% CI P-value 
Allele 9 1.24 0.72-2.14 0.493 
Allele 10 0.96 0.84-1.10 0.585 
Allele 12 1.03 0.89-1.18 0.747 
 *SLC6A4 (VNTR)=serotonin transporter protein (variable number of tandem 
repeats); OR=odds ratio; 95% CI=95% confidence interval 
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Figure 1.1: Tryptophan Metabolic Pathways.  As demonstrated in this 
diagram, tryptophan is the precursor of serotonin (5-HT).  The rate-limiting 
step in the synthesis of 5-HT is the conversion of tryptophan into 5-
Hydroxytryptophan by the enzyme tryptophan hydroxylase.  Additionally, the 
alternate pathway for tryptophan, the kynurenine pathway (right-side), is its 
major route of degradation in the brain and liver.  In depressed individuals, an 
increase in kynurenine concentration and a subsequent decrease in serotonin 
concentration has been demonstrated (adapted from Struder (152)). 
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Figure 1.2: Schematic Drawing of a Serotonin Neuron Synapse.  This 
diagram depicts a serotonin neuron synapse, which could easily be a 
norepinephrine synapse.  In the presynaptic neuron, plasma tryptophan 
comes into the brain and is converted to serotonin which is then transported 
into the synapse when a signal (action potential) is sent.  Once serotonin is in 
the synapse, three different actions can occur: 1) serotonin (5-HT) reuptake 
into the presynaptic neuron via the serotonin transporter; 2) 5-HT in the 
synapse is degraded into 5-HIAA via the enzyme monoamine oxidase (MAO); 
or 3) 5-HT binds to its postsynaptic neuron receptor (5-HT 1a, b, c, d, e; 2; 3; 
4; 5; 6) where it ultimately leads to the regulation of gene expression and 
protein synthesis.  Serotonin that is re-uptaken into the presynaptic neuron is 
either stored for subsequent release into the synapse again or is degraded by 
MAO into 5-HIAA.  The action of the serotonin transporter is thus important 
because it determines the length of time 5-HT remains in the synapse.  
Antidepressants act on serotonin and norepinephrine transporters, to return 
neurotransmitter levels to those within the range of normal variation in a non-
depressed population of individuals. 
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2 RESEARCH AIMS AND METHODS 
2.1 RATIONALE OF PROPOSED STUDY 
There are relatively few published studies at the population level using 
the Rome II criteria for IBS and it is unknown whether the risk factor 
associations of Rome II defined IBS are the same as those of Rome I or 
Manning defined IBS.  Additionally, since there is evidence of substantial 
overlap between IBS and MDD, it is thought that MDD may demonstrate a 
significant association with IBS.  Despite knowledge of the overlap between 
these two disorders, little is known about the etiology of their co-occurrence.  
Although both IBS and MDD have demonstrated familial transmission, 
associations with serotonin, and similar epidemiologic risk factors, not much 
is known about the heritability, familiality, or biologic mechanism of their co-
occurrence.  Thus this study will examine whether a common familial biologic 
mechanism (genetic or environmental) may be underlying the co-occurrence 
of IBS and MDD.  Results from this study would be a first step in 
demonstrating a need for further research into biologic mechanisms 
responsible for a demonstrated lifetime co-occurrence.   This could include a 
better understanding of how 5-HT3 and 5-HT4 agonists and antagonists work 
for alleviating IBS symptoms.  Additionally, a better understanding of their 
biology could lead to investigation of the use of other serotonin and 
antidepressant drugs for the treatment of IBS.  Further, if in fact these 
disorders do share some common biologic mechanism, it is possible that 
eventually a new drug could be developed and tested specifically for those 
individuals with both IBS and MDD.  Aside from the implications for 
medications, increased knowledge about the biology of their co-occurrence 
would also be the background for the justification of candidate gene studies in 
IBS and in those with IBS and MDD.  Moreover, our results will be important 
for future research, as statistical genetic models incorporating these 
interactions should better approximate the biological reality of these traits, 
and make it easier to detect, localize, and identify genes contributing to the 
covariation of MDD and IBS, two common co-morbid disorders of public 
health burden and significance.  
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2.2 SPECIFIC AIMS 
Aim 1:  Estimate the prevalence of Rome II IBS in various twin populations. 
1. Evaluate Rome II IBS prevalence in two different populations: 
one US twin study and one Swedish twin study. 
2. Determine prevalence of Rome II IBS in subgroups based on 
age, gender, co-morbid disorders, and family history. 
Aim 2:  Describe the personal and disease history associations of Rome II 
IBS in the two population-based twin samples. 
1. Evaluate association between personal risk factors and IBS, 
specifically gender, self-rated health, and BMI. 
2. Evaluate association between specific diseases and IBS, such 
as lifetime MDD, chronic widespread pain, and chronic fatigue. 
Aim 3:  Estimate the contributions of genetic and environmental sources of 
variation in liability to co-morbid IBS and MDD. 
1. Evaluate association between IBS and zygosity. 
2. Assess significance of genetic, shared environment, and unique 
environment in lifetime co-morbid IBS and MDD. 
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2.3 MATERIALS AND METHODS 
2.3.1 Reliability and Validity of Questionnaire Instruments 
A. Irritable bowel syndrome (IBS) 
  All of the aforementioned criteria for IBS (Manning, Rome I, and 
Rome II) are based on symptomatology (1).  At this time, no validation studies 
of the Rome II criteria for IBS have been published, although a few are in 
progress (personal communication with DA Drossman on 10/21/2003).  
However, by examining the history and evolution of the symptom criteria, from 
Manning to Rome I and then Rome II, the validity of IBS by Rome II criteria is 
implied. 
Beginning with the Manning criteria for IBS, two factor analyses of the 
criteria were completed (2, 3).  Results of both these studies demonstrated an 
IBS factor that was defined by only three of the Manning criteria.  These 
studies helped to refine the criteria for IBS and have subsequently been 
incorporated into both the Rome I and the Rome II criteria.  The three factors 
identified were relief of pain with defecation, loose stools with onset of pain, 
and more frequent bowel movements with the onset of pain (2, 3).  Both of 
these studies used participant administered questionnaires to obtain 
information on bowel symptoms.  The Rome I criteria were established as a 
refined subset of the Manning criteria.  Another factor analysis was completed 
using the Rome I criteria (4).  This study mailed the Bowel Disease 
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Questionnaire (BDQ) to individuals in the USA, Australia, Germany, and 
Sweden.  A different validated questionnaire was used in Sweden, however it 
was considered to be comparable to the BDQ.  In this factor analysis, an IBS 
factor was demonstrated in all four countries, which suggests that the 
patterns of GI symptoms and groupings of individuals are similar across these 
cultures.  The common items that significantly defined the IBS factor in all four 
countries were: lower abdominal pain, pain relieved by a bowel movement, 
more bowel movements with pain, and looser stools with pain (4), which 
happen to form the core of the Rome I (and II) criteria for IBS. 
Using the clinician’s diagnosis of IBS as a gold standard, a study of the 
predictive value of the Rome I criteria was completed using both a 
prospective component and a retrospective component.  Both the prospective 
and retrospective components of the study were completed in patients 
referred to gastroenterology clinics and obtained all necessary information 
from medical record reviews.  In the retrospective analysis, the sensitivity of 
the Rome I criteria and the absence of red flags was 65%, specificity of 
100%, and positive predictive value of 100%.  Additionally, at the end of 2 
years of follow-up none of the patients diagnosed with IBS had their diagnosis 
changed.  The prospective analysis had a positive predictive value of 98%.  
Taken together, these results suggest that the Rome I criteria for IBS 
combined with a lack of red flags correspond to an IBS diagnosis (5). 
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Preliminary results from one of the Rome II validation studies that is 
currently in progress demonstrated that patient responses to a questionnaire 
would correctly identify 58% of IBS patients in primary care clinics, and 66% 
in gastroenterology clinics (6).  A drawback of the Rome II criteria 
demonstrated in this study was that while Rome II identified more IBS cases 
than were diagnosed by a physician using the Rome I criteria, the Rome II 
criteria were not as accurate as the Rome I criteria in diagnosing patients with 
an alternative  clinical diagnosis (6).  Thus the Rome II criteria may be 
problematic for other diagnosing GI disorders in gastrointestinal studies that 
are not examining IBS. 
Since the Rome II criteria are generally accepted by researchers in 
IBS, assessment by self-report began.  The use of self-report questionnaires 
to assess gastrointestinal symptoms is available.  Liebbrand and colleagues 
created the Gastro-Questionnaire for the screening and psychometric 
measurement of functional gastrointestinal disorders (7).  The reproducibility 
and validity of this instrument was performed in Germany on an unselected 
sample of the population, and thus may not be representative of the general 
German population.  Nonetheless, the results from this study demonstrated 
good reliability and good internal consistency (Cronbach’s alpha for frequency 
and severity items were 0.86 and 0.87, respectively).  The factor analysis 
performed explained 60.7% of the variance and obtained a six-factor solution.  
Based on this study, the Gastro-Questionnaire is thought to be a reliable and 
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valid instrument for the assessment of functional gastrointestinal disorders 
(7). 
In 2003, the self-administered Biliary Symptom Questionnaire (BSQ) 
and the shortened version (sBSQ) were created and assessed (8).  
Reproducibility of the instrument was assessed using the test-retest method, 
and median kappa values were 0.65.  Comparing BSQ responses with 
symptoms obtained by structured interview assessed concurrent validity.  The 
median kappa value for concurrent validity was 0.61.  Discriminant validity 
compared the BSQ-based diagnoses of biliary symptoms, gastroesophageal 
reflux disease (GERD), and IBS with patients’ final diagnoses.  Using the 
BSQ responses, investigators distinguished IBS and GERD 79% and 90% of 
the time, respectively.  Therefore, for biliary symptoms, the BSQ is 
reproducible, and has good concurrent and discriminant validity (8). 
Specifically examining the IBS subsection of the BSQ, the 
reproducibility has a kappa of 0.65, with 84% agreement.  The kappa for the 
concurrent validity is 0.63 with 79% agreement.  Additionally, when the BSQ 
score was compared with the diagnosis by a clinical gastroenterologist, the 
kappa value was 0.51 with 78.9% agreement.  Overall, the BSQ performed 
well and thus is shown to be reproducible, with concurrent and discriminant 
validity for IBS (8). 
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Based on results of these prior studies, the IBS component of the Adult 
Health and Personality (AHP) Survey questionnaire uses the Rome II 
research diagnostic criteria for IBS, adapted to a self-report format.  
Responses to questions were then converted into a dichotomized response 
(IBS yes or no) using the algorithm for the research diagnostic criteria of the 
Rome II committee (1).  This was thought to be a valid assessment of IBS 
status as it is similar to the BSQ.  The Screening Across the Lifespan Twin 
(SALT) survey does not contain these questions.  As such, a concordance 
between the AHP survey and the SALT survey questions was determined.   
Concordance of IBS definition.  Questions obtaining information on 
IBS in the SALT study were mapped onto appropriate questions dealing with 
IBS in the AHP study, and corresponding kappa statistics were determined by 
applying the AHP study’s Rome II IBS definition and the SALT-mapped IBS 
definition to the entire AHP sample.  By doing this, it was shown that there 
was good agreement (Cohen’s kappa=0.85-0.92) between a subset of 
questions on the SALT study, and the Rome II definition of IBS obtained in 
the AHP study.  Additionally, only 18 IBS cases out of the 203 total were 
misclassified during this procedure.  Therefore, I used the subset of questions 
that led to this concordance to define IBS in the SALT study.  This choice was 
made to make results from both studies comparable due to the use of the 
same (statistically speaking) definition of IBS in both studies. 
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B. Major Depressive Disorder (MDD) 
The diagnosis of major depression is a subjective diagnosis by the 
physician, as no biological test is available to determine whether a person 
definitely has the disorder.  With that caveat in mind, a physician diagnosis of 
major depression according to DSM criteria is considered the gold standard 
(9).  An instrument has been developed to diagnose and differentiate 
psychiatric disorders (10).  This instrument is the Structured Clinical Interview 
for DSM-III-R (SCID) (11, 12), and the revised SCID for the updated DSM-IV 
criteria.  This proposal uses self-report of MDD symptoms that is based on 
the SCID for DSM-IV diagnoses.   
The purpose of the SCID was to be able to extract all information 
necessary for a psychiatric diagnosis through the use of trained interviewers, 
not necessarily physicians (12).  The SCID was organized to systematically 
examine the DSM-III-R criteria, and the subsequent DSM-IV criteria, for each 
psychiatric disorder in a systematic approach (10).  It has a modular structure 
and approximates the decision tree approach of the DSM-III-R criteria (10, 11, 
13).  Using the modular approach, only certain sections are necessary for 
certain disorders, and as such, it can be adapted based on which psychiatric 
disorder diagnosis is of interest in a particular study (10, 11).  Additionally, by 
using the decision tree approach, the interviewer can skip modules based on 
the patients responses to key questions, which are considered essential 
criteria for a diagnosis in that module (10, 11). 
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The SCID is a semi-structured diagnostic interview (10, 11).  Its 
structure is such that it can systematically cover all psychiatric diagnoses in 
one interview.  It is considered semi-structured as opposed to fully structured 
because the trained interviewers are allowed to aide in the diagnosis by  
incorporating not only verbal responses, but also behaviors demonstrated 
during the interview, non-verbal actions seen during the face-to-face 
interview, and the patient’s documented medical history (12).  Additionally, if 
answers to questions are unclear or indeterminant, the interviewer is allowed 
to probe the participant with their own questions until enough information has 
been obtained to make a diagnostic decision (12).  The SCID was designed 
for use as a face-to-face interview, with the interviewer being someone with 
clinical experience and knowledge of psychopathology and psychiatric 
diagnosis, so as to conduct a diagnostic interview without an interview guide 
(11).  Most studies have trained individuals with professional backgrounds in 
psychiatry, psychology, or social work to be able to perform the SCID 
interview and obtain reliable diagnoses from its use (11). 
The reliability and validity of the SCID is important, as the basis of the 
MDD definition used in the Adult Health and Personality (AHP) survey is from 
an instrument similar to the SCID that is modified to a self-report format.  
Reliability of psychiatric diagnoses obtained through a SCID interview have 
been assessed in previous studies (10, 12-14).  In the reliability study of the 
SCID for all psychiatric disorders by Williams, et al., the test-retest reliability 
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method was used in four patient and two non-patient sites in the US, and one 
patient site in Germany (14).  In this reliability testing method, two 
interviewers, all with mental health training (either Masters, PhD, or MD), 
independently interview and diagnose the same subject.  Diagnoses are then 
compared to determine the reliability of the instrument.  In this study, the 
amount of information available to the interviewers was limited to a summary 
of the hospital admission evaluation and the interviewers were not allowed to 
consult with the patients full medical record, or full hospitalization file (14).  
Five hundred ninety two subjects were included in this study.  The results 
indicate a fair agreement in the use of the SCID for major depression in the 
patient sample, with kappa statistics ranging from 0.37 to 0.82 for current 
depression and from 0.53 to 0.80 for lifetime depression (14).  For both of 
these ranges, it must be noted that the lowest kappa values are from the 
population of patients that are in a substance abuse treatment unit, which 
may impose additional uncertainty in the use of the SCID (15), as a 20-30% 
correlation between MDD and substance abuse disorders has been reported 
(16).  Without the results from the substance abuse treatment unit, the ranges 
for the kappa values change to 0.54-0.82 for current depression, and 0.61-
0.80 for lifetime depression, all demonstrating moderate to good agreement 
(14).  In the non-patient samples, the SCID performed poorly, with an overall 
study kappa of 0.42 for current depression, and 0.49 for lifetime depression.  
These results are not that encouraging when presented by themselves.  
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However, when compared to other diagnostic instruments for psychiatry, such 
as the diagnostic interview schedule (DIS) which has a kappa for lifetime 
major depression of 0.61, and the composite international diagnostic interview 
(CIDI) which has a kappa of 0.66 for lifetime major depression and 0.52 for 
current lifetime depression, the results of the SCID appear similar.  In regard 
to the SCID and the DIS, the results from the SCID are very encouraging, 
especially since the DIS is a fully structured interview, where the only 
variability in a test-retest reliability study is when a patient responds yes to 
one interviewer and no to the other interviewer for the same question (14).  
Using the SCID, the variation comes from differences in interviewing style, 
depth of probing, and clinical judgment (14), so while there is more room for 
variability and thereby a lower kappa value, it appears to perform similarly to 
a structured interview where there is less variability. 
In the reliability study by Skre, et al., a different method of assessing 
reliability was used.  Here, each interview using the SCID was audiotaped, 
and two additional raters besides the interviewer determined a diagnosis 
based on that interview.  Thus, the kappa statistics in this study measured the 
inter-rater agreement (12).  This study was specifically examining the 
reliability of the SCID for major depression, and the interviewers were a 
medical doctor, psychologist, and psychiatry graduate students (12).  For this 
study both current and lifetime depressions were grouped together.  The 
resulting kappa value for inter-rater agreement for major depressive disorder 
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was 0.93, indicating excellent agreement (12).  Thus, both the Williams and 
Skre studies demonstrate acceptable reliability for the diagnosis of major 
depression using the SCID.   
 Riskind et al., performed another reliability study on the SCID (10).  In 
this study, interviews of 75 psychiatric patients were videotaped and two 
independent diagnoses were made, again testing inter-rater agreement.  In 
this study, the kappa statistic value was 0.72 for major depressive disorder, 
however MDD was not separated into current or lifetime depression.  
Additionally, the kappa statistic is associated with an 82% agreement rate 
between interviewers in the study.  Thus this study demonstrated that there is 
satisfactory diagnostic reliability amongst interviewers who are trained to use 
the SCID (10). 
Results from the Williams, Skre, and Riskind studies demonstrate 
adequate reliability of the SCID for diagnosing major depression.  Moreover, 
both inter-rater agreement and test-retest agreement were satisfactory.  
Therefore, the SCID is a reliable and valid instrument to diagnose major 
depression, higher among those diagnosed with MDD than non-patient 
samples.  The studies used in this proposal are non-patient samples, and 
thus lower kappa statistics for reliability should apply to these data. 
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Since the development and validation of the SCID, researchers 
became interested in the use of self-reported depression questionnaires in 
research.  One such self-report questionnaire is the Inventory to Diagnose 
Depression (IDD) which was designed as a self-report scale to diagnose 
MDD based on DSM-III criteria (17).  Scoring was completed by summing the 
scores for each question  based on a predetermined value; a diagnosis was 
determined when the summation surpassed a predetermined critical value 
(17). 
In an inpatient population, the IDD was shown to have high test retest 
reliability and high internal consistency.  The diagnostic agreement between 
the IDD and a clinician diagnosis of MDD was as high as that demonstrated in 
studies examining the inter-rater reliability of a diagnosis of MDD (17).  In this 
study, the kappa values for the IDD were 0.66 and 0.58, for symptoms only 
and symptoms plus duration of symptoms for MDD, respectively.  Thus, the 
IDD demonstrated good agreement with clinical diagnosis (17). 
The IDD has also shown good discriminant validity (18).  Uehara et al. 
demonstrated that the IDD was able to differentiate between individuals with 
MDD, individuals with anxiety disorders, and general controls with a 
concordance between the IDD and clinical diagnosis of 0.81.  Thus the IDD is 
able to clinically distinguish individuals with MDD from individuals with other 
mood disorders (18). 
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When the IDD was used in a population of alcohol-dependent men and 
women, the overall agreement of the IDD to the SCID was good (kappa=0.66) 
(15).  However, the agreement changed based on whether the responders 
were alcohol abstainers (κ=0.78) or recent alcohol consumers (κ=0.55) (15).  
Therefore, the IDD should be used with caution in a population of recent 
alcohol consumers. 
Another self-report instrument for depression is the Short Depression 
Interview (SDI) (19).  The diagnosis of depression using this instrument is 
based on the DSM-IV criteria.  Using this instrument in general practitioners 
clinics, the reproducibility of a major depression diagnosis was good, with a 
kappa of 0.63 (19).  The validity of major depression as a diagnosis as 
assessed by general practitioner compared to self-report was demonstrated 
to be satisfactory (r=0.35-0.61).  However the correlation coefficient for the 
test retest of the number of depressive symptoms was 0.82, and in 75% of 
patients the test retest difference in symptom number did not exceed one 
symptom (19).  Based on these results, the SDI has moderate to good 
agreement with general practitioner diagnoses of major depressive disorder. 
The Diagnostic Inventory for Depression (DID) is a self-report 
questionnaire that diagnoses depression based on the DSM-IV criteria (20).  
This instrument was compared with three other validated self-report 
questionnaires, the Beck Depression Inventory (BDI), the Hamilton Rating 
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Scale for depression, and the Clinical Global Index of Depression Severity.  
The correlation between the DID and each of these instruments was 0.83, 
0.73, and 0.73, respectively.  Additionally, it was shown that the threshold 
scoring used in the DID performed comparably to the DSM-IV based 
algorithmic approach in identifying cases of depression.  The DID also 
performed as well as the BDI in identifying SCID diagnosed cases of current 
depression (20).  These results demonstrate that the DID is another validated 
and reliable method of obtaining a DSM major depression diagnosis using 
self-report. 
As these studies have demonstrated, reliable and valid instruments 
exist for the self-report of depression in certain populations, such as 
inpatients, general practitioners clinics, and alcohol-consumers.  The 
concordance with the SCID is good, and the SCID has also been shown to be 
a valid and reliable instrument for diagnosing depression when compared with 
a physician diagnosis.  Thus the use of self-report for depression is a good 
estimate of a physician diagnosis of major depressive disorder.  Indeed 
Tondo et al. demonstrated that patients tend to rate their symptoms of 
depression to be worse than their physicians’ assessment when both patient 
and physician use their respective forms of the Inventory for Depressive 
Symptomatology (IDS) (21).  Additionally, self-report of depression has 
yielded similar lifetime prevalences, gender ratios, and heritability estimates 
as direct interview studies (22, 23).   
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C. Self-Rated Health 
The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-
36) has been used to determine a person’s summary physical health and 
summary mental health scores (24), and is used as a quality of life indicator.  
The SF-36 is a shortened version of the 149 health status questions 
developed as a potential tool for monitoring patient outcomes in a clinical 
setting (25).  Three aspects of health are covered in the SF-36; functional 
status, well-being, and overall evaluation of health using eight separate 
scales (physical functioning, social functioning, role limitations attributable to 
physical limitations, role limitations attributable to emotional problems, mental 
health, energy and fatigue, pain, and general health perception) (25-27).  This 
questionnaire has been validated and shown to be reproducible (24).  Results 
from studies performed in different populations have consistently 
demonstrated internal consistency of the SF-36 with corresponding 
Cronbach’s α coefficients ranging from 0.76-0.93 (25-27).  Two of these 
studies also evaluated the test-retest reliability of the SF-36, and it received 
acceptable pearson correlation coefficients, ranging from 0.60-0.89 (25, 26).  
Another study examined criterion validity of the SF-36 by comparing scores 
for the seven multi-item dimensions assessing functional status and well-
being with a single global health question and the results strongly supported a 
linear trend of decreasing SF-36 score corresponding to worse reported 
health on the initial question (27).  Taken together, these results suggest that 
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the SF-36 is reliable to monitor health.  However, due to economic 
considerations, space considerations on questionnaires, as well as the 
amount of time it takes for individuals to complete the questions (24),  the SF-
36 has been condensed into a 12-Item Short-Form Health Survey (SF-12) 
(24).   
The SF-12 has been validated against the SF-36, and has 
demonstrated a multiple R2 of 0.911 in the prediction of the SF-36 physical 
component summary score, and 0.918 in the prediction of the SF-36 mental 
component summary score in the general US population (24).  Therefore the 
questions contained on the SF-12 were the best predictors of both scales on 
the SF-36.  The SF-12 physical and mental component scores also were 
highly correlated to the corresponding SF-36 physical and mental component 
scores (r=0.951 and 0.969, respectively) (24).  Additionally, independence 
between the physical and mental components was maintained, as the two 
components were very weakly correlated with each other (r=0.06) (24).  Test 
retest reliability of the physical and mental components of the SF-12 yielded 
coefficients of 0.890 and 0.760, respectively, in a US sample (24).  These 
coefficients compare favorably with those for the corresponding SF-36 
components.  All of these statistics lead to the conclusion that the SF-12 is 
able to maintain satisfactory reliability to the SF-36 while reducing the number 
of items in the questionnaire (24). 
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The AHP questionnaire included a section of questions on self-rated 
health.  This section consisted of 12 questions, namely the questions that 
comprise the Medical Outcomes Study 12-Item Short Form Health Survey 
(SF-12) (24).  As was discussed previously, this instrument was found to be 
valid and reliable in other US studies. 
2.3.2 Description of Study Populations 
In order to address the aims of this proposal, two studies were used.  
The first study, the Adult Health and Personality (AHP) Survey, is a subset of 
the Mid-Atlantic Twin Registry (MATR).  This study was used to investigate 
aims 1 and 2.  The second study, the Screening Across the Lifespan Twin 
Study (SALT) study, is a subset of the Swedish Twin Registry (STR).  This 
study was used to primarily investigate aim 3, however aims 1 and 2 were 
also investigated but not incorporated into a manuscript due to negotiations 
with the STR. 
A. Parent Study: Mid-Atlantic Twin Registry (MATR) 
The Mid-Atlantic Twin Registry is a population-based registry of twins 
of all ages who are born in or live in North Carolina, South Carolina, and 
Virginia, and who are willing to consider participating in health-related 
research.  There are more than 51,000 twins in the registry.  Complete twin 
pairs are responsible for roughly 46,000 of the twins in the registry.  The 
identification of twins and their families is done by using publicly available 
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birth records, public driver's license information, and through public and 
private school records, which are made available only for the purpose of 
medical research.  Scientists connected to the MATR have explored such 
topics as epilepsy, cardiovascular disease, diabetes, cancer, obesity, 
inflammatory bowel disease, attention-deficit hyperactivity disorder, clinical 
depression, anxiety, pregnancy complications, periodontal disease, alcohol, 
nicotine and other drug abuse, stress and coping, religiosity and spirituality, 
social support, and parenting styles (28).  
B. Adult Health and Personality (AHP) Survey 
Data collection.  Approximately 16,000 twins participating in the 
MATR were initially mailed a self-report questionnaire.  If the questionnaire 
was not returned within five weeks, a reminder was sent to the same address.  
An attempt was also made to telephone non-responders if there was no 
response to the reminder mailing.  The initial mailing was sent out in late 
2001, and all data collection was complete by early 2002.   
Response rate.  Completed questionnaires were returned by 4,591 
twins.  Response rate for this survey is not known due to not knowing who in 
the MATR was actually mailed a survey.  Therefore, the denominator is not 
enumerated, but it is estimated that 30% of individuals responded, which is 
thought to be an underestimate of the true response rate, as 10-25% of the 
mailed questionnaires never reached potential participants due to incorrect 
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mailing addresses, incorrect forwarding of mail, etc.  Zygosity was determined 
for 79% of these respondents.  This represents 3764 twins, 988 (26.3%) 
monozygotic, 1985 (52.7%) dizygotic, and 791 (21.0%) twins of unknown 
zygosity. 
Questionnaire.  The information collected in this questionnaire dealt 
with personal history of many chronic diseases, current status of some 
disorders, limited information on family history for an assortment of diseases, 
personality disorders, and behaviors related to smoking and exercise.  The 
variables that were used in this analysis are age, gender, calculated body 
mass index (BMI, which is kg/m2), mental health standardized score on the 
SF-12, physical health standardized score on the SF-12, chronic fatigue 
syndrome-like illness (a surrogate for chronic fatigue syndrome, as all that is 
missing for a diagnosis is the physical exam), chronic widespread pain (a 
surrogate for fibromyalgia, as all that is missing for a diagnosis is the physical 
exam), Rome II irritable bowel syndrome, DSM-IV major depression, and self 
history of IBS, Crohn’s disease, and ulcerative colitis.  These variables were 
chosen based on prior literature that stated an association of these variables 
with either IBS or MDD.  The directed acyclic graph for this analysis is shown 
in Figure 2.1. 
Working definition of IBS.  The questionnaire contained items that 
followed the research diagnostic criteria of the Rome II criteria for an IBS 
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diagnosis (1) , and the accompanying diagnostic algorithms for IBS are 
applied to the questionnaire responses to obtain an IBS diagnosis.  The 
Rome II criteria were decided upon through consensus by gastroenterologists 
and are used in research in order to be able to compare results (1).  For the 
analysis of the AHP study, any twin that fulfilled the Rome II criteria based on 
the questionnaire responses and did not report a self-history of Crohn’s 
disease or ulcerative colitis were considered an IBS case.  Those who did not 
fulfill the Rome II criteria were the non-IBS controls. 
Working definition of MDD.  Major depressive disorder (MDD) was  
determined based on the guidelines in the Diagnostic and Statistical Manual, 
4th edition (DSM-IV) (29).  This determination is through responses to a self-
administered depression screener containing expanded versions of the 
section of the SCID interview for MDD, adapted to a self-report format (23).  
The DSM-IV criteria were then applied to questionnaire responses by a 
computer algorithm to assess the presence of MDD during any two week 
period over the participants’ lifetime (lifetime MDD).   
C. Parent Study: Swedish Twin Registry (STR) 
The Swedish Twin Registry was established in 1961 and is a research 
resource maintained at the Karolinska Institutet. The Swedish Twin Registry 
(http://www.mep.ki.se/twinreg/index_en.html) includes more than 140,000 
twins, thus making it the largest registry of twins in the world.  It was 
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established in the 1950’s to study the risk factors for cancer and 
cardiovascular diseases, while controlling for genetic risk of disease.  The 
registry is updated monthly through linkages to three national registries: the 
address registry, the cancer registry, and the cause of death registry (30, 31). 
There are three age cohorts in the registry: the older cohort, comprised 
of 10,945 pairs of like-sexed twins born 1886 through 1925; the middle 
cohort, comprised of approximately 50,000 pairs of like- and unlike sexed 
twins born 1926 through 1967; and the younger cohort, twin pairs born since 
1967 which number roughly 25,000. Questionnaire data has been collected 
from members of the old cohort in 1961, 1963, 1967, and 1970, and from like-
sexed members (born 1926-1958) of the middle cohort in 1973. The 
questionnaire data include items about health (cardiovascular disease, 
cancer, asthma), health-related behaviors (tobacco, alcohol, and caffeine 
consumption), personality, physical activity, eating habits, and environmental 
stressors (30).  
D. Screening Across the Lifespan Twin (SALT) Study 
Data collection.  Twins born in Sweden in 1958 or earlier were 
included.  A computer assisted telephone interview about different diseases 
and symptoms was used.  In order to minimize the risk of bias due to potential 
age effects, an attempt was made to interview both members of a twin pair 
within a month of each other.   
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Following the pilot study that was completed during the fall of 1996 and 
spring of 1997, full-scale data collection began in March 1998.  The telephone 
interviews were completed by trained interviewers, with adequate medical 
background, using a computer-based data collection system.  The interview 
structure began with an introductory section containing questions about birth 
order and weight, validated zygosity questions, contact with twin partner and 
family.  Once those were completed, a checklist of common illnesses, 
prescription and nonprescription medication use, and permission to collect 
medical records was asked for.  Basic demographic and social data were 
obtained, including occupation, education, consumption of alcohol, tobacco, 
and caffeine.  If it was determined that the twin could not be interviewed, the 
interview was conducted with an informant (32). 
Questionnaire.  The portion of the interview concerned with common 
illnesses was designed to obtain as much information as necessary to screen 
for most common complex diseases, including obesity and eating disorders, 
heart and vascular diseases, diabetes, women’s health, asthma, allergy, 
eczema, headache, gastrointestinal problems, arthritis, osteoporosis, muscle 
pain, sleep problems, chronic fatigue syndrome, Parkinson’s disease, 
depression, anxiety, mania, epilepsy, smoking, coffee, and alcohol habits, 
fibromyalgia, and irritable bowel syndrome (32).  Emphasis was put on 
diagnostic items rather than just asking a twin whether they have a disease.  
These diagnostic items were presented in a branching format so that within a 
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disease area follow-up items were asked only if the participant responded 
positively to the key introductory items.  These items were compiled by 
experts in each of the disease areas (32, 33).  If standardized instruments 
were available, such as the short Computerized International Diagnostic 
Interview (CIDI) for psychiatric disorders (34), these were used. 
Working definition of IBS.  The diagnostic algorithm used to 
diagnose IBS was not an exact match of the Rome II criteria.  Therefore, 
using exact Rome II criteria for the analysis in this study was not possible 
because the questions were not specific enough to fulfill the Rome II criteria.  
In an effort to allow this study and the AHP study to have similar definitions of 
IBS, a concordance between the questions pertaining to abdominal problems 
in the SALT study, and the Rome II questions of the AHP study was 
undertaken as described on page 150.  Based on this analysis, the questions 
from the SALT questionnaire that best correspond to the Rome II criteria were 
used for a diagnosis of IBS.  The IBS definition was comprised of positive 
responses to the following questions: recurrent abdominal discomfort, 
abdominal discomfort that lasted as least 7 days a month, if intestinal 
problems were more prominent when feces became looser and defecation 
more frequent, and reporting recurrent problems with pain in either the upper 
abdomen, lower abdomen, or another part of the abdomen.  Subjects 
reporting a history of Crohn’s disease (n=34), ulcerative colitis (n=55), 
stomach ulcers (n=59), intestinal ulcers (n=46), or any combination of these 
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(n=52) were excluded.  Together, the subset of questions combined with the 
exclusions was applied to the cohort to identify Rome II IBS cases in the 
SALT study.  By employing this method of definition in the SALT study, it was 
thought that the results would be more readily comparable due to the use of 
the same (statistically speaking) definition of IBS in both studies.   
Working definition of MDD.  This determination was done through an 
algorithm using the participant’s answers to the short form of the 
computerized international diagnostic interview (CIDI) which was obtained 
through a telephone interview, completed by trained medical interviewers 
(33). 
2.3.3 Data Analysis 
Due to the breadth of information available from the interview 
performed in the SALT study, it is safe to assume that variables included in 
the AHP study were also available in the SALT study.  Additionally, since this 
questionnaire is funded through the Karolinska Institutet, the variables that I 
had access to were limited due to the permission that I was given to use this 
data.  Thus, the same variables that were used to analyze the AHP study 
were also used in the SALT study.  In this way, I was able to compare results 
of the prevalence and associations of Rome II IBS, and additionally was able 
to perform a co-twin control analysis using the SALT study due to near 
complete zygosity determination for the entire sample.  
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A. Outcome of Interest 
The outcome of interest was Rome II defined IBS.  This outcome was 
dichotomous, that is either IBS was present or absent.  In both studies, this 
variable was derived by utilizing the responses to the corresponding 
gastrointestinal questions, excluding those with Crohn’s disease and 
ulcerative colitis, and translating them into a Rome II IBS diagnosis based on 
the algorithm defined by the Rome committee (1).   
B. Exposure of Interest 
For aims 1 and 2, the exposure of interest varied depending on which 
previously reported covariate was investigated in relation to its association 
with Rome II defined IBS.  Thus, the exposures were gender, lifetime major 
depression, chronic widespread pain, chronic fatigue syndrome-like illness, 
mental and physical scores of the SF-12, body mass index, and age.  For aim 
3, lifetime major depression was the main exposure of interest for the co-twin 
control analysis of Rome II IBS.   
C. Statistical Analysis Related to Specific Aims 
Aim 1: Estimate the prevalence of Rome II IBS in various twin 
populations. 
In order to describe the prevalence of IBS, basic descriptive statistics 
were calculated for each study.  The SAS program, version 8.02, (35) was 
used to obtain the appropriate frequencies.  Of particular interest was the 
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frequency of Rome II defined IBS in the whole sample, as well as stratified by 
gender (Tables 2.2, 2.3, 2.31, 2.32, 2.38, and 2.39).       
Bivariate frequencies were then calculated with those covariates 
thought to influence IBS (36).  Variables of interest were gender, age, lifetime 
MDD, chronic fatigue syndrome-like illness (all criteria but physical exam 
needed for chronic fatigue syndrome) (37), chronic widespread pain (measure 
of fibromyalgia), SF-12 (mental and physical components), and body mass 
index.   
Aim 2: Describe the personal and disease history associations with 
Rome II IBS in the two population-based twin samples. 
To assess the personal and disease history associations with Rome II 
IBS, generalized estimating equations were used in the SAS software (35) in 
order to adjust for the clustered nature of the twin data while determining the 
relevant associations with IBS among the previous covariates that have 
demonstrated an association with IBS.  A crude bivariate analysis of IBS 
(yes/no) and each exposure mentioned above, including estimates of the 
odds ratios and corresponding 95% confidence intervals were obtained (36, 
38) (Tables 2.5, 2.6, 2.33, 2.34, 2.41, and 2.42).  The continuous variables 
were age, BMI, SF-12 mental health score, and SF-12 physical health score.  
BMI and the SF-12 scores were also analyzed as dichotomous variables 
(above/below the BMI for obese, and for SF-12 scores, as above/below the 
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population mean score), and as quartiles.  Based on previous research, the 
directed acyclic graphs (DAGs) in Figures 2.1-2.8 were used to aid in 
determining the appropriate confounders and covariates to be included in the 
modeling of IBS which was incorporated into the modeling strategy of 
Kleinbaum (39).  The covariates of interest are presented in Table 2.1 as well 
as a description of the variables with their potential coding schemes. 
To use DAGs to determine which covariates should be included in the 
multivariable models,  a graph (Figures 2.1-2.8) was drawn to visually depict 
the causal associations between exposure, outcome, and covariates (40, 41).  
The arrows on the graph signify associations, and the association of interest 
was depicted by a question mark above that arrow (41, 42).  Graphical rules 
of analysis were then used on these graphs to determine which variables 
were potential confounders and needed to be considered as such during the 
multivariable modeling (40). 
Stratification analysis (effect measure modification assessment).  
For the remaining analyses of this aim, lifetime major depression is used as 
the main exposure to illustrate the process of assessing effect measure 
modification that was conducted for several other covariates, including BMI, 
chronic widespread pain, chronic fatigue syndrome-like illness, SF-12 
physical and mental health score, gender, and age.  This further elucidated 
the relevant associations with Rome II defined IBS. 
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Effect measure modification (EMM) was assessed on both the additive 
and multiplicative scales.  All assessments were completed prior to 
confounding assessment.  To determine which covariates were effect 
modifiers, crude and adjusted odds ratios (ORs), corresponding 95% 
confidence intervals (CIs), and Breslow-Day p-value were calculated.  The 
crude estimate was obtained from the bivariate analysis of lifetime MDD and 
IBS result.  Covariates were considered as strong potential effect modifiers if 
the Breslow-Day p-value was < 0.20, as possible effect modifiers if the 
Breslow-Day p-value was between 0.20 and 0.5, and as unlikely effect 
modifiers if the Breslow-Day p-value was > 0.5.  Tables 2.7, 2.10, 2.13, 2.16, 
2.19, 2.22, 2.25, 2.28, 2.35, and 2.43 provide a summary of the evaluation of 
effect measure modification when each covariate was used as the main 
exposure.  To determine appropriate reference groups and to further examine 
which variables should be kept as potential effect measure modifiers, 
analyses of joint effects on both the additive and multiplicative scale were 
conducted as necessary (39). 
On the additive scale, the estimate of the association between MDD 
and IBS was stratified by levels of the potential effect modifier.  Stratified odds 
ratios, 95% confidence intervals, and the interaction contrast ratio (ICR) were 
calculated.  If the ICR is 1, EMM was not considered to be present for that 
potential effect modifier.  An ICR less than 1.0 was suggestive of the 
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antagonistic EMM, and an ICR greater than 1 suggested synergistic EMM 
(36).   
For assessment of EMM on the multiplicative scale, logistic regression 
models of the association between MDD and IBS with and without interaction 
terms between MDD and the potential effect modifiers were compared using 
the likelihood ratio test.  If the likelihood ratio test was significant (p<0.2), then 
the interaction terms modified the association between MDD and IBS.  
However if the likelihood ratio test was not significant, the interaction term did 
not modify the association between MDD and IBS. 
Confounding assessment.  To assess for confounding by those 
variables found not to be effect modifiers, I incorporated the following three 
methods: directed acyclic graphs (DAGs), bivariate distribution of the 
exposure by each covariate among the controls and distribution of IBS by 
each covariate conditional on non-exposure, and change in the odds ratio.  
DAGs were drawn based on a review of the literature, and helped to establish 
potential covariates as confounders.  I obtained and compared the odds ratios 
from the bivariate distribution among controls and among non-exposed for 
each covariate (Tables 2.8, 2.11, 2.14, 2.17, 2.20, 2.23, 2.26, 2.29, 2.36, and 
2.44, depending on the exposure of interest).  The change in the estimated 
odds ratio was obtained by using the following formula: ln[ORcrude/ORadjusted].  If 
the result of this comparison was less then 0.10, the potential confounder of 
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interest was not a confounder.  If the result of this comparison was greater 
than or equal to 0.10, then the exposure-covariate (E-C) and covariate-
disease (C-D) relationships were examined to further assess confounding 
(37, 39).  Additionally, if our DAG illustrated that a covariate was associated 
with the exposure and related to the outcome, it was included in our model, 
even if the change in ln[ORcrude/ORadjusted] was less than 0.10.  However 
variables that were affected by the exposure or affected by the outcome were 
not considered as potential confounders. 
In order to examine the E-C relationship, odds ratios were calculated 
examining lifetime major depression by each of the dichotomous and 
categorical covariates (i.e. gender, BMI, age, chronic widespread pain, 
chronic fatigue syndrome-like illness, self-rated mental health score, and self-
rated physical health score).  All study participants were included in this 
analysis. Odds ratios (ORs) and 95% confidence intervals were calculated, as 
was a precision estimate (upper confidence limit divided by lower confidence 
limit) (43).  Tables 2.8, 2.11, 2.14, 2.17, 2.20, 2.23, 2.26, 2.29, 2.36, and 2.44 
summarize these results. 
The covariate-disease (C-D) relationship was examined by calculating 
odds ratios of the main outcome (IBS) among individuals in the control 
exposure group (no lifetime MDD) by each of the dichotomous and 
categorical covariates (i.e. gender, BMI, age, chronic widespread pain, 
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chronic fatigue syndrome-like illness, self-rated mental health score, and self-
rated physical health score). Odds ratios (ORs) and 95% confidence intervals 
were calculated, as was a precision estimate (upper confidence limit / lower 
confidence limit) (43).  Tables 2.8, 2.11, 2.14, 2.17, 2.20, 2.23, 2.26, 2.29, 
2.36, and 2.44 summarize the results of the exposure-covariate and 
covariate-disease relationships when each covariate was used as the main 
exposure and the remaining covariates were used as explanatory variables 
(37, 39).  For each variable, the OR and 95% CI was calculated. 
Multivariate analysis.  The model of interest is specified below. 
Logit P(lifetime IBS) =α +β1(lifetime MDD) +β2Var1 +β3Var2 + β4Var3 +… 
Unconditional logistic regression was used to obtain a valid estimate of 
the lifetime MDD—IBS relationship that accounts for confounding and effect 
modification.  Unconditional logistic regression was chosen since the data 
was not matched, the dependent variable was dichotomous, and because 
there were a small number of parameters relative to the number of subjects 
(37).  Additionally, the natural clustering due to the use of twins was 
accounted for by a clustering variable in generalized estimating equations. 
Modeling strategy.  The modeling strategy for this analysis is 
discussed below, and was adapted from Kleinbaum (39).  The first step was 
to specify the variables that were included in the full model.  The goal of this 
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was to determine independent variables that may be meaningful in order to 
obtain a valid measure of effect.  The variables to be considered were 
selected because they were biologically or clinically relevant to the 
occurrence of IBS, or because they were determined to be relevant based on 
a review of the literature.  The full model included all the relevant variables.  
Tables 2.9, 2.12, 2.15, 2.18, 2.21, 2.24, 2.27, 2.30, 2.37, 2.45, 2.46, and 2.47 
show the results for the full model where each covariate was the main 
exposure. 
The next step was to make sure that the full model (and all subsequent 
models during the modeling process) was hierarchically well-formulated.  This 
meant that any variable that was included in an interaction term was also 
included as a lower-order component variable in the model (39).  When this 
was completed, assessment of interaction began.  The first step for 
interaction assessment was to run two models, the full model and the model 
with no interaction terms.  By doing this, a ‘chunk’ test was completed to test 
for overall interaction by using the likelihood ratio test to determine if the 
interaction terms as a whole can be eliminated from the model (39).  An α of 
0.20 was used for the likelihood ratio test when comparing models with and 
without interaction term(s).  Thus, if the p-value associated with the likelihood 
ratio test was less than 0.20, the interaction term(s) that were removed from 
the model were returned to the model, whereas if the p-value was greater 
than 0.20, the removed interaction terms were not significant to the model 
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and remained eliminated from the model (39).  If this initial ‘chunk’ test was 
not significant then all the interaction terms were eliminated from the model.  
If however the ‘chunk’ test was significant, then at least some or all of the 
interaction terms were significant and further assessment of the interaction 
terms was performed (39). 
If the ‘chunk’ test was significant, and thus some or all of the 
interaction terms were relevant to the model, then the backward elimination 
method was used to examine the interaction terms one at a time in order to 
eliminate insignificant variables from the model.  This began by examining the 
least significant interaction term in the model (the interaction term that was 
associated with the largest p-value in the full model).  To determine if this 
term was significant or not, the full model and the model without this 
interaction term were compared using the likelihood ratio test as explained 
above.  If this interaction term was not significant, it was removed from the 
model.  If the interaction term was significant, it was retained in the model.  
The remaining interaction terms were assessed in the same manner.  Any 
covariates that were included in interaction terms that remained in the model 
at the end of this process were not assessed for confounding (39). 
Once the assessment of interaction was complete, the assessment of 
confounding began.  For this, the least significant variable that was identified 
as a potential confounder in the stratified analysis was removed from the 
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model.  In order to determine if the inclusion of this term confounded the 
association, the adjusted OR was compared to the crude OR.  If ln 
|ORcrude/ORadjusted| > 0.10, then the variable was kept in the model; otherwise it 
was eliminated from the model.  As stated previously, variables involved in an 
interaction term were not considered as confounders because they must 
remain in the model in order for the model to be hierarchically nested, and 
thus comparable to the previous model.  Only those variables that were not 
included in significant interaction terms were considered when assessing 
confounding (39).  Tables 2.9, 2.12, 2.15, 2.18, 2.21, 2.24, 2.27, 2.30, 2.37, 
2.45, 2.46, and 2.47 concisely summarize all of the modeling information 
using each covariate as the main exposure in its own model.  These tables in 
combination with the precision estimates for the calculated odds ratios for 
each model were used to decide upon the most appropriate, unbiased, 
precise, and parsimonious model (39). 
Lastly, since the data describe lifetime prevalence of MDD and lifetime 
IBS with limited information on age of onset for both disorders, no causality 
was implied.  In order to determine if causality influenced the association 
between lifetime MDD and lifetime IBS, modeling was also performed with 
lifetime MDD as the dependent variable (outcome) and lifetime IBS as the 
independent variable (exposure).  This was a sensitivity analysis of the 
implied causality of these models, thereby determining how sensitive the 
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statistics and associations were to changes in the causality assumption (44).  
The DAG for this analysis is shown in Figure 2.7. 
Aim 3: Estimate the contributions of genetic and environmental sources 
of variation in liability to co-morbid IBS and MDD. 
To assess the genetic and individual-specific environmental sources of 
variation in lifetime co-morbid IBS and MDD, a co-twin control analysis was 
performed using the data from the SALT study.  This analysis was completed 
in the SALT study because it had a larger sample size and because the 
zygosity of the twins was near complete.  The zygosity being near complete  
was very important, as this analysis takes advantage of the fact that 
monozygotic and dizygotic twins share different degrees of genetic 
relatedness, and so in order for the analysis to be informative, the zygosity 
information must be complete.  In this study, I used disease discordant twins, 
that are twin pairs discordant for IBS, and two control groups: external (not 
related) controls, and internal (co-twin) controls.  The first step in this analysis 
was to assess the association between MDD and IBS.  This was essentially a 
case-control study in which I compared twins diagnosed with IBS with 
external controls (other twins not related to the index probands), and 
evaluated the association between MDD and IBS (32, 33).  To complete this 
step, the methods and analysis plan that was outlined for specific aim 2 was 
employed with the modification of using conditional logistic regression as 
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these twin pairs were matched by gender and 3-year age band (37) 
throughout the remaining twin analyses.  This determined if there was an 
association between MDD and IBS in this population, and the magnitude of 
the association. 
I then determined the extent to which this association was influenced 
by genetic variation and the extent to which it was influenced by the 
environmental variation beginning in the second step, which controlled for 
confounding from unmeasured early environment.  In this step, the healthy 
co-twin of the pair (i.e. the twin without IBS) was used as the control for the 
diseased (IBS) twin.  This minimized confounding by differences in 
unmeasured childhood or adolescent environments because the twin pair 
shared the same intrauterine environment and was typically reared together 
in this sample (32, 33).  Again, the methods outlined in specific aim 2, 
modified to use conditional logistic regression due to age and gender 
matching of the twins, was employed with the caveat of the specific control 
used for each IBS case.  If the association demonstrated in the first step of 
this process remained after this process, then the association was not 
influenced by the common environment. 
The third step was to control for unmeasured genetic background.  
During this step of the analysis, only disease discordant monozygotic twin 
pairs were used.  This controlled for potential confounding from genetic 
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factors as the cases and controls were genetically identical.  Therefore, an 
observed effect was not confounded by genetic predisposition (32).  The 
same methods were used as previously stated, except that the analysis was 
restricted to disease discordant monozygotic twin pairs for both the cases and 
the controls, and conditional logistic regression was used since the twin pairs 
were age and gender matched.  Table 2.48 explains how to interpret results 
from this analysis. 
D. Power Calculations 
Allowing major depression to be the exposure of interest, the 
prevalence of this exposure was allowed to vary between 10 and 20% in 
order to perform power calculations for this cross-sectional study.  
Additionally, I allowed the outcome (IBS) prevalence to vary between 5 and 
10%.  EpiSheet by Rothman (45) was used to obtain the power estimates 
presented in Table 2.49.  These calculations were based on having 203 IBS 
cases, as that was the number of IBS cases in the AHP study, the smaller of 
the two studies used in these analyses.  By examining Table 2.49, assuming 
to obtain an association with a prevalence odds ratio (POR) of 1.5, the power 
in the AHP study varied between 59 and 78%, depending on the actual 
exposure and outcome prevalence in the study.  It was thought that the SALT 
study will be better powered to detect modest effects, as it is a larger study 
and thus there should be a larger number of IBS cases. 
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2.3.4 Human Population, Ethical Consideration, and IRB Issues 
The research was conducted in accordance with the principles 
embodied in the Declaration of Helsinki and under the approval of the 
University of North Carolina School of Public Health Institutional Review 
Board.    
Procedures were implemented to ensure the privacy of the 
participants.  Every precaution to maintain the confidentiality of participants’ 
records was employed.  No subjects were identified in any report or 
publication about this study.  Anonymous identification numbers were 
assigned to all information from the interviews and surveys.  Participants were 
not represented by name in the data files.  Access to these names was 
limited to the principle investigators.        
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Table 2.1: Description of variables and potential coding for analysis. 
Variable Description Coding Scheme 
Outcome of Interest   
Irritable bowel syndrome 
(IBS) 
Lifetime diagnosis of IBS 1= Have had IBS in lifetime 
0= No IBS in lifetime 
Exposure of Interest   
Major depressive disorder 
(MDD) 
Have/had an episode of 
major depression during 
lifetime 
1= Have had MDD in lifetime 
0= No MDD in lifetime 
Other Covariates   
Gender  1= Female 
0= Male 
Age Age when completed 
questionnaire 
Continuous 
Body mass index Calculated, kg/m2 4= 18.5-24.9 kg/m2
3=<18.5 kg/m2 
2=25-19.9 kg/m2
1=≥30 kg/m2
Chronic fatigue syndrome 
(CFS)-like illness 
Have/had chronic fatigue 
during lifetime 
1= Have had CF in lifetime 
0= No CF in lifetime 
Chronic Widespread Pain 
(CWP) 
Have/had CWP during 
lifetime 
1= Have had CWP in lifetime 
0= No CWP in lifetime 
SF-12, Mental health  Continuous 
SF-12, Physical health   Continuous 
Personal History 
Variables 
  
Crohn’s Disease History of yourself having 
Crohn’s disease during 
lifetime  
1= Yes, had Crohn’s disease 
0= No Crohn’s disease 
Ulcerative Colitis History of yourself having 
Ulcerative Colitis during 
lifetime 
1=Yes, had ulcerative colitis 
0=No ulcerative colitis 
IBS History of yourself having 
IBS during lifetime  
1= Yes, had IBS 
0= No IBS 
Table 2.2: Characteristics of IBS cases and controls, AHP study, 1999. 
185
      Total Cases Controls Chi-Square
 No. %    
       
      
No. % No. % statistic 
 (p-value)*
 Total 4,548 212 4.7 4,336 95.3
Age at interview (years)        2.0043 (0.9809)
  < 36 years old 1,120 24.63 52 24.53 1,068 24.64  
  36-43 years old 1,194 26.26 59 27.83 1,135 26.19  
  44-51 years old 1,204 26.48 56 26.42 1,148 26.49  
  > 51 years old 1,028 22.61 45 21.23 983 22.68  
  Missing 2  0  2   
  Mean (SE)   42.77 (0.25) 
 
 42.83 (0.16) 
 
 0.37 (0.7113) 
 Sex     
       
       
       
  Male 1,609 35.39 46 21.7 1,563 36.06 -3.41 (0.0006) 
  Female 2,938 64.61 166 78.3 2,772 63.94  
  Missing 1  0  1   
MDD 
  Yes 861 19.1 69 32.5 792 18.4 -4.83 (<0.0001) 
  No 3,667 80.9 143 67.5 3,524 81.6  
  Missing 20  0  20   
CWP 
  Yes 362 7.96 51 24.1 311 7.2 -8.10 (<0.0001) 
  No 4,183 92.04 161 75.9 4,022 92.8  
  Missing 3  0  3   
CFS-like illness 
  Yes 163 3.6 30 14.2 133 3.1 -7.47 (<0.0001) 
  No 4,385 96.4 182 85.8 4,203 96.9  
  Missing 0  0  0   
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      Total Cases Controls Chi-Square
 No. %     
       
      
No. % No. % statistic
 (p-value)*
 BMI 
  ≤24.9 kg/m2 1,983       
      
      
       
    
       
    
43.6 80 37.7 1,903 43.9 4.7160 (0.0946)
   25-29.9 kg/m2 1,509 33.2 71 33.5 1,438 33.2
  ≥30 kg/m2 1,056 23.2 61 28.8 995 22.9 
  Missing 0  0  0   
Mental Health Score 
  < mean 1,395 31.4 100 48.3 1,295 30.6 -5.06 (<0.0001) 
  ≥ mean 3,042 68.6 107 51.7 2,935 69.4  
  Missing 111  5  106   
  Mean (SE)   47.00 
(0.66) 
51.02 (0.15) 5.93 (<0.0001)
Physical Health Score 
  < mean 1,135 25.6 107 51.7 1,028 24.3 -8.10 (<0.0001) 
  ≥ mean 3,302 74.4 100 48.3 3,202 75.7  
  Missing 111  5  106   
  Mean (SE)   45.59 
(0.63) 
51.52 (0.15) 9.19 (<0.0001)
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   Males Females
 Cases    
            
         
        
Controls Chi-
Square  
Cases Controls Chi-Square
 No. % No. % statistic No.
 
% No. % statistic
 (p-value)*
 
(p-value)*
 Total 46 2.9 1,563 97.1 166 5.7 2,772 94.3
Age at 
interview 
(years) 
          3.8859
(0.6921) 
4.3345
(0.8258) 
  < 36 years old 8          
          
          
          
          
        
        
     
         
   
    
         
           
17.4 308 19.7 44 26.5 760 27.4
  36-43 years old 10 21.7 380 24.3 49 29.5 755 27.2
  44-51 years old 13 28.3 447 28.6 43 25.9 701 25.3
  > 51 years old 
 
15 32.6 428 27.4 30 18.1 555 20.0
  Missing 0 0 0 1
  Mean (SE) 44.19 
(0.27) 
44.38
(0.25) 
1.80
(0.0740) 
 
41.98 
(0.20) 
41.96
(0.19) 
-0.45
(0.6502) 
 MDD 
  Yes 9 19.6 213 13.7 -1.20 
(0.2300) 
 
60 36.1 579 21.0 -4.32
(<0.0001) 
   No 37 80.4 1,343 86.3 106 63.9 2,180 79.0
  Missing 0 
 
 7 
 
 
 
 0 
 
 
 
13 
 
 
 
 
CWP 
  Yes 8 17.4 95 6.1 -2.90 
(0.0037) 
 
43 25.9 216 7.8 -7.29
(<0.0001) 
   No 38 82.6 1,465 93.9 123 74.1 2,556 92.2
  Missing 0 3 0 0
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   Males Females
 Cases    
            
         
        
Controls Chi-
Square  
Cases Controls Chi-Square
 No. % No. % statistic No.
 
% No. % statistic
 (p-value)*
 
(p-value)*
 CFS-like 
illness 
  Yes 2 4.3 26 1.7 -1.34 
(0.1799) 
 
28     
         
           
          
          
        
          
           
          
     
         
           
        
16.9 107 3.9 -6.95
(<0.0001) 
   No 44 95.7 1,537 98.3 138 83.1 2,665 96.1
  Missing 0 0 0 0
BMI 
  ≤24.9 kg/m2 11 23.9 522 33.4 2.6202
(0.6232) 
 
69 41.6 1,381 49.8 4.8271
(0.3055) 
   25-29.9 
kg/m2
21 45.7 686 43.9 50 30.1 751 27.1
  ≥30 kg/m2 14 30.4 355 22.7 47 28.3 640 23.1
  Missing 0 0 0 0
Mental 
Health Score 
  < mean 19 43.2 390 25.6 -2.60 
(0.0093) 
 
81 49.7 905 33.5 -3.99
(<0.0001) 
   ≥ mean 25 56.8 1,135 74.4 82 50.3 1,799 66.5
  Missing 2 38 3 68
  Mean (SE) 49.18 
(1.31) 
52.26
(0.22) 
2.32
(0.0216) 
46.40 
(0.77) 
50.29
(0.20) 
4.92
(<0.0001) 
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   Males Females
 Cases    
            
         
        
Controls Chi-
Square  
Cases Controls Chi-Square
 No. % No. % statistic No.
 
% No. % statistic
 (p-value)*
 
(p-value)*
 Physical 
Health Score 
  < mean 20 45.5 336 22.0 -3.22 
(0.0013) 
 
87     
         
           
        
53.4 691 25.6 -7.24
(<0.0001) 
   ≥ mean 24 54.5 1,189 78.0 76 46.6 2,013 74.4
  Missing 2 38 3 68
  Mean (SE) 48.03 
(1.26) 
51.83
(0.23) 
2.97
(0.0034) 
44.98 
(0.74) 
51.32
(0.19) 
8.41
(<0.0001) 
 
 
Table 2.4: Association between IBS status and missing covariate information, AHP study, 1999. 
 Case (212) Control (4,336) χ2 p-value 
   No. % No. %  
Major Depressive Disorder       
   Missing 0 0 20 0.46 0.9822 0.3217 
   Not missing 212 100 4316 99.54   
Chronic Widespread Pain       
   Missing 0 0 3 0.07 0.1468 0.7016 
   Not missing 
 
212 100 4333 99.93   
Gender       
       
   Missing 0 0 1 0.02 0.0489 0.8250 
   Not missing 212 100 4335 99.98   
Physical self-rated health       
   Missing 5 2.36 106 2.44 0.0063 0.9367 
   Not missing 207 97.64 4230 97.56   
Mental self-rated health       
   Missing 5 2.36 106 2.44 0.0063 0.9367 
   Not missing 207 97.64 4230 97.56   
Chronic Fatigue Syndrome-like illness       
   Missing 0 0 0 0 0 1.0 
   Not missing 212 100 4336 100   
Body Mass Index
   Missing 0 0 0 0 0 1.0 
   Not missing 212 100 4336 100   
190
 
 
Table 2.5: Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors and risk for 
irritable bowel syndrome, AHP study, 1999. 
 Cases (203) Controls (4,104) OR 95% CI 
    
      
No. % No. %  
Age at interview (years) 
  < 36 years old 49 24.1 1,016 24.8 1.04 0.68, 1.60 
  36-43 years old 57 28.1 1,080 26.3 1.13 0.75, 1.71 
  44-51 years old 54 26.6 1,091 26.6 1.06 0.70, 1.61 
  > 51 years old 43 21.2 917 22.3 1.00  
Sex       
      
      
      
      
      
      
      
      
  Male 44 21.7 1,478 36.0 1.00  
  Female 159 78.3 2,626 64.0 2.03 1.44, 2.85 
MDD 
  Yes 64 31.5 762 18.6 2.00 1.48, 2.71 
  No 139 68.5 3,342 81.4 1.00  
CWP 
  Yes 47 23.2 294 7.2 3.89 2.74, 5.53 
  No 156 76.8 3,810 92.8 1.00  
CFS-like illness 
  Yes 29 14.3 129 3.1 5.13 3.30, 7.97 
   No 174 85.7 3,975 96.9 1.00
BMI 
  ≤24.9 kg/m2 75 36.9 1,744 42.5 1.00
  25-29.9 kg/m2 70 34.5 1,393 33.9 1.17 0.83, 1.64
  ≥30 kg/m2 58 28.6 967 23.6 1.40 0.98, 2.00
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Table 2.5 (Continued): Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors 
and risk for irritable bowel syndrome, AHP study, 1999. 
 Cases (203) Controls (4,104) OR 95% CI 
    
      
No. % No. %  
Mental Health Score 
  < mean 98 48.3 1,266 30.8 2.09 1.56, 2.78 
   ≥ mean      
      
      
      
      
       
       
       
105 51.7 2,838 69.2 1.00
Physical Health Score 
  < mean 103 50.7 997 24.3 3.20 2.41, 4.26 
   ≥ mean 100 49.3 3,107 75.7 1.00
 
Continuous Covariates 
Age  1.00 0.98, 1.01
Mental Health Score 0.97 0.95, 0.98
Physical Health Score  0.95 0.94, 0.97
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Table 2.6: Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors and risk for 
irritable bowel syndrome, by sex, AHP study, 1999. 
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   Males Females
           
    
            
  
 Cases 
 
Controls 
 
OR 
 
95% CI 
 
Cases 
 
Controls 
 
OR 
 
95% CI 
  No. % No. % No. % No. %
Age at interview 
(years) 
  < 36 years old 8            
            
            
          
            
            
         
            
            
         
            
            
         
            
           
            
            
18.2 295 20.0 0.83 0.34, 2.02 41 25.8 721 27.5 1.00 0.61, 1.65
  36-43 years old 10 22.7 361 24.4 0.85 0.37, 1.95 47 29.6 719 27.4 1.13 0.69, 1.84
  44-51 years old 13 29.5 423 28.6 0.94 0.43, 2.04
 
41 25.8 668 25.4 1.06 0.64, 1.75
   > 51 years old 13 29.5 399 27.0 1.0 30 18.9 518 19.7 1.0
MDD 
  Yes 9 20.5 204 13.8 1.60 0.76, 3.38
 
55 34.6 558 21.2 1.93 1.38, 2.70
   No 35 79.5 1,274 86.2 1.0 104 65.4 2,068 78.8 1.0
CWP 
  Yes 8 18.2 89 6.0 3.46 1.56, 7.68
 
39 24.5 205 7.8 3.81 2.57, 5.65
   No 36 81.8 1,389 94.0 1.0 120 75.5 2,421 92.2 1.0
CFS-like illness 
  Yes 2 4.5 26 1.8 2.72 0.64, 11.52
 
27 17.0 103 3.9 5.01 3.14, 8.00
   No 42 95.5 1,452 98.2 1.0 132 83.0 2,523 96.1 1.0
BMI 
  ≤24.9 kg/m2 11 25.0 466 31.5 1.0 64 40.3 1,278 48.9 1.0
  25-29.9 kg/m2 21 47.7 668 45.2 1.34 0.64, 2.80 49 30.8 725 27.6 1.36 0.92, 2.00
  ≥30 kg/m2 12 27.3 344 23.3 1.48 0.64, 3.39 46 28.9 623 23.7 1.48 1.00, 2.20
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Table 2.6 (Continued): Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors 
and risk for irritable bowel syndrome, by sex, AHP study, 1999. 
 Males Females
           
        
    
            
  
 Cases
 
Controls
 
OR
 
95% CI
 
Cases
 
Controls
 
OR
 
95% CI
  No. % No. % No. % No. %
Mental Health 
Score 
  < mean 19 43.2 382 25.8 2.17 
 
1.18, 3.99 
 
79 49.7 884 33.7 1.94 
 
1.39, 2.69 
   ≥ mean         
            
         
            
          
          
          
25 56.8 1,096 74.2 1.0 80 50.3 1,742 66.3 1.0
Physical Health 
Score 
  < mean 20 45.5 329 22.3 2.93 
 
1.60, 5.36 
 
83 52.2 668 25.4 3.20 
 
2.31, 4.43 
   ≥ mean 24 54.5 1,149 77.7 1.0 76 47.8 1,958 74.6 1.0
Continuous 
Covariates 
Age  1.00 0.97, 1.03 1.00 0.98, 1.02
Mental Health 
Score 
0.97 0.94, 1.00 0.97 0.95, 0.98
Physical Health 
Score  
0.96 0.94, 0.99 0.95 0.94, 0.97
 
Table 2.7: Assessing effect measure modification for MDD-IBS model, AHP study, 
1999. 
 OR, (95% CI) for 
MDD 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/
Maybe) 
Age (years)  2.02 (1.49, 2.74) 4.3499 
(0.2261) 
Maybe 
  < 36 years old 2.43 (1.33, 4.43)    
  36-43 years old 2.92 (1.68, 5.07)    
  44-51 years old 1.34 (0.70, 2.54)    
  > 51 years old 1.98 (1.17, 3.35)    
Sex  1.89 (1.39, 2.58) 0.2267 
(0.6340) 
No 
Male 1.61 (0.76, 3.39)    
Female 1.96 (1.40, 2.75)    
CWP  1.75 (1.28, 2.38) 2.6681 
(0.1024) 
Yes 
  Yes 1.12 (0.59, 2.12)    
  No 2.05 (1.44, 2.91)    
CFS-like 
illness 
 1.57 (1.15, 2.15) 15.0354 
(0.0001) 
Yes 
  Yes 0.39 (0.17, 0.89)    
  No 2.11 (1.51, 2.95)    
BMI  2.00 (1.47, 2.72) 0.0617 
(0.9696) 
No 
  ≤24.9 kg/m2 2.01 (1.21, 3.34)    
  25-29.9 kg/m2 1.90 (1.11, 3.25)    
  ≥30 kg/m2 2.10 (1.20, 3.66)    
Mental Health 
Score 
 1.66 (1.21, 2.28) 0.2849 
(0.5935) 
Maybe 
  < mean 1.55 (1.02, 2.35)    
  ≥ mean 1.85 (1.13, 3.02)    
Physical 
Health Score 
 1.77 (1.30, 2.41) 2.2758 
(0.1314) 
Yes 
  < mean 1.42 (0.91, 2.19)    
  ≥ mean 2.27 (1.47, 3.51)    
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Table 2.8: Evaluation of confounding for the association between lifetime MDD and 
risk of lifetime IBS, AHP study, 1999. 
 Lifetime MDD 
and covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted OR Ln[CoRR] 
OR (95% CI) for 
lifetime MDD 
2.00 (1.48, 
2.71) 
OR, (95% CI)  OR, (95% CI)  OR, (95% CI)  Ln(ORcrude
/ORadj) 
Total=4,307    4,104 (controls) 3,481 (no lifetime 
MDD) 
  
     
Age (years)     
  Continuous 0.99 (0.99, 1.00) 1.01 (0.99, 1.02) 2.00 (1.48, 2.70) 0 
     
  < 36 years old 1.22 (0.97, 1.53) 0.87 (0.53, 1.45)   
  36-43 years old 1.20 (0.95, 1.50) 0.90 (0.55, 1.47)   
  44-51 years old 1.16 (0.92, 1.46) 1.08 (0.67, 1.73)   
  > 51 years old 1.0  2.00 (1.48, 2.70) 0 
Sex     
  Male 1.0    
  Female 1.72 (1.45, 2.05) 1.83 (1.24, 2.70) 1.88 (1.39, 2.55) 0.0619 
CWP     
  Yes 2.30 (1.81, 2.92) 4.44 (2.89, 6.84) 1.76 (1.28, 2.41) 0.1278 
  No 1.0    
CFS-like illness     
  Yes 5.76 (4.17, 7.97) 9.82 (5.56, 17.33) 1.63 (1.16, 2.30) 0.2045 
  No 1.0    
BMI Categorical    
  ≤24.9 kg/m2 1.0  1.98 (1.46, 2.69) 0.0101 
  25-29.9 kg/m2 0.96 (0.80, 1.15) 1.19 (0.80, 1.78)   
  ≥30 kg/m2 1.26 (1.04, 1.54) 1.34 (0.87, 2.05)   
Mental Health 
Score 
    
  Continuous 0.93 (0.92, 0.94) 0.96 (0.95, 0.98) 1.53 (1.09, 2.15) 0.2679 
     
  < mean 3.69 (3.14, 4.33) 1.95 (1.37, 2.77)   
  ≥ mean 1.0  1.65 (1.20, 2.28) 0.1924 
Physical Health 
Score 
    
  Continuous 0.98 (0.97, 0.99) 0.95 (0.94, 0.96) 1.78 (1.31, 2.43) 0.1165 
     
  < mean 1.66 (1.41, 1.96) 3.52 (2.50, 4.97)   
  ≥ mean 1.0  1.77 (1.30, 2.41) 0.1222 
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Table 2.9: Assessing confounding and effect measure modification using backward elimination for the model of lifetime MDD, 
AHP study, 1999. 
Min Model
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
N (cases/controls) 4,307 (203/4,104) 
 
Main Exposure: 
Lifetime MDD 
 
4,307 (203/4,104) 
 
 
0.6946 (0.1545) 
4,307 (203/4,104) 
 
 
1.6820 (0.8170) 
 
 
0.6329 (0.1545) 
 
   
 
|ln(crude/adj)| of beta 0.88 0.98
Compare to: 
-2log L 
df 
Chi-square p-value 
 
1617.9962 
1 
Min Model 
1599.684 
5 
 
Full 
1602.5418 
3 
2.8578 (p>0.2) 
OR (95% CI) for main 
effect:  
lifetime MDD 
 
 
2.00 (1.48, 2.71) 
 
 
 
5.38 (1.08, 26.66) 
 
 
 
1.88 (1.39, 2.55) 
Crude vs Adjusted 
|ln(crude/adj)| 0.99 1.05 
Notes/Conclusions about 
current model: 
MDL, adjusted for twin 
relatedness. 
First-order interactions  
with age and sex, and 
linear terms. 
All interaction terms excluded 
from model to assess effect 
modification.  No effect 
modification is present based 
on likelihood ratio test. 
Variable to be dropped 
next (Wald p-value) 
 All interaction terms 
(chunk test) 
Age (0.9513) 
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Table 2.9 (Continued): Assessing confounding and effect measure modification using backward elimination for the model of 
lifetime MDD, AHP study, 1999. 
Model 3
β (SE) 
Model 4 
β (SE) 
FINAL MODEL  
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Lifetime MDD 
 
4,307 (203/4,104) 
 
 
0.6327 (0.1548) 
4,307 (203/4,104) 
 
 
0.6946 (0.1545) 
4,307 (203/4,104) 
 
 
0.6946 (0.1545) 
|ln(crude/adj)| of beta 0.0003   0.09 0.09
Compare to: 
-2log L 
df 
Chi-square p-value 
Model 2 
1602.5494 
2 
N/A 
Model 3 
1617.9962 
1 
N/A 
 
Model 3 
1617.9962 
1 
N/A 
 
OR (95% CI) for main 
effect:  
lifetime MDD 
 
 
1.88 (1.39, 2.55) 
 
 
2.0 (1.48, 2.71) 
 
 
2.0 (1.48, 2.71) 
Crude vs Adjusted 
|ln(crude/adj)| 
 
0 
 
0.06 
 
0.06 
Notes/Conclusions about 
current model: 
OR for main effect did 
not change by >10%.  
Age is not confounder. 
OR for main effect did 
not change by >10%.  
Gender is not 
confounder. 
OR for main effect is not 
confounded by any potential 
covariates examined, but is 
adjusted for twin relatedness. 
Variable to be dropped 
next (Wald p-value) 
Gender (0.0002) none  
 
Table 2.10: Assessing effect measure modification for gender-IBS model, AHP 
study, 1999. 
 OR, (95% CI) 
for gender 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/ 
Maybe) 
Age (years)  2.05 (1.45, 2.88) 0.3448 
(0.9514) 
No 
  < 36 years old 2.09 (0.97, 4.53)    
  36-43 years old 2.36 (1.18, 4.72)    
  44-51 years old 2.00 (1.06, 3.77)    
  > 51 years old 1.78 (0.92, 3.45)    
MDD  1.92 (1.36, 2.71) 0.2271 
(0.6337) 
No 
  Yes 2.23 (1.08, 4.60)    
  No 1.83 (1.24, 2.70)    
CWP  1.95 (1.38, 2.74) 0.0504 
(0.8224) 
No 
  Yes 2.12 (0.95, 4.71)    
  No 1.91 (1.31, 2.79)    
CFS-like illness  1.89 (1.34, 2.66) 0.06679 
(0.4138) 
Maybe 
  Yes 3.41 (0.76, 15.26)    
  No 1.81 (1.27, 2.57)    
BMI  2.13 (1.51, 3.01) 0.0017 
(0.9992) 
No 
  ≤24.9 kg/m2 2.12 (1.11, 4.06)    
  25-29.9 kg/m2 2.15 (1.28, 3.62)    
  ≥30 kg/m2 2.12 (1.11, 4.05)    
Mental Health 
Score 
 1.91 (1.36, 2.69) 0.1053 
(0.7455) 
No 
  < mean 1.80 (1.07, 3.01)    
  ≥ mean 2.01 (1.28, 3.17)    
Physical Health 
Score 
 1.94 (1.38, 2.73) 0.0739 
(0.7858) 
No 
  < mean 2.04 (1.23, 3.39)    
  ≥ mean 1.86 (1.17, 2.96)    
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Table 2.11: Evaluation of confounding for the association between gender and risk of 
lifetime IBS, AHP study, 1999. 
 Gender and 
covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted 
OR 
Ln[CoRR] 
OR (95% CI) for 
gender 
2.03 (1.44, 
2.85) 
OR, (95% CI)  OR, (95% CI)  OR, (95% 
CI)  
Ln(ORcrude
/ORadj) 
Total=4,307    4,104 (controls) 1,522 (male)   
Age (years)     
  Continuous 0.97  
(0.97, 0.98) 
1.00  
(0.97, 1.03) 
2.03  
(1.44, 2.86) 
0 
  < 36 years old 1.92 (1.58, 2.34) 0.83 (0.34, 2.02)   
  36-43 years old 1.56 (1.29, 1.89) 0.85 (0.37, 1.95)   
  44-51 years old 1.22 (1.01, 1.46) 0.94 (0.43, 2.04)   
  > 51 years old 1.0  2.03  
(1.44, 2.86) 
0 
MDD     
  Yes 1.56  
(1.34, 1.83) 
1.60  
(0.76, 3.38) 
1.91  
(1.36, 2.69) 
0.0609 
  No 1.0    
CWP     
  Yes 1.30  
(1.05, 1.61) 
3.46  
(1.56, 7.68) 
1.94  
(1.38, 2.74) 
0.0453 
  No 1.0    
CFS-like illness     
  Yes 2.18  
(1.58, 3.01) 
2.72  
(0.64, 11.52) 
1.88  
(1.34, 2.65) 
0.0768 
  No 1.0    
BMI Categorical    
  ≤24.9 kg/m2 1.0  2.12  
(1.50, 3.00) 
0.0434 
  25-29.9 kg/m2 0.45 (0.39, 0.52) 1.34 (0.64, 2.80)   
  ≥30 kg/m2 0.69 (0.58, 0.81) 1.48 (0.64, 3.39)   
Mental Health 
Score 
    
  Continuous 0.98  
(0.97, 0.99) 
0.97  
(0.94, 1.00) 
1.88  
(1.33, 2.64) 
0.0768 
  < mean 1.39 (1.22, 1.58) 2.17 (1.18, 3.99)   
  ≥ mean 1.0  1.91  
(1.35, 2.69) 
0.0609 
Physical Health 
Score 
    
  Continuous 0.99  
(0.99, 1.00) 
0.96  
(0.94, 0.99) 
1.96  
(1.39, 2.76) 
0.0351 
  < mean 1.18 (1.03, 1.35) 2.93 (1.60, 5.36)   
  ≥ mean 1.0  1.94  
(1.37, 2.73) 
0.0453 
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Table 2.12: Assessing confounding and effect measure modification using backward elimination for the model of gender, AHP 
study, 1999. 
Min Model Full Model 
β (SE) β (SE) 
Model 2 
β (SE) 
Model 3/FINAL 
MODEL 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Gender 
 
4,307 (203/4,104) 
 
 
0.7061 (0.1740) 
4,307 (203/4,104) 
 
 
0.7474 (0.5024) 
4,307 (203/4,104) 
 
 
0.7523 (0.1769) 
 
4,307 (203/4,104) 
 
 
0.7061 (0.1740) 
|ln(crude/adj)| of beta     
 
0.06 0.01 0.06
Compare to: 
-2log L 
df 
Chi-square p-value 
 
1617.7616 
1 
Min Model 
1612.3442 
3 
 
Full 
1612.3442 
2 
0 (p>0.2) 
Model 2 
1617.7616 
1 
N/A 
OR (95% CI) for main 
effect:  
Gender 
 
 
2.03 (1.44, 2.85) 
 
 
 
2.11 (0.79, 5.65) 
 
 
 
2.12 (1.50, 3.00) 
 
 
2.03 (1.44, 2.85) 
Crude vs Adjusted 
|ln(crude/adj)| 0.04 
 
0.005 
 
0.04 
Notes/Conclusions about 
current model: 
gender, adjusted 
for twin 
relatedness. 
First-order 
interaction with 
BMI and linear 
terms. 
All interaction terms 
excluded from model 
to assess effect 
modification.  No 
effect modification is 
present based on 
likelihood ratio test. 
OR for main effect is 
not confounded by any 
potential covariates, 
but is adjusted for twin 
relatedness. 
Variable to be dropped 
next (Wald p-value) 
All interaction
terms (chunk test)
 BMI (0.0699) none 
Table 2.13: Assessing effect measure modification for CWP-IBS model, AHP study, 
1999. 
 OR, (95% CI) for 
CWP 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/
Maybe) 
Age (years)  4.02 (2.83, 5.72) 11.7795 
(0.0082) 
Yes 
< 36 years old 1.16 (0.27, 4.96)    
36-43 years old 9.19 (5.03, 16.80)    
44-51 years old 2.86 (1.46, 5.62)    
> 51 years old 3.58 (1.81, 7.09)    
MDD  3.47 (2.45, 4.93) 2.6944 
(0.1007) 
Yes 
  Yes 2.42 (1.34, 4.39)    
  No 4.44 (2.89, 6.82)    
Gender  3.77 (2.66, 5.34) 0.0504 
(0.8223) 
No 
  Male 3.47 (1.57, 7.68)    
  Female 3.84 (2.60, 5.66)    
CFS-like 
illness 
 3.02 (2.06, 4.42) 0.1327 
(0.7157) 
No 
  Yes 3.43 (1.47, 7.99)    
  No 2.88 (1.89, 4.41)    
BMI  3.74 (2.64, 5.31) 5.5494 
(0.0624) 
Yes 
  ≤24.9 kg/m2 3.72 (1.93, 7.15)    
  25-29.9 kg/m2 6.06 (3.51, 10.44)    
  ≥30 kg/m2 2.23 (1.17, 4.26)    
Mental Health 
Score 
 3.50 (2.46, 4.96) 0.7960 
(0.3723) 
Maybe 
  < mean 3.05 (1.88, 4.94)    
  ≥ mean 4.18 (2.53, 6.93)    
Physical 
Health Score 
 2.58 (1.78, 3.73) 0.0644 
(0.7997) 
No 
  < mean 2.52 (1.64, 3.87)    
  ≥ mean 2.80 (1.37, 5.71)    
 
 202
 203
Table 2.14: Evaluation of confounding for the association between CWP and risk of 
lifetime IBS, AHP study, 1999. 
 CWP and 
covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted OR Ln[CoRR] 
OR (95% CI) for 
CWP 
3.89 (2.74, 
5.53) 
OR, (95% CI)  OR, (95% CI)  OR, (95% CI)  Ln(ORcrude
/ORadj) 
Total=4,307    4,104 (controls) 3,966 (no CWP)   
     
Age (years)     
  Continuous 1.05 (1.03, 1.06) 0.99 (0.97, 1.01) 4.06 (2.84, 5.81) 0.0428 
     
  < 36 years old 0.28 (0.19, 0.41) 1.32 (0.82, 2.12)   
  36-43 years old 0.57 (0.42, 0.77) 0.99 (0.61, 1.63)   
  44-51 years old 0.81 (0.61, 1.07) 1.16 (0.71, 1.89)   
  > 51 years old 1.0  4.02 (2.81, 5.75) 0.0329 
MDD     
  Yes 2.35 (1.85, 2.98) 2.04 (1.44, 2.90) 3.54 (2.47, 5.09) 0.0943 
  No 1.0    
Gender     
  Male 1.0    
  Female 1.41 (1.10, 1.79) 1.91 (1.30, 2.79) 3.76 (2.64, 5.34) 0.0340 
CFS-like illness     
  Yes 9.74 (6.93, 13.70) 3.09 (1.56, 6.09) 2.98 (2.05, 4.33) 0.2665 
  No 1.0    
BMI Categorical    
  ≤24.9 kg/m2 1.0  3.78 (2.64, 5.42) 0.0287 
  25-29.9 kg/m2 1.59 (1.20, 2.10) 0.97 (0.66, 1.43)   
  ≥30 kg/m2 2.44 (1.85, 3.22) 1.38 (0.93, 2.04)   
Mental Health 
Score 
    
  Continuous 0.97 (0.96, 0.98) 0.96 (0.95, 0.98) 3.49 (2.43, 5.01) 0.1085 
     
  < mean 2.02 (1.61, 2.53) 2.02 (1.46, 2.80)   
  ≥ mean 1.0  3.52 (2.46, 5.03) 0.0999 
Physical Health 
Score 
    
  Continuous 0.91 (0.90, 0.92) 0.96 (0.95, 0.98) 2.46 (1.63, 3.72) 0.4582 
     
  < mean 6.94 (5.48, 8.79) 2.64 (1.90, 3.67)   
  ≥ mean 1.0  2.58 (1.77, 3.76) 0.4106 
Table 2.15: Assessing confounding and effect measure modification using backward elimination for the model of CWP, AHP 
study, 1999. 
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  Min Model Full Model 
β (SE) β (SE) 
Model 2 
β (SE) 
Model 3 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
CWP 
 
4,307 (203/4,104) 
 
 
1.3585 (0.1797) 
4,307 (203/4,104) 
 
 
0.4415 (1.1276) 
4,307 (203/4,104) 
 
 
1.3191 (0.1862) 
 
4,307 (203/4,104) 
 
 
1.2847 (0.1836) 
|ln(crude/adj)| of beta     
 
1.12 1.09 0.03
Compare to: 
-2log L 
df 
Chi-square p-value 
 
1588.792 
1 
Min Model 
1567.158 
7 
 
Full 
1568.7278 
4 
1.5698 (p>0.2) 
Model 2 
1570.1196 
3 
N/A 
OR (95% CI) for main 
effect:  
CWP 
 
 
3.89 (2.74, 5.53) 
 
 
 
1.56 (0.17, 14.18) 
 
 
 
3.74 (2.60, 5.39) 
 
 
3.61 (2.52, 5.18) 
Crude vs Adjusted 
|ln(crude/adj)| 0.91 
 
0.87 
 
0.04 
Notes/Conclusions about 
current model: 
CWP, adjusted 
for twin 
relatedness. 
First-order 
interactions with 
gender, age, and 
BMI, and linear 
terms. 
All interaction terms 
excluded from model to 
assess effect modification.  
No effect modification is 
present based on 
likelihood ratio test. 
OR for main effect 
did not change by 
>10%.  Age is not 
confounder. 
Variable to be dropped 
next (Wald p-value) 
All interaction
terms (chunk test)
 Age (0.2221) BMI (0.2994) 
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Table 2.15 (Continued): Assessing confounding and effect measure modification using backward elimination for the model of 
CWP, AHP study, 1999. 
Model 4
β (SE) 
Model 5 
β (SE) 
FINAL MODEL  
β (SE) 
N (cases/controls) 
 
Main Exposure: 
CWP 
 
4,307 (203/4,104) 
 
 
1.3232 (0.1800) 
4,307 (203/4,104) 
 
 
1.3585 (0.1797) 
4,307 (203/4,104) 
 
 
1.3585 (0.1797) 
|ln(crude/adj)| of beta 0.03   0.03 0.03
Compare to: 
-2log L 
df 
Chi-square p-value 
 
Model 3 
1572.5696 
2 
N/A 
 
Model 4 
1588.792 
1 
N/A 
Model 4 
1588.792 
1 
N/A 
OR (95% CI) for main effect:  
CWP 
 
 
3.76 (2.64, 5.34) 
 
 
3.89 (2.74, 5.53) 
 
 
3.89 (2.74, 5.53) 
Crude vs Adjusted 
|ln(crude/adj)| 
 
0.04 
 
0.03 
 
0.03 
Notes/Conclusions about 
current model: 
OR for main effect did not 
change by >10%.  BMI is 
not confounder. 
OR for main effect did 
not change by >10%.  
Gender is not 
confounder. 
OR for main effect is not 
confounded by any potential 
confounders, but is adjusted 
for twin relatedness. 
Variable to be dropped next 
(Wald p-value) 
Gender (0.0001) none  
 
 
Table 2.16: Assessing effect measure modification for CFS-like illness and IBS 
model, AHP study, 1999. 
 OR, (95% CI) for 
CF 
ORM-H (95% 
CI) 
Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/
Maybe) 
Age (years)  5.08  
(3.31, 7.81) 
12.11 
(0.007) 
Yes 
< 36 years old 2.57 (0.87, 7.55)    
36-43 years old 13.74 (6.68, 28.28)    
44-51 years old 2.32 (0.88, 6.09)    
> 51 years old 6.03 (2.33, 15.65)    
MDD  3.84  
(2.47, 5.95) 
15.96 
(<0.0001) 
Yes 
  Yes 1.79 (0.90, 3.58)    
  No 9.79 (5.55, 17.29)    
Gender  4.71  
(3.05, 7.27) 
0.67 
(0.415) 
Maybe 
  Male 2.66 (0.61, 11.57)    
  Female 5.01 (3.17, 7.92)    
CWP  3.40  
(2.12, 5.46) 
0.13 
(0.717) 
No 
  Yes 3.66 (1.89, 7.09)    
  No 3.08 (1.56, 6.05)    
BMI  5.08  
(3.30, 7.83) 
0.49 
(0.785) 
No 
  ≤24.9 kg/m2 4.05 (1.84, 8.87)    
  25-29.9 kg/m2 5.58 (2.75, 11.35)    
  ≥30 kg/m2 5.72 (2.67, 12.25)    
Mental Health 
Score 
 4.38  
(2.82, 6.81) 
0.098 
(0.754) 
No 
  < mean 4.59 (2.68, 7.87)    
  ≥ mean 3.95 (1.84, 8.51)    
Physical 
Health Score 
 3.84  
(2.46, 6.01) 
0.43 
(0.510) 
Maybe 
  < mean 4.19 (2.47, 7.11)    
  ≥ mean 2.99 (1.26, 7.07)    
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Table 2.17: Evaluation of confounding for the association between CFS-like illness 
and risk of lifetime IBS, AHP study, 1999. 
 CFS-like illness 
and covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted 
OR 
Ln[CoRR] 
OR (95% CI) for 
CFS-like illness 
5.13 (3.30, 7.97) 
OR, (95% CI)  OR, (95% CI)  OR, (95% 
CI)  
Ln(ORcrude
/ORadj) 
Total=4,307    4,104 (controls) 4,149 (no CF)   
Age (years)     
  Continuous 1.00  
(0.98, 1.02) 
1.00  
(0.98, 1.01) 
5.13  
(3.30, 7.97) 
0 
     
  < 36 years old 1.14 (0.70, 1.86) 1.11 (0.71, 1.74)   
  36-43 years old 1.09 (0.67, 1.78) 0.98 (0.63, 1.54)   
  44-51 years old 1.45 (0.92, 2.30) 1.13 (0.73, 1.76)   
  > 51 years old 1.0  5.13  
(3.30, 7.99) 
0 
MDD     
  Yes 6.11  
(4.42, 8.45) 
2.10  
(1.51, 2.93) 
4.23  
(2.58, 6.93) 
0.1929 
  No 1.0    
Gender     
  Male 1.0    
  Female 2.60  
(1.72, 3.94) 
1.81  
(1.27, 2.57) 
4.67  
(3.01, 7.26) 
0.0939 
CWP     
  Yes 9.74  
(6.92, 13.70) 
2.87  
(1.87, 4.40) 
3.36  
(2.10, 5.36) 
0.4232 
  No 1.0    
BMI Categorical    
  ≤24.9 kg/m2 1.0  5.06  
(3.26, 7.85) 
0.0137 
  25-29.9 kg/m2 1.22 (0.84, 1.78) 1.11 (0.77, 1.59)   
  ≥30 kg/m2 1.36 (0.90, 2.04) 1.30 (0.89, 1.90)   
Mental Health 
Score 
    
  Continuous 0.95  
(0.94, 0.96) 
0.97  
(0.96, 0.98) 
4.14  
(2.61, 6.56) 
0.2144 
  < mean 3.13 (2.26, 4.33) 1.85 (1.36, 2.51)   
  ≥ mean 1.0  4.36  
(2.79, 6.81) 
0.1626 
Physical Health 
Score 
    
  Continuous 0.94  
(0.93, 0.95) 
0.96  
(0.95, 0.97) 
3.57  
(2.21, 5.76) 
0.3625 
  < mean 3.76 (2.73, 5.18) 2.78 (2.04, 3.78)   
  ≥ mean 1.0  3.79  
(2.42, 5.94) 
0.3027 
Table 2.18: Assessing confounding and effect measure modification using backward elimination for the model of CFS-like 
illness, AHP study, 1999. 
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   Min Model
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
CFS-like illness 
 
4,307 (203/4,104) 
 
 
1.6345 (0.2250) 
4,307 (203/4,104) 
 
 
1.0631 (1.7462) 
4,307 (203/4,104) 
 
 
1.5144 (0.2247) 
 
|ln(crude/adj)| of beta    0.43 0.35
Compare to: 
-2log L 
df 
Chi-square p-value 
 
1594.9494 
1 
Min Model 
1575.6346 
7 
 
Full 
1576.2848 
4 
0.6502 (p>0.2) 
OR (95% CI) for main 
effect:  
CFS-like illness 
 
 
5.13 (3.30, 7.97) 
 
 
 
2.90 (0.09, 88.73) 
 
 
 
4.55 (2.93, 7.06) 
Crude vs Adjusted 
|ln(crude/adj)| 0.57 
 
0.45 
Notes/Conclusions about 
current model: 
CFS-like illness, adjusted 
for twin relatedness. 
First-order interactions with 
gender, BMI, and age, and 
linear terms. 
All interaction terms 
excluded from model to 
assess effect modification.  
No effect modification is 
present based on likelihood 
ratio test. 
Variable to be dropped 
next (Wald p-value) 
 All interaction terms (chunk 
test) 
Age (0.7285) 
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Table 2.18 (Continued): Assessing confounding and effect measure modification using backward elimination for the model of 
CFS-like illness, AHP study, 1999. 
Model 3
β (SE) 
Model 4 
β (SE) 
Model 5 
β (SE) 
FINAL MODEL 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
CFS-like illness 
 
4,307 (203/4,104) 
 
 
1.5178 (0.2247) 
4,307 (203/4,104) 
 
 
1.5419 (0.2246) 
4,307 (203/4,104) 
 
 
1.6345 (0.2250) 
4,307 (203/4,104) 
 
 
1.5419 (0.2246) 
|ln(crude/adj)| of beta 0.002    0.02 0.06 0.02
Compare to: 
-2log L 
df 
Chi-square p-value 
 
Model 2 
1576.6758 
3 
N/A 
Model 3 
1580.4936 
2 
N/A 
 
Model 4 
1594.9494 
1 
N/A 
Model 3 
1580.4936 
2 
N/A 
 
OR (95% CI) for main 
effect:  
CFS-like illness 
 
 
4.56 (2.94, 7.09) 
 
 
4.67 (3.01, 7.26) 
 
 
5.13 (3.30, 7.97) 
 
 
4.67 (3.01, 7.26) 
Crude vs Adjusted 
|ln(crude/adj)| 
 
0.002 
 
0.02 
 
0.094 
 
0.02 
Notes/Conclusions about 
current model: 
OR for main effect 
did not change by 
>10%.  Age is not 
confounder. 
OR for main effect 
did not change by 
>10%.  BMI is not 
confounder. 
OR for main effect 
did change by >10%.  
Gender is 
confounder, return it 
to model. 
OR for main effect is 
confounded by 
gender, and adjusted 
for twin relatedness. 
Variable to be dropped 
next (Wald p-value) 
BMI (0.0471) Gender (0.0003) None  
 
Table 2.19: Assessing effect measure modification for mental self-rated health and 
IBS model, AHP study, 1999. 
 OR, (95% CI) 
for Mental self-
rated health 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/ 
Maybe) 
Age (years)  2.10 (1.58, 2.79) 2.9393 
(0.4011) 
Maybe 
  < 36 years old 1.66 (0.94, 2.95)    
  36-43 years old 3.11 (1.80, 5.36)    
  44-51 years old 1.87 (1.07, 3.26)    
  > 51 years old 1.89 (1.01, 3.54)    
MDD  1.84 (1.37, 2.47) 0.2850 
(0.5935) 
Maybe 
  Yes 1.63 (0.95, 2.80)    
  No 1.94 (1.37, 2.76)    
Gender  1.99 (1.50, 2.65) 0.1054 
(0.7454) 
No 
  Male 2.18 (1.19, 4.00)    
  Female 1.95 (1.41, 2.68)    
CWP  1.89 (1.42, 2.51) 0.7903 
(0.3740) 
Maybe 
  Yes 1.48 (0.80, 2.75)    
  No 2.03 (1.47, 2.80)    
CFS-like illness  1.88 (1.41, 2.51) 0.0981 
(0.7542) 
Maybe 
  Yes 2.14 (0.88, 5.20)    
  No 1.85 (1.36, 2.51)    
BMI  2.08 (1.56, 2.76) 1.8496 
(0.3966) 
Maybe 
  ≤24.9 kg/m2 1.61 (1.00, 2.57)    
  25-29.9 kg/m2 2.46 (1.52, 3.98)    
  ≥30 kg/m2 2.36 (1.39, 4.03)    
Physical Health 
Score 
 1.94 (1.46, 2.59) 0.0304 
(0.8616) 
No 
  < mean 1.99 (1.33, 2.99)    
  ≥ mean 1.89 (1.27, 2.83)    
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Table 2.20: Evaluation of confounding for the association between mental self-rated 
health and risk of lifetime IBS, AHP study, 1999. 
 Mental self-
rated health  
and covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted OR Ln[CoRR] 
OR (95% CI) for 
Mental health 
score 
2.09 (1.56, 
2.78) 
OR, (95% CI)  OR, (95% CI)  OR, (95% CI)  Ln(ORcrude
/ORadj) 
Total=4,307    4,104 (controls) 2,943 (MH >50)   
     
Age (years)     
  Continuous 0.98 (0.97, 0.99) 1.00 (0.98, 1.02) 2.08 (1.56, 2.78) 0.0048 
     
  < 36 years old 1.63 (1.34, 1.97) 1.03 (0.58, 1.83)   
  36-43 years old 1.40 (1.15, 1.69) 0.83 (0.46, 1.49)   
  44-51 years old 1.15 (0.94, 1.39) 1.06 (0.61, 1.83)   
  > 51 years old 1.0  2.09 (1.57, 2.79) 0 
MDD     
  Yes 3.68 (3.14, 4.32) 1.84 (1.13, 2.99) 1.85 (1.37, 2.50) 0.1220 
  No 1.0    
Gender     
  Male 1.0    
  Female 1.47 (1.28, 1.69) 2.00 (1.27, 3.15) 1.99 (1.49, 2.66) 0.0490 
CWP     
  Yes 2.00 (1.60, 2.50) 4.12 (2.48, 6.84) 1.89 (1.41, 2.54) 0.1006 
  No 1.0    
CFS-like illness     
  Yes 2.97 (2.15, 4.09) 3.90 (1.84, 8.29) 1.88 (1.40, 2.52) 0.1059 
  No 1.0    
BMI Categorical    
  ≤24.9 kg/m2 1.0  2.07 (1.55, 2.76) 0.0096 
  25-29.9 kg/m2 0.96 (0.83, 1.12) 0.98 (0.62, 1.56)   
  ≥30 kg/m2 1.22 (1.04, 1.44) 1.15 (0.70, 1.88)   
Physical Health 
Score 
    
  Continuous 1.00 (0.99, 1.01) 0.96 (0.94, 0.97) 2.04 (1.52, 2.73) 0.0242 
     
  < mean 1.39 (1.20, 1.61) 3.00 (2.01, 4.47)   
  ≥ mean 1.0  1.93 (1.44, 2.59) 0.0796 
Table 2.21: Assessing confounding and effect measure modification using backward elimination for the model of mental self-
rated health, AHP study, 1999. 
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  Min Model Full Model 
β (SE) β (SE) 
Model 2 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Mental Health Score 
 
4,307 (203/4,104) 
 
 
-0.0352 (0.0059) 
4,307 (203/4,104) 
 
 
-0.0760 (0.0323) 
4,307 (203/4,104) 
 
 
-0.0285 (0.0065) 
 
|ln(crude/adj)| of beta    0.77 0.98
Compare to: 
-2log L 
df 
Chi-square p-value 
 
1606.2196 
1 
Min Model 
1593.3566 
7 
 
Full 
1597.4954 
4 
4.1388 (p>0.2) 
OR (95% CI) for main 
effect:  
Mental Health Score 
 
 
0.97 (0.95, 0.98) 
 
 
 
0.93 (0.87, 0.99) 
 
 
 
0.97 (0.96, 0.98) 
Crude vs Adjusted 
|ln(crude/adj)| 0.04 
 
0.04 
Notes/Conclusions about 
current model: 
Mental self-rated 
health, adjusted for 
twin relatedness. 
First-order interactions with 
BMI, age, and MDL, and 
linear terms. 
All interaction terms excluded 
from model to assess effect 
modification.  No effect 
modification is present based on 
likelihood ratio test. 
Variable to be dropped 
next (Wald p-value) 
 All interaction terms (chunk 
test) 
Age (0.7585) 
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Table 2.21 (Continued): Assessing confounding and effect measure modification using backward elimination for the model of 
mental self-rated health, AHP study, 1999. 
Model 3 Model 4 
β (SE) β (SE) 
Model 5 
β (SE) 
FINAL MODEL 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Mental Health Score 
 
4,307 (203/4,104) 
 
 
-0.0286 (0.0065) 
4,307 (203/4,104) 
 
 
-0.0289 (0.0065) 
4,307 (203/4,104) 
 
 
-0.0352 (0.0059) 
4,307 (203/4,104) 
 
 
-0.0352 (0.0059) 
|ln(crude/adj)| of beta 0.004    0.01 0.20 0.20
Compare to: 
-2log L 
df 
Chi-square p-value 
 
Model 2 
1597.5442 
3 
N/A 
Model 3 
1600.0432 
2 
N/A 
 
Model 4 
1606.2196 
1 
N/A 
Model 4 
1606.2196 
1 
N/A 
OR (95% CI) for main 
effect:  
Mental Health Score 
 
 
0.97 (0.96, 0.98) 
 
 
0.97 (0.96, 0.98) 
 
 
0.97 (0.95, 0.98) 
 
 
0.97 (0.95, 0.98) 
Crude vs Adjusted 
|ln(crude/adj)| 
 
0 
 
0.01 
 
0 
 
0 
Notes/Conclusions about 
current model: 
OR for main effect 
did not change by 
>10%.  Age is not 
confounder. 
OR for main effect 
did not change by 
>10%.  BMI is not 
confounder. 
OR for main effect 
did not change by 
>10%.  MDL is not 
confounder. 
OR for main effect not 
confounded by any 
covariates, but is 
adjusted for twin 
relatedness. 
Variable to be dropped 
next (Wald p-value) 
BMI (0.2822) MDL (0.0144) none  
 
Table 2.22: Assessing effect measure modification for physical self-rated health and 
IBS model, AHP study, 1999. 
 OR, (95% CI) for 
Physical self-
rated health 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/
Maybe) 
Age (years)  3.38  
(2.53, 4.53) 
10.3898 
(0.0155) 
Yes 
  < 36 years old 2.82 (1.51, 5.25)    
  36-43 years old 6.30 (3.61, 11.00)    
  44-51 years old 1.81 (1.03, 3.18)    
  > 51 years old 4.05 (2.08, 7.87)    
MDD  3.01  
(2.26, 4.00) 
2.2726 
(0.1317) 
Yes 
  Yes 2.19 (1.31, 3.66)    
  No 3.52 (2.50, 4.95)    
Gender  3.14  
(2.36, 4.17) 
0.0739 
(0.7857) 
No 
  Male 2.91 (1.59, 5.33)    
  Female 3.20 (2.32, 4.42)    
CWP  2.59  
(1.91, 3.52) 
0.0647 
(0.7991) 
No 
  Yes 2.38 (1.11, 5.11)    
  No 2.65 (1.91, 3.68)    
CFS-like 
illness 
 2.89  
(2.16, 3.87) 
0.4376 
(0.5083) 
Maybe 
  Yes 3.89 (1.49, 10.19)    
  No 2.77 (2.04, 3.77)    
BMI  3.17  
(2.36, 4.25) 
0.6036 
(0.7395) 
Maybe 
  ≤24.9 kg/m2 3.72 (2.31, 5.99)    
  25-29.9 kg/m2 3.01 (1.85, 4.88)    
  ≥30 kg/m2 2.86 (1.64, 4.99)    
Mental Health 
Score 
 3.07  
(2.31, 4.08) 
0.0304 
(0.8615) 
No 
  < mean 3.15 (2.08, 4.78)    
  ≥ mean 2.99 (2.02, 4.43)    
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Table 2.23: Evaluation of confounding for the association between physical self-rated 
health and risk of lifetime IBS, AHP study, 1999. 
 Physical self-
rated health 
and covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted OR Ln[CoRR] 
OR (95% CI) for 
Physical health 
score 
3.20 (2.41, 
4.26) 
OR, (95% CI)  OR, (95% CI)  OR, (95% CI)  Ln(ORcrude
/ORadj) 
Total=4,307    4,104 (controls) 3,207 (PH >50)   
     
Age (years)     
  Continuous 1.05 (1.04, 1.05) 0.99 (0.97, 1.01) 3.42 (2.54, 4.61) -0.0665 
     
  < 36 years old 0.30 (0.25, 0.38) 1.73 (0.88, 3.42)   
  36-43 years old 0.51 (0.42, 0.62) 1.12 (0.54, 2.31)   
  44-51 years old 0.60 (0.50, 0.73) 1.84 (0.93, 3.63)   
  > 51 years old 1.0  3.37 (2.52, 4.52) 0.0518 
MDD     
  Yes 1.63 (1.38, 1.92) 2.26 (1.46, 3.50) 3.05 (2.28, 4.07) 0.0480 
  No 1.0    
Gender     
  Male 1.0    
  Female 1.23 (1.06, 1.42) 1.85 (1.16, 2.94) 3.13 (2.35, 4.17) 0.0221 
CWP     
  Yes 6.49 (5.16, 8.17) 2.76 (1.35, 5.64) 2.61 (1.92, 3.53) 0.2038 
  No 1.0    
CFS-like illness     
  Yes 3.42 (2.49, 4.69) 3.01 (1.28, 7.09) 2.87 (2.15, 3.84) 0.1088 
  No 1.0    
BMI Categorical    
  ≤24.9 kg/m2 1.0  3.20 (2.37, 4.30) 0 
  25-29.9 kg/m2 1.64 (1.39, 1.94) 1.13 (0.72, 1.78)   
  ≥30 kg/m2 3.43 (2.88, 4.10) 1.15 (0.67, 1.96)   
Mental Health 
Score 
    
  Continuous 0.99 (0.98, 1.00) 0.97 (0.95, 0.98) 3.09 (2.32, 4.12) 0.0350 
     
  < mean 1.38 (1.20, 1.60) 1.88 (1.25, 2.83)   
  ≥ mean 1.0  3.06 (2.30, 4.08) 0.0447 
Table 2.24: Assessing confounding and effect measure modification using backward elimination for the model of physical self-
rated health, AHP study, 1999. 
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   Min Model
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Physical Health Score 
 
4,307 (203/4,104) 
 
 
-0.0464 (0.0058) 
4,307 (203/4,104) 
 
 
-0.0905 (0.0350) 
4,307 (203/4,104) 
 
 
-0.0499 (0.0063) 
 
|ln(crude/adj)| of beta    0.67 0.60
Compare to: 
-2log L 
df 
Chi-square p-value 
 
1581.9058 
1 
Min Model 
1573.7552 
5 
 
Full 
1576.3028 
3 
2.5476 (p>0.2) 
OR (95% CI) for main 
effect:  
Physical Health Score 
 
 
0.95 (0.94, 0.97) 
 
 
 
0.91 (0.85, 0.98) 
 
 
 
0.95 (0.94, 0.96) 
Crude vs Adjusted 
|ln(crude/adj)| 0.04 
 
0.04 
Notes/Conclusions about 
current model: 
STDPH, adjusted for twin 
relatedness. 
First-order interactions with 
age and BMI, and linear terms. 
All interaction terms 
excluded from model to 
assess effect modification.  
No effect modification is 
present based on 
likelihood ratio test. 
Variable to be dropped 
next (Wald p-value) 
 All interaction terms (chunk 
test) 
BMI (0.8419) 
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Table 2.24 (Continued): Assessing confounding and effect measure modification using backward elimination for the model of 
physical self-rated health, AHP study, 1999. 
Model 3
β (SE) 
Model 4 
β (SE) 
FINAL MODEL  
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Physical Health Score 
 
4,307 (203/4,104) 
 
 
-0.0504 (0.0062) 
4,307 (203/4,104) 
 
 
-0.0464 (0.0058) 
4,307 (203/4,104) 
 
 
-0.0464 (0.0058) 
|ln(crude/adj)| of beta 0.01   0.08 0.08
Compare to: 
-2log L 
df 
Chi-square p-value 
 
Model 2 
1576.6368 
2 
N/A 
Model 3 
1581.9058 
1 
N/A 
Model 3 
1581.9058 
1 
N/A 
OR (95% CI) for main 
effect:  
Physical Health Score 
 
 
0.95 (0.94, 0.96) 
 
 
0.95 (0.94, 0.97) 
 
 
0.95 (0.94, 0.97) 
Crude vs Adjusted 
|ln(crude/adj)| 
 
0 
 
0 
 
0 
Notes/Conclusions about 
current model: 
OR for main effect did not 
change by >10%.  BMI is 
not confounder. 
OR for main effect did not 
change by >10%.  Age is 
not confounder. 
OR for main effect is not 
confounded by any covariates, 
but is adjusted for twin 
relatedness. 
Variable to be dropped 
next (Wald p-value) 
Age (0.0178) none  
 
Table 2.25: Assessing effect measure modification for age-IBS model, AHP study, 
1999. 
 OR, (95% CI) for 
age 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/
Maybe) 
MDD  0.98 (0.74, 1.30) 5.0467 
(0.0247) 
Yes 
  Yes 1.61 (0.96, 2.71)    
  No 0.79 (0.56, 1.11)    
Gender  0.94 (0.71, 1.25) 0.0247 
(0.8750) 
No 
  Male 0.90 (0.49, 1.66)    
  Female 0.95 (0.69, 1.31)    
CWP  1.12 (0.84, 1.49) 0.6057 
(0.4364) 
Maybe 
  Yes 1.41 (0.74, 1.66)    
  No 1.06 (0.77, 1.46)    
CFS-like 
illness 
 1.00 (0.75, 1.33) 2.2476 
(0.1338) 
Yes 
  Yes 1.79 (0.79, 4.05)    
  No 0.92 (0.68, 1.25)    
BMI  1.03 (0.77, 1.36) 0.2119 
(0.8995) 
No 
  ≤24.9 kg/m2 1.00 (0.63, 1.59)    
  25-29.9 
kg/m2
0.97 (0.60, 1.59)    
  ≥30 kg/m2 1.14 (0.67, 1.94)    
Physical 
Health Score 
    
  < mean 1.43 (0.95, 2.16) 1.19 (0.89, 1.58) 1.5119 
(0.2188) 
Maybe 
  ≥ mean 1.00 (0.67, 1.49)    
Mental 
Health Score 
 0.93 (0.70, 1.24) 0.0250 
(0.8744) 
No 
  < mean 0.91 (0.60, 1.38)    
  ≥ mean 0.95 (0.64, 1.41)    
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Table 2.26: Evaluation of confounding for the association between age and risk of 
lifetime IBS, AHP study, 1999. 
 Age and 
covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted OR Ln[CoRR] 
OR (95% CI) for 
age 
1.00 (0.75, 
1.33) 
OR, (95% CI)  OR, (95% CI)  OR, (95% CI)  Ln(ORcrude
/ORadj) 
Total=4,307    4,104 (controls) 2,246  
(age ≥42.89) 
  
     
MDD     
  Yes 1.00 (1.00, 1.01) 1.35 (0.85, 2.13) 0.99 (0.74, 1.31) 0.0101 
  No 1.0    
Gender     
  Male 1.0    
  Female 1.01 (0.95, 1.08) 1.98 (1.26, 3.11) 0.94 (0.71, 1.25) 0.0619 
CWP     
  Yes 0.97 (0.96, 0.98) 3.59 (2.28, 5.66) 1.13 (0.84, 1.51) 0.1222 
  No 1.0    
CFS-like illness     
  Yes 1.00 (0.99, 1.01) 3.66 (1.92, 6.97) 1.01 (0.76, 1.34) 0.0099 
  No 1.0    
BMI Categorical    
  ≤24.9 kg/m2 1.0  1.03 (0.77, 1.38) 0.0296 
  25-29.9 kg/m2 0.97 (0.91, 1.02) 1.19 (0.73, 1.94)   
  ≥30 kg/m2 0.99 (0.96, 1.00) 1.33 (0.80, 2.22)   
Physical Health 
Score 
    
  Continuous 1.00 (1.00, 1.00) 0.96 (0.95, 0.97) 1.24 (0.92, 1.68) 0.2151 
     
  < mean 0.97 (0.96, 0.98) 2.81 (1.88, 4.20)   
  ≥ mean 1.0 1.0 1.20 (0.89, 1.61) 0.1823 
Mental Health 
Score 
    
  Continuous 1.00 (1.00, 1.00) 0.97 (0.95, 0.98) 0.94 (0.71, 1.26) 0.0619 
     
  < mean 0.97 (0.92, 1.02) 2.11 (1.40, 3.18)   
  ≥ mean 1.0  0.94 (0.71, 1.25) 0.0619 
Table 2.27: Assessing confounding and effect measure modification using backward elimination for the model of age, AHP 
study, 1999. 
220
   Min Model
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
age 
 
4,307 (203/4,104) 
 
 
-0.0037 (0.0073) 
4,307 (203/4,104) 
 
 
-0.0075 (0.0248) 
4,307 (203/4,104) 
 
 
-0.0030 (0.0075) 
 
|ln(crude/adj)| of beta    0.71 0.92
Compare to: 
-2log L 
df 
Chi-square p-value 
 
1636.3244 
1 
Min Model 
1612.1446 
5 
 
Full 
1612.2208 
3 
0.0762 (p>0.2) 
OR (95% CI) for main 
effect:  
age 
 
 
1.00 (0.98, 1.01) 
 
 
 
0.99 (0.95, 1.04) 
 
 
 
1.00 (0.98, 1.01) 
Crude vs Adjusted 
|ln(crude/adj)| 0.01 
 
0.01 
Notes/Conclusions about 
current model: 
Age, adjusted for twin 
relatedness. 
First-order interactions 
with gender and BMI, 
and linear terms. 
All interaction terms excluded 
from model to assess effect 
modification.  No effect 
modification is present based 
on likelihood ratio test. 
Variable to be dropped 
next (Wald p-value) 
 All interaction terms 
(chunk test) 
BMI (0.0666) 
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Table 2.27 (Continued): Assessing confounding and effect measure modification using backward elimination for the model of 
age, AHP study, 1999. 
Model 3
β (SE) 
Model 4 
β (SE) 
FINAL MODEL 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
age 
 
4,307 (203/4,104) 
 
 
0.0000 (0.0074) 
4,307 (203/4,104) 
 
 
-0.0037 (0.0073) 
4,307 (203/4,104) 
 
 
-0.0037 (0.0073) 
|ln(crude/adj)| of beta 0   0 0
Compare to: 
-2log L 
df 
Chi-square p-value 
 
Model 2 
1617.7604 
2 
N/A 
Model 3 
1636.3244 
1 
N/A 
 
Model 3 
1636.3244 
1 
N/A 
 
OR (95% CI) for main 
effect:  
age 
 
 
1.00 (0.99, 1.01) 
 
 
1.00 (0.98, 1.01) 
 
 
1.00 (0.98, 1.01) 
Crude vs Adjusted 
|ln(crude/adj)| 
 
0 
 
0 
 
0 
Notes/Conclusions about 
current model: 
OR for main effect did not 
change by >10%.  BMI is 
not confounder. 
OR for main effect did 
not change by >10%.  
Gender is not 
confounder. 
OR for main effect is not 
confounded by any covariates, 
but is adjusted for twin 
relatedness. 
Variable to be dropped 
next (Wald p-value) 
Gender (<0.0001) None  
 
Table 2.28: Assessing effect measure modification for BMI-IBS model, AHP study, 
1999. 
 OR, (95% CI) 
for BMI 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/ 
Maybe) 
     
Age (years)  1.27 (0.95, 1.71) 0.2334 
(0.9720) 
No 
  < 36 years old 1.28 (0.72, 2.28)    
  36-43 years old 1.35 (0.78, 2.34)    
  44-51 years old 1.32 (0.74, 2.35)    
  > 51 years old 1.10 (0.56, 2.18)    
MDD  1.25 (0.93, 1.68) 0 (0.9963) No 
  Yes 1.25 (0.74, 2.12)    
  No 1.25 (0.88, 1.78)    
Gender  1.40 (1.04, 1.88) 0.0023 
(0.9620) 
No 
  Male 1.38 (0.69, 2.76)    
  Female 1.41 (1.02, 1.95)    
CWP  1.15 (0.85, 1.54) 0.0108 
(0.9173) 
No 
  Yes 1.19 (0.59, 2.39)    
  No 1.14 (0.82, 1.58)    
CFS-like illness  1.23 (0.92, 1.65) 0.4948 
(0.4818) 
Maybe 
  Yes 1.66 (0.68, 4.04)    
  No 1.19 (0.87, 1.62)    
Physical Health 
Score 
 1.02 (0.76, 1.38) 0.5993 
(0.4389) 
Maybe 
  < mean 0.90 (0.58, 1.40)    
  ≥ mean 1.14 (0.76, 1.70)    
Mental Health 
Score 
 1.25 (0.93, 1.68) 1.9092 
(0.1670) 
Yes 
  < mean 1.57 (1.01, 2.43)    
  ≥ mean 1.03 (0.70, 1.53)    
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Table 2.29: Evaluation of confounding for the association between BMI and risk of 
lifetime IBS, AHP study, 1999. 
 BMI and 
covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted OR Ln[CoRR] 
OR (95% CI) for 
BMI 
1.26 (0.94, 
1.70) 
OR, (95% CI)  OR, (95% CI)  OR, (95% CI)  Ln(ORcrude
/ORadj) 
Total=4,307    4,104 (controls) 1,819 (BMI<25)   
     
Age (years)     
  Continuous 1.04 (1.03, 1.05) 0.99 (0.97, 1.02) 1.29 (0.95, 1.75) 0.0235 
     
  < 36 years old 0.34 (0.28, 0.42) 1.00 (0.48, 2.10)   
  36-43 years old 0.55 (0.46, 0.67) 1.01 (0.48, 2.14)   
  44-51 years old 0.66 (0.55, 0.80) 0.97 (0.44, 2.14)   
  > 51 years old 1.0  1.28 (0.95, 1.73) 0.0157 
MDD     
  Yes 1.07 (0.92, 1.25) 2.00 (1.22, 3.30) 1.25 (0.93, 1.69) 0.0080 
  No 1.0    
Gender     
  Male 1.0    
  Female 0.50 (0.43, 0.57) 2.08 (1.09, 3.99) 1.40 (1.04, 1.89) 0.1054 
CWP     
  Yes 1.84 (1.45, 2.33) 3.73 (1.97, 7.09) 1.15 (0.85, 1.55) 0.0913 
  No 1.0    
CFS-like illness     
  Yes 1.26 (0.92, 1.72) 4.10 (1.89, 8.91) 1.23 (0.92, 1.66) 0.0241 
  No 1.0    
Physical Health 
Score 
    
  Continuous 0.96 (0.95, 0.97) 0.95 (0.93, 0.97) 1.04 (0.76, 1.41) 0.1919 
     
  < mean 2.20 (1.91, 2.55) 3.67 (2.29, 5.91)   
  ≥ mean 1.0  1.03 (0.76, 1.40) 0.2607 
Mental Health 
Score 
    
  Continuous 1.00 (0.99, 1.01) 0.98 (0.96, 1.00) 1.26 (0.93, 1.69) 0 
     
  < mean 1.06 (0.93, 1.21) 1.57 (0.97, 2.55)   
  ≥ mean 1.0  1.26 (0.93, 1.69) 0 
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Table 2.30: Assessing confounding and effect measure modification using backward elimination for the model of BMI, AHP 
study, 1999. 
 Min Model 
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
N (cases/controls) 
Main Exposure: 
BMI 
  ≤24.9 kg/m2
  25-29.9 kg/m2
  ≥30 kg/m2
4,307 (203/4,104) 
 
 
0 (0) 
0.1567 (0.1729) 
0.3376 (0.1801) 
4,307 (203/4,104) 
 
 
0 (0) 
0.4219 (0.4751) 
0.6424 (0.9209) 
4,307 (203/4,104) 
 
 
0 (0) 
0.3043 (0.1777) 
0.4005 (0.1834) 
|ln(crude/adj)| of beta  0.99; 0.64 0.33; 0.47 
Compare to: 
-2log L 
df 
Chi-square p-value 
 
1633.1152 
1 
Min Model 
1612.153 
5 
 
Full 
1612.2208 
3 
0.0678 (p>0.2) 
OR (95% CI) for main 
effect:  
BMI 
  ≤24.9 kg/m2
  25-29.9 kg/m2
  ≥30 kg/m2
 
 
 
1.00 
1.17 (0.83, 1.64) 
1.40 (0.98, 2.00) 
 
 
 
1.00 
1.52 (0.60, 3.87) 
1.90 (0.31, 11.56) 
 
 
 
1.00 
1.36 (0.96, 1.92) 
1.49 (1.04, 2.14) 
Crude vs Adjusted 
|ln(crude/adj)| 
 0.26 
0.31 
0.11 
0.24 
Notes/Conclusions about 
current model: 
BMI, adjusted for twin 
relatedness. 
First-order interactions with 
gender and age, and linear 
terms. 
All interaction terms excluded 
from model to assess effect 
modification.  No effect 
modification is present based on 
likelihood ratio test. 
Variable to be dropped 
next (Wald p-value) 
 All interaction terms (chunk 
test) 
Age (0.6934) 
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Table 2.30 (Continued): Assessing confounding and effect measure modification using backward elimination for the model of 
BMI, AHP study, 1999. 
 Model 3 
β (SE) 
Model 4 
β (SE) 
FINAL MODEL 
β (SE) 
N (cases/controls) 
Main Exposure: 
BMI 
  ≤24.9 kg/m2
  25-29.9 kg/m2
  ≥30 kg/m2
4,307 (203/4,104) 
 
 
0 (0) 
0.2945 (0.1760) 
0.3910 (0.1807) 
4,307 (203/4,104) 
 
 
0 (0) 
0.1567 (0.1792) 
0.3376 (0.1801) 
4,307 (203/4,104) 
 
 
0 (0) 
0.2945 (0.1760) 
0.3910 (0.1807) 
|ln(crude/adj)| of beta 0.03; 0.02 0.63; 0.15 0.03; 0.02 
Compare to: 
-2log L 
df 
Chi-square p-value 
Model 2 
1612.3442 
2 
N/A 
Model 3 
1633.1152 
1 
N/A 
Model 2 
1612.3442 
2 
N/A 
OR (95% CI) for main 
effect:  
BMI 
  ≤24.9 kg/m2
  25-29.9 kg/m2
  ≥30 kg/m2
 
 
 
1.00 
1.34 (0.95, 1.90) 
1.48 (1.04, 2.11) 
 
 
 
 
 
 
 
1.00 
1.34 (0.95, 1.90) 
1.48 (1.04, 2.11) 
Crude vs Adjusted 
|ln(crude/adj)| 
0.01 
0.01 
0.14 
0.06 
0.01 
0.01 
Notes/Conclusions about 
current model: 
OR for main effect did not 
change by >10%.  Age is 
not confounder. 
OR for main effect did 
change by >10%.  Gender 
is confounder, return it to 
model. 
OR for main effect is 
confounded by gender, and 
adjusted for twin relatedness. 
Variable to be dropped 
next (Wald p-value) 
Gender (<0.0001) None  
1.00 
1.17 (0.83, 1.64) 
1.40 (0.98, 2.00) 
Table 2.31: Characteristics of MDD cases and controls, AHP study, 1999 (Sensitivity 
analysis of timing). 
 Total Cases Controls Chi-Square  
 No. % No. % No. % statistic  
       (p-value)* 
Total 4,558  866 19.0 3,692 81.0  
Age at 
interview 
(years) 
      18.8083 
(0.0159) 
  < 36 years old 1,121 24.6 223 25.8 898 24.3  
  36-43 years old 1,201 26.4 242 28.0 959 26.0  
  44-51 years old 1,208 26.5 231 26.7 977 26.5  
  > 51 years old 1,026 22.5 169 19.5 857 23.2  
  Missing 2  1  1   
  Mean (SE)   42.76 
(0.18)
 42.84 
(0.16) 
 0.63 
(0.5296) 
Sex       -5.71 
(<0.0001) 
  Male 2,530 55.5 223 25.8 2,307 62.5  
  Female 2,027 44.5 643 74.2 1,384 37.5  
  Missing 1  0  1   
IBS        
  Yes 212 4.7 69 8.0 143 3.9 -5.05 
(<0.0001) 
  No 4,316 95.3 792 92.0 3,524 96.1  
  Missing 30  5  25   
CWP        
  Yes 363 8.0 123 14.2 240 6.5 -7.36 
(<0.0001) 
  No 4,187 92.0 742 85.8 3,445 93.5  
  Missing 8  1  7   
CFS-like 
illness 
       
  Yes 162 3.6 94 10.9 68 1.8 -11.40 
(<0.0001) 
  No 4,396 96.4 772 89.1 3,624 98.2  
  Missing 0  0  0   
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Table 2.31 (Continued): Characteristics of MDD cases and controls, AHP study, 
1999. 
 Total Cases Controls Chi-Square 
 No. % No. % No. % statistic  
       (p-value)* 
BMI        
  ≤24.9 kg/m2 1,986 43.6 367 42.4 1,619 43.9 9.3646 
(0.0526) 
  25-29.9 
kg/m2
1,509 33.1 268 30.9 1,241 33.6  
  ≥30 kg/m2 1,063 23.3 231 26.7 832 22.5  
  Missing 0  0  0   
Mental Health 
Score 
       
  < mean 1,397 31.5 480 56.4 917 25.6 -16.41 
(<0.0001) 
  ≥ mean 3,041 68.5 371 43.6 2,670 74.4  
  Missing 120  15  105   
  Mean (SE)   44.24 
(0.31) 
 52.38 
(0.15) 
 23.62 
(<0.0001) 
Physical 
Health Score 
       
  < mean 1,137 25.6 291 34.2 846 23.6 -5.83 
(<0.0001) 
  ≥ mean 3,301 74.4 560 65.8 2,741 76.4  
  Missing 120  15  105   
  Mean (SE)   49.79 
(0.32) 
 51.56 
(0.16) 
 5.03 
(<0.0001) 
228
Table 2.32: Characteristics of MDD cases and controls, by sex, AHP study, 1999. 
 Males Females 
 Cases Controls Chi-
Square  
Cases Controls Chi-
Square  
 No. % No. % statistic  No. % No. % statistic  
     (p-value)*     (p-value)* 
Total 223 13.9 1,384 86.1  643 21.8 2,307 78.2  
Age at interview 
(years) 
    5.6979 
(0.4579) 
    17.7716 
(0.0230) 
  < 36 years old 38 17.0 280 20.2  185 28.8 618 26.8  
  36-43 years old 62 27.8 328 23.7  180 28.0 631 27.4  
  44-51 years old 68 30.5 390 28.2  163 25.4 587 25.4  
  > 51 years old 55 24.7 386 27.9  114 17.8 471 20.4  
  Missing 0  0   1  0   
  Mean (SE) 44.27 
(0.26) 
 44.36 
(0.25) 
 1.50 
(0.1357) 
41.97 
(0.19) 
 41.98 
(0.19) 
 0.33 
(0.7382) 
IBS           
  Yes 9 4.1 37 2.7 -1.12 
(0.2625) 
60 9.4 106 4.6 -4.47 
(<0.0001) 
  No 213 95.9 1,343 97.3  579 90.6 2,180 95.4  
  Missing 1  4   4  21   
CWP           
  Yes 25 11.3 78 5.7 -3.12 
(0.0018) 
98 15.2 162 7.0 -6.30 
(<0.0001) 
  No 197 88.7 1,302 94.3  545 84.8 2,142 93.0  
  Missing 1  4   0  3   
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Table 2.32 (Continued): Characteristics of MDD cases and controls, by sex, AHP study, 1999. 
 Males Females 
 Cases Controls Chi-
Square  
Cases Controls Chi-
Square  
 No. % No. % statistic  No. % No. % statistic  
     (p-value)*     (p-value)* 
CFS-like illness           
  Yes 16 7.2 12 0.9 -5.61 
(<0.0001) 
78 12.1 56 2.4 -9.41 
(<0.0001) 
  No 207 92.8 1,372 99.1  565 87.9 2,251 97.6  
  Missing 0  0   0  0   
BMI           
  ≤24.9 kg/m2 69 30.9 463 33.4 4.4929 
(0.3434) 
298 46.3 1,156 50.1 10.3189 
(0.0354) 
  25-29.9 kg/m2 104 46.6 600 43.4  164 25.5 640 27.7  
  ≥30 kg/m2 50 22.4 321 23.2  181 28.1 511 22.1  
  Missing 0  0   0  0   
Mental Health 
Score 
          
  < mean 121 55.3 287 21.3 -10.03 
(<0.0001) 
359 56.8 630 28.1 -12.55 
(<0.0001) 
  ≥ mean 98 44.7 1,059 78.7  273 43.2 1,610 71.9  
  Missing 4  38   11  67   
  Mean (SE) 44.78 
(0.55) 
 53.38 
(0.22) 
 14.41 
(<0.0001) 
44.11 
(0.38) 
 51.74 
(0.20) 
 18.03 
(<0.0001) 
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Table 2.32 (Continued): Characteristics of MDD cases and controls, by sex, AHP study, 1999. 
 Males Females 
 Cases Controls Chi-
Square  
Cases Controls Chi-
Square  
 No. % No. % statistic  No. % No. % statistic  
     (p-value)*     (p-value)* 
Physical 
Health Score 
          
  < mean 70 32.0 287 21.3 -3.35 
(0.0008) 
221 35.0 558 24.9 -4.46 
(<0.0001) 
  ≥ mean 149 68.0 1,059 78.7  411 65.0 1,682 75.1  
  Missing 4  38   11  67   
  Mean (SE) 50.42 
(0.58) 
 51.89 
(0.25) 
 2.37 
(0.0189) 
49.66 
(0.38) 
 51.32 
(0.21) 
 3.89 
(0.0001) 
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Table 2.33: Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors and risk for 
major depressive disorder, AHP study, 1999 (sensitivity analysis). 
 Cases (866) Controls (3,692) OR 95% CI 
 No. % No. %   
Age at interview (years)       
  < 36 years old 223 25.8 898 24.3 1.22 0.97, 1.53 
  36-43 years old 242 28.0 959 26.0 1.20 0.95, 1.50 
  44-51 years old 231 26.7 977 26.5 1.16 0.92, 1.46 
  > 51 years old 169 19.5 857 23.2 1.0  
Sex       
  Male 223 25.8 2,307 62.5 1.0  
  Female 643 74.2 1,384 37.5 1.72 1.45, 2.05 
IBS       
  Yes 69 8.0 143 3.9 1.95 1.44, 2.64 
  No 792 92.0 3,524 96.1 1.0  
CWP       
  Yes 123 14.2 240 6.5 2.30 1.81, 2.92 
  No 742 85.8 3,445 93.5 1.0  
CFS-like illness       
  Yes 94 10.9 68 1.8 5.76 4.17, 7.97 
  No 772 89.1 3,624 98.2 1.0  
BMI       
  ≤24.9 kg/m2 367 42.4 1,619 43.9 1.0  
  25-29.9 kg/m2 268 30.9 1,241 33.6 0.96 0.80, 1.15 
  ≥30 kg/m2 231 26.7 832 22.5 1.26 1.04, 1.54 
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Table 2.33 (Continued): Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors 
and risk for major depressive disorder, AHP study, 1999 (sensitivity analysis). 
 Cases (866) Controls (3,692) OR 95% CI 
 No. % No. %   
Mental Health Score       
  < mean 480 56.4 917 25.6 3.69 3.14, 4.33 
  ≥ mean 371 43.6 2,670 74.4 1.0  
Physical Health Score       
  < mean 291 34.2 846 23.6 1.66 1.41, 1.96 
  ≥ mean 560 65.8 2,741 76.4 1.0  
       
Continuous Covariates       
Age      0.99 0.99, 1.00 
Mental Health Score     0.93 0.92, 0.94 
Physical Health Score      0.98 0.97, 0.99 
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Table 2.34: Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors and risk for 
major depressive disorder, by sex, AHP study, 1999. 
 Males Females 
             
 Cases Controls OR 95% CI Cases Controls OR 95% CI 
 No. % No. %   No. % No. %   
Age at 
interview 
(years) 
            
  < 36 years old 38 17.0 280 20.2 0.89 0.56, 1.43 185 28.8 618 26.8 1.20 0.91, 1.57 
  36-43 years old 62 27.8 328 23.7 1.23 0.81, 1.85 180 28.0 631 27.4 1.10 0.83, 1.44 
  44-51 years old 68 30.5 390 28.2 1.18 0.80, 1.74 163 25.4 587 25.4 1.11 0.84, 1.47 
  > 51 years old 55 24.7 386 27.9 1.0  114 17.8 471 20.4 1.0  
IBS             
  Yes 9 4.1 37 2.7 1.61 0.79, 3.28 60 9.4 106 4.6 1.89 1.35, 2.65 
  No 213 95.9 1,343 97.3 1.0  579 90.6 2,180 95.4 1.0  
CWP             
  Yes 25 11.3 78 5.7 1.96 1.20, 3.20 98 15.2 162 7.0 2.32 1.76, 3.06 
  No 197 88.7 1,302 94.3 1.0  545 84.8 2,142 93.0 1.0  
CFS-like 
illness 
            
  Yes 16 7.2 12 0.9 8.62 4.07, 
18.22 
78 12.1 56 2.4 4.89 3.41, 7.01 
  No 207 92.8 1,372 99.1 1.0  565 87.9 2,251 97.6 1.0  
BMI             
  ≤24.9 kg/m2 69 30.9 463 33.4 1.0  298 46.3 1,156 50.1 1.0  
  25-29.9 kg/m2 104 46.6 600 43.4 1.17 0.83, 1.65 164 25.5 640 27.7 1.00 0.80, 1.25 
  ≥30 kg/m2 50 22.4 321 23.2 1.10 0.74, 1.65 181 28.1 511 22.1 1.40 1.12, 1.76 
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Table 2.34 (Continued): Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors 
and risk for major depressive disorder, by sex, AHP study, 1999. 
 Males Females 
             
 Cases Controls OR 95% CI Cases Controls OR 95% CI 
 No. % No. %   No. % No. %   
Mental Health 
Score 
            
  < mean 121 55.3 287 21.3 4.67 3.46, 6.31 359 56.8 630 28.1 3.23 2.68, 3.90 
  ≥ mean 98 44.7 1,059 78.7 1.0  273 43.2 1,610 71.9 1.0  
Physical 
Health Score 
            
  < mean 70 32.0 287 21.3 1.74 1.26, 2.39 221 35.0 558 24.9 1.58 1.30, 1.92 
  ≥ mean 149 68.0 1,059 78.7 1.0  411 65.0 1,682 75.1 1.0  
Continuous 
Covariates 
            
Age      1.00 0.98, 1.01     1.00 0.99, 1.01 
Mental Health 
Score 
    0.92 0.90, 0.93     0.93 0.93, 0.94 
Physical 
Health Score  
    0.98 0.96, 1.00     0.98 0.97, 0.99 
Table 2.35: Assessing effect measure modification for IBS-MDD model, AHP study, 
1999 (Sensitivity Analysis). 
 OR, (95% CI) for 
IBS 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/
Maybe) 
Age (years)  2.02 (1.49, 2.74) 4.3499 
(0.2261) 
Maybe 
  < 36 years old 2.43 (1.33, 4.43)    
  36-43 years old 2.92 (1.68, 5.07)    
  44-51 years old 1.34 (0.70, 2.54)    
  > 51 years old 1.50 (0.72, 3.11)    
Sex  1.89 (1.39, 2.58) 0.2267 
(0.6340) 
Maybe 
Male 1.61 (0.76, 3.39)    
Female 1.96 (1.39, 2.75)    
CWP  1.75 (1.28, 2.38) 2.6681 
(0.1024) 
Yes 
  Yes 1.12 (0.59, 2.12)    
  No 2.05 (1.44, 2.91)    
CFS-like 
illness 
 1.57 (1.15, 2.15) 15.0354 
(0.0001) 
Yes 
  Yes 0.39 (0.17, 0.89)    
  No 2.11 (1.51, 2.95)    
BMI  2.00 (1.47, 2.72) 0.0617 
(0.9696) 
No 
  ≤24.9 kg/m2 2.01 (1.21, 3.34)    
  25-29.9 kg/m2 1.90 (1.11, 3.25)    
  ≥30 kg/m2 2.10 (1.20, 3.66)    
Mental Health 
Score 
 1.66 (1.21, 2.28) 0.2849 
(0.5935) 
Maybe 
  < mean 1.55 (1.02, 2.35)    
  ≥ mean 1.85 (1.13, 3.02)    
Physical 
Health Score 
 1.77 (1.30, 2.41) 2.2758 
(0.1314) 
Yes 
  < mean 1.42 (0.91, 2.19)    
  ≥ mean 2.27 (1.47, 3.51)    
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Table 2.36: Evaluation of confounding for the association between lifetime IBS and 
risk of lifetime MDD, AHP study, 1999. 
 Lifetime IBS 
and covariate 
relationship 
Relationship 
between 
covariate and 
lifetime MDD 
Adjusted OR Ln[CoRR] 
OR (95% CI) for 
lifetime IBS 
1.95 (1.44, 
2.64) 
OR, (95% CI)  OR, (95% CI)  OR, (95% CI)  Ln(ORcrude
/ORadj) 
Total=4,307    3,481 (controls) 4,104 (no lifetime 
IBS) 
  
     
Age (years)     
  Continuous 1.00 (0.98, 1.01) 1.00 (0.99, 1.00) 1.94 (1.44, 2.63) 0.005 
     
  < 36 years old 1.04 (0.68, 1.60) 1.18 (0.93, 1.49)   
  36-43 years old 1.13 (0.75, 1.71) 1.13 (0.90, 1.44)   
  44-51 years old 1.06 (0.70, 1.61) 1.17 (0.93, 1.48)   
  > 51 years old 1.0  1.94 (1.44, 2.63) 0.005 
Sex     
  Male 1.0    
  Female 2.03 (1.44, 2.85) 1.68 (1.40, 2.01) 1.84 (1.36, 2.49) 0.058 
CWP     
  Yes 3.89 (2.74, 5.53) 2.35 (1.82, 3.04) 1.72 (1.25, 2.35) 0.126 
  No 1.0    
CFS-like illness     
  Yes 5.13 (3.30, 7.97) 7.23 (5.01, 10.41) 1.61 (1.15, 2.26) 0.192 
  No 1.0    
BMI Categorical    
  ≤24.9 kg/m2 1.0  1.93 (1.42, 2.61) 0.010 
  25-29.9 kg/m2 1.17 (0.83, 1.64) 0.96 (0.79, 1.15)   
  ≥30 kg/m2 1.40 (0.98, 2.00) 1.25 (1.02, 1.52)   
Mental Health 
Score 
    
  Continuous 0.97 (0.95, 0.98) 0.93 (0.92, 0.94) 1.50 (1.08, 2.09) 0.262 
     
  < mean 2.09 (1.56, 2.78) 3.68 (3.12, 4.35)   
  ≥ mean 1.0  1.62 (1.18, 2.22) 0.185 
Physical Health 
Score 
    
  Continuous 0.95 (0.94, 0.97) 0.98 (0.97, 0.99) 1.76 (1.29, 2.39) 0.103 
     
  < mean 3.20 (2.41, 4.26) 1.66 (1.40, 1.97)   
  ≥ mean 1.0  1.73 (1.27, 2.36) 0.120 
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Table 2.37: Assessing confounding and effect measure modification using backward elimination for the model of lifetime IBS, 
AHP study, 1999. 
 Min Model 
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Lifetime IBS 
 
4,307 (826/3,481) 
 
 
0.6666 (0.1548) 
4,307 (826/3,481) 
 
 
2.0263 (0.9940) 
4,307 (826/3,481) 
 
 
0.5921 (0.1548) 
 
|ln(crude/adj)| of beta  1.11 1.23 
Compare to: 
-2log L 
df 
Chi-square p-value 
 
4191.9522 
1 
Min Model 
4141.2142 
7 
 
Full 
4144.5022 
4 
3.288 (p>0.2) 
OR (95% CI) for main 
effect:  
lifetime IBS 
 
 
1.95 (1.44, 2.64) 
 
 
7.59 (1.08, 53.23) 
 
 
1.81 (1.33, 2.45) 
Crude vs Adjusted 
|ln(crude/adj)| 
  
1.36 
 
1.43 
Notes/Conclusions about 
current model: 
IBS, adjusted for twin 
relatedness. 
First-order interactions with 
gender, BMI, and age, and 
linear terms. 
All interaction terms excluded 
from model to assess effect 
modification.  No effect 
modification is present based 
on likelihood ratio test. 
Variable to be dropped 
next (Wald p-value) 
 All interaction terms (chunk 
test) 
Age (0.2886) 
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Table 2.37 (Continued): Assessing confounding and effect measure modification using backward elimination for the model of 
lifetime IBS, AHP study, 1999. 
 Model 3 
β (SE) 
Model 4 
β (SE) 
MODEL 5/FINAL MODEL 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Lifetime IBS 
 
4,307 (826/3,481) 
 
 
0.5932 (0.1552) 
4,307 (826/3,481) 
 
 
0.6075 (0.1549) 
4,307 (826/3,481) 
 
 
0.6666 (0.1548) 
|ln(crude/adj)| of beta 0.002 0.02 0.09 
Compare to: 
-2log L 
df 
Chi-square p-value 
 
Model 2 
4145.6714 
3 
N/A 
Model 3 
4152.8428 
2 
N/A 
 
Model 4 
4191.9522 
1 
N/A 
OR (95% CI) for main 
effect:  
lifetime IBS 
 
 
1.81 (1.34, 2.45) 
 
 
1.84 (1.36, 2.49) 
 
 
1.95 (1.44, 2.64) 
Crude vs Adjusted 
|ln(crude/adj)| 
 
0 
 
0.02 
 
0.06 
Notes/Conclusions about 
current model: 
OR for main effect did not 
change by >10%.  Age is 
not confounder. 
OR for main effect did not 
change by >10%.  BMI is 
not confounder. 
OR for main effect is not 
confounded by any potential 
covariates, but is adjusted for 
twin relatedness. 
Variable to be dropped 
next (Wald p-value) 
BMI (0.0288) Gender (<0.0001)  
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Table 2.38: Characteristics of IBS cases and controls, SALT study, 2002. 
 Total Cases Controls Chi-Square  
 No. % No. % No. % statistic  
       (p-value)* 
Total 29,616  611 2.06 29,005 97.94  
Age at interview (years)       25.9913 (0.0005) 
  42-44 2,494 8.42 68 11.13 2,426 8.36  
  45-47 3,796 12.82 91 14.89 3,705 12.77  
  48-50 3,727 12.58 97 15.88 3,630 12.52  
  51-53 4,063 13.72 93 15.22 3,970 13.69  
  54-56 7,221 24.38 131 21.44 7,090 24.44  
  57-59 3,743 12.64 60 9.82 3,683 12.70  
  60-62 3,033 10.24 48 7.86 2,985 10.29  
  63+ 1,539 5.20 23 3.76 1,516 5.23  
Sex        
  Male 14,187 47.9 221 36.17 13,966 48.15 -5.56 (<0.0001) 
  Female 15,429 52.1 390 63.83 15,039 51.85  
MDD        
  Yes 6,502 21.95 275 45.01 6,227 21.47 -12.84 (<0.0001) 
  No 23,114 78.05 336 54.99 22,778 78.53  
CWP        
  Yes 760 2.57 69 11.29 691 2.38 -12.01 (<0.0001) 
  No 28,856 97.43 542 88.71 28,314 97.62  
CF-like illness        
  Yes 669 2.26 72 11.78 597 2.06 -13.75 (<0.0001) 
  No 28,947 97.74 539 88.22 28,408 97.94  
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Table 2.38 (Continued): Characteristics of IBS cases and controls, SALT study, 2002. 
 Total Cases Controls Chi-Square  
 No. % No. % No. % statistic  
       (p-value)* 
BMI        
  <18.5 349 1.18 12 1.96 337 1.16 13.3592 (0.0039) 
  18.5-24.9 kg/m2 15,561 52.54 316 51.72 15,245 52.56  
  25-29.9 kg/m2 11,246 37.97 212 34.70 11,034 38.04  
  ≥30 kg/m2 2,460 8.31 71 11.62 2,389 8.24  
Health compared to 5 
years ago 
       
  Better 22,830 77.09 361 59.08 22,469 77.47 10.27 (<0.0001) 
  Worse 6,786 22.91 250 40.92 6,536 22.53  
Does health limit your 
activities? 
       
  Not limited 21,973 74.19 306 50.08 21,667 74.70 12.96 (<0.0001) 
  Limited 7,643 25.81 305 49.92 7,338 25.30  
Number of days health 
limited activities 
       
  > a week 3,549 11.98 144 23.57 3,405 11.74 8.54 (<0.0001) 
  < a week 26,067 88.02 467 76.43 25,600 88.26  
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Table 2.39: Characteristics of IBS cases and controls, by sex, SALT study, 2002. 
 Males Females 
 Cases Controls Chi-Square Cases Controls Chi-Square 
 No. % No. % statistic  No. % No. % statistic  
     (p-value)*     (p-value)* 
Total 221 1.6 13,966 98.4  390 2.5 15,039 97.5  
Age at 
interview 
(years) 
    17.8124 
(0.0128) 
    13.3388 
(0.0643) 
  42-44 26 11.8 1,166 8.3  42 10.8 1,260 8.4  
  45-47 40 18.1 1,814 13.0  51 13.1 1,891 12.6  
  48-50 34 15.4 1,778 12.7  63 16.2 1,852 12.3  
  51-53 35 15.8 1,921 13.8  58 14.9 2,049 13.6  
  54-56 43 19.5 3,367 24.1  88 22.6 3,723 24.8  
  57-59 22 9.9 1,762 12.6  38 9.7 1,921 12.8  
  60-62 12 5.4 1,405 10.1  36 9.2 1,580 10.5  
  63+ 9 4.1 753 5.4  14 3.6 763 5.1  
MDD     -6.43 
(<0.0001) 
    -10.08 
(<0.0001) 
  Yes 69 31.2 2,037 14.6  206 52.8 4,190 27.9  
  No 152 68.8 11,929 85.4  184 47.2 10,849 72.1  
CWP     -3.97 
(<0.0001) 
    -10.24 
(<0.0001) 
  Yes 8 3.6 113 0.8  61 15.6 578 3.8  
  No 213 96.4 13,853 99.2  329 84.4 14,461 96.2  
CF-like illness     -5.74 
(<0.0001) 
    -11.51 
(<0.0001) 
  Yes 11 5.0 120 0.9  61 15.6 477 3.2  
  No 210 95.0 13,846 99.1  329 84.4 14,562 96.8  
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Table 2.39 (Continued): Characteristics of IBS cases and controls, by sex, SALT study, 2002. 
 Males Females 
 Cases Controls Chi-
Square  
Cases Controls Chi-Square 
 No. % No. % statistic  No. % No. % statistic  
     (p-value)*     (p-value)* 
BMI     10.8808 
(0.0124) 
    7.2821 
(0.0634) 
  <18.5 0 0 47 0.3  12 3.1 290 1.9  
  18.5-24.9 
kg/m2
100 45.2 6,123 43.8  216 55.4 9,122 60.7  
  25-29.9 kg/m2 89 40.3 6,568 47.0  123 31.5 4,466 29.7  
  ≥30 kg/m2 32 14.5 1,228 8.8  39 10.0 1,161 7.7  
Health 
compared to 5 
years ago 
    6.17 
(<0.0001) 
    7.94 
(<0.0001) 
  Better 135 61.1 11,037 79.0  226 57.9 11,432 76.0  
  Worse 86 38.9 2,929 21.0  164 42.1 3,607 24.0  
Does health 
limit your 
activities? 
    6.93 
(<0.0001) 
    10.52 
(<0.0001) 
  Not limited 125 56.6 10,808 77.4  181 46.4 10,859 72.2  
  Limited 96 43.4 3,158 22.6  209 53.6 4,180 27.8  
Number of days 
health limited 
activities 
    3.28 
(0.0010) 
    7.48 
(<0.0001) 
  > a week 36 16.3 1,336 9.6  108 27.7 2,069 13.8  
  < a week 185 83.7 12,630 90.4  282 72.3 12,970 86.2  
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Table 2.40: Association between IBS status and missing covariate information, SALT study, 2002. 
 Case (647) Control (30,524) χ2 p-value 
 No. % No. %   
Major Depressive Disorder       
   Missing 20 3.09 622 2.04 3.4856 0.0619 
   Not missing 627 96.91 29,902 97.96   
Chronic Widespread Pain       
   Missing 5 0.77 59 0.19 10.38 0.0013 
   Not missing 642 99.23 30, 465 99.81   
Gender       
   Missing 0 0 0 0 0 1.0 
   Not missing 647 100 30,524 100   
Health compared to 5 years ago       
   Missing 1 0.15 63 0.21 0.0831 0.7732 
   Not missing 646 99.85 30,461 99.79   
Does health limit your activities?       
   Missing 1 0.15 57 0.19 0.0353 0.8509 
   Not missing 646 99.85 30,467 99.81   
Number of days health limited 
activities 
      
   Missing 0 0 0 0 0 1.0 
   Not missing 647 100 30,524 100   
Chronic Fatigue-like illness       
   Missing 1 0.15 180 0.59 2.08 0.1494 
   Not missing 646 99.85 30,344 99.41   
Body Mass Index       
   Missing 0 0 0 0 0 1.0 
   Not missing 647 100 30,524 100   
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Table 2.41: Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors and risk for 
irritable bowel syndrome, SALT study, 2002. 
 Cases (611) Controls (29,005) OR 95% CI 
 No. % No. %   
Age at interview (years)       
  42-44 68 11.13 2,426 8.36 1.85 1.15, 2.97 
  45-47 91 14.89 3,705 12.77 1.62 1.02, 2.57 
  48-50 97 15.88 3,630 12.52 1.77 1.12, 2.79 
  51-53 93 15.22 3,970 13.69 1.54 0.98, 2.44 
  54-56 131 21.44 7,090 24.44 1.22 0.78, 1.90 
  57-59 60 9.82 3,683 12.70 1.08 0.67, 1.75 
  60-62 48 7.86 2,985 10.29 1.06 0.64, 1.75 
  63+ 23 3.76 1,516 5.23 1.0 Referent 
Sex       
  Female 390 63.83 15,039 51.85 1.64 1.39, 1.93 
  Male 221 36.17 13,966 48.15   
MDD       
  Yes 275 45.01 6,227 21.47 2.98 2.53, 3.51 
  No 336 54.99 22,778 78.53   
CWP       
  Yes 69 11.29 691 2.38 5.17 3.97, 6.73 
  No 542 88.71 28,314 97.62   
CF-like illness       
  Yes 72 11.8 597 2.1 6.31 4.87, 8.18 
  No 539 88.2 28,408 97.9   
BMI       
  <18.5 12 1.96 337 1.16 1.74 0.97, 3.12 
  18.5-24.9 kg/m2 316 51.72 15,245 52.56 1.0 Referent 
  25-29.9 kg/m2 212 34.70 11,034 38.04 0.93 0.78, 1.11 
  ≥30 kg/m2 71 11.62 2,389 8.24 1.43 1.10, 1.87 
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Table 2.41 (Continued): Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors 
and risk for irritable bowel syndrome, SALT study, 2002. 
 Cases (611) Controls (29,005) OR 95% CI 
 No. % No. %   
Health compared to 5 years ago       
  Better 361 59.08 22,469 77.47 0.42 0.36, 0.50 
  Worse 250 40.92 6,536 22.53   
Does health limit your 
activities? 
      
  Not limited 306 50.08 21,667 74.70 0.34 0.29, 0.40 
  Limited 305 49.92 7,338 25.30   
Number of days health limited 
activities 
      
  > a week 144 23.57 3,405 11.74 0.43 0.36, 0.52 
  < a week 467 76.43 25,600 88.26   
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Table 2.42: Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors and risk for 
irritable bowel syndrome, by sex, SALT study, 2002. 
 Males Females 
             
 Cases Controls OR 95% CI Cases Controls OR 95% CI 
 No. % No. %   No. % No. %   
Age at interview 
(years) 
            
  42-44 26 11.8 1,166 8.3 1.86 0.87, 3.98 42 10.8 1,260 8.4 1.83 0.99, 3.36 
  45-47 40 18.1 1,814 13.0 1.84 0.89, 3.82 51 13.1 1,891 12.6 1.39 0.82, 2.69 
  48-50 34 15.4 1,778 12.7 1.60 0.76, 3.36 63 16.2 1,852 12.3 1.87 1.05, 3.35 
  51-53 35 15.8 1,921 13.8 1.52 0.73, 3.17 58 14.9 2,049 13.6 1.56 0.87, 2.79 
  54-56 43 19.5 3,367 24.1 1.07 0.52, 2.20 88 22.6 3,723 24.8 1.30 0.74, 2.29 
  57-59 22 9.9 1,762 12.6 1.04 0.48, 2.28 38 9.7 1,921 12.8 1.09 0.59, 2.01 
  60-62 12 5.4 1,405 10.1 0.71 0.30, 1.69 36 9.2 1,580 10.5 1.25 0.67, 2.33 
  63+ 9 4.1 753 5.4 1.0 Referent 14 3.6 763 5.1 1.0 Referent 
MDD             
  Yes 69 31.2 2,037 14.6 2.65 1.99, 3.55 206 52.8 4,190 27.9 2.89 2.36, 3.55 
  No 152 68.8 11,929 85.4   184 47.2 10,849 72.1   
CWP             
  Yes 8 3.6 113 0.8 4.54 2.16, 9.53 61 15.6 578 3.8 4.62 3.46, 6.15 
  No 213 96.4 13,853 99.2   329 84.4 14,461 96.2   
CF-like illness             
  Yes 11 5.0 120 0.9 6.08 3.24, 
11.43 
61 15.6 477 3.2 5.62 4.21, 7.51 
  No 210 95.0 13,846 99.1   329 84.4 14,562 96.8   
BMI             
  <18.5 0 0 47 0.3   12 3.1 290 1.9 1.77 0.98, 3.19 
  18.5-24.9 kg/m2 100 45.2 6,123 43.8 1.0 Referent 216 55.4 9,122 60.7 1.0 Referent 
  25-29.9 kg/m2 89 40.3 6,568 47.0 0.83 0.62, 1.11 123 31.5 4,466 29.7 1.16 0.93, 1.46 
  ≥30 kg/m2 32 14.5 1,228 8.8 1.60 1.07, 2.39 39 10.0 1,161 7.7 1.42 0.99, 2.03 
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Table 2.42 (Continued): Odds ratios (OR) and 95% confidence intervals (CI) for the association between selected risk factors 
and risk for irritable bowel syndrome, by sex, SALT study, 2002. 
 Males Females 
             
 Cases Controls OR 95% CI Cases Controls OR 95% CI 
 No. % No. %   No. % No. %   
Health compared 
to 5 years ago 
            
  Better 135 61.1 11,037 79.0 0.42 0.32, 0.55 226 57.9 11,432 76.0 0.44 0.35, 0.53 
  Worse 86 38.9 2,929 21.0   164 42.1 3,607 24.0   
Does health limit 
your activities? 
            
  Not limited 125 56.6 10,808 77.4 0.38 0.29, 0.50 181 46.4 10,859 72.2 0.33 0.27, 0.41 
  Limited 96 43.4 3,158 22.6   209 53.6 4,180 27.8   
Number of days 
health limited 
activities 
            
  > a week 36 16.3 1,336 9.6 0.55 0.38, 0.78 108 27.7 2,069 13.8 0.42 0.33, 0.52 
  < a week 185 83.7 12,630 90.4   282 72.3 12,970 86.2   
 
Table 2.43: Assessing effect measure modification for MDD-IBS model, SALT study, 
2002. 
 OR, (95% CI) 
for MDD 
ORM-H (95% CI) Breslow-
Day test 
statistic 
(p-value) 
Effect 
Modifier 
(Yes/No/ 
Maybe) 
Age at interview 
(years) 
 2.92 (2.49, 3.44) 4.2838 
(0.7466) 
No 
  42-44 3.05 (1.88, 4.95)    
  45-47 3.53 (2.32, 5.36)    
  48-50 2.50 (1.67, 3.76)    
  51-53 3.09 (2.04, 4.67)    
  54-56 2.78 (1.96, 3.95)    
  57-59 3.75 (2.24, 6.28)    
  60-62 1.89 (1.01, 3.55)    
  63+ 2.97 (1.24, 7.08)    
Sex  2.83 (2.39, 3.33) 0.2337 
(0.6288) 
No 
  Female 2.90 (2.37, 3.55)    
  Male 2.66 (1.99, 3.55)    
CWP  2.71 (2.30, 3.19) 8.1131 
(0.0044) 
Yes 
  Yes 1.41 (0.86, 2.31)    
  No 2.98 (2.51, 3.54)    
CF-like illness  2.63 (2.23, 3.11) 3.2720 
(0.0705) 
Yes 
  Yes 1.72 (1.03, 2.85)    
  No 2.80 (2.36, 3.33)    
BMI  2.97 (2.53, 3.49) 2.4854 
(0.4779) 
Maybe 
  <18.5 1.99 (0.62, 6.43)    
  18.5-24.9 kg/m2 3.03 (2.42, 3.79)    
  25-29.9 kg/m2 3.28 (2.49, 4.31)    
  ≥30 kg/m2 2.19 (1.35, 3.56)    
Health 
compared to 5 
years ago 
 2.70 (2.30, 3.18) 10.4088 
(0.0013) 
Yes 
  Better 3.42 (2.78, 4.23)    
  Worse 1.99 (1.55, 2.57)    
Does health 
limit your 
activities? 
 2.41 (2.12, 2.94) 8.8540 
(0.0029) 
Yes 
  Not limited 3.26 (2.59, 4.10)    
  Limited 2.00 (1.59, 2.51)    
Number of days 
health limited 
activities 
 2.78 (2.36, 3.28) 0.1731 
(0.6774) 
No 
  > a week 2.96 (2.10, 4.16)    
  < a week 2.72 (2.26, 3.28)    
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Table 2.44: Evaluation of confounding for the association between lifetime MDD and 
risk of lifetime IBS, SALT study, 2002. 
 Lifetime MDD and 
covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted 
OR 
Ln[CoRR] 
OR (95% CI) for 
lifetime MDD 
2.98 (2.53, 
3.51) 
OR, (95% CI)  OR, (95% CI)  OR, (95% 
CI)  
Ln(ORcrude
/ORadj) 
Total=29,616    29,005 (controls) 23,114 (no 
lifetime MDD) 
  
Age at 
interview 
(years) 
  2.91  
(2.47, 3.43) 
0.0238 
  42-44 1.74 (1.46, 2.06) 1.61 (0.88, 2.96)   
  45-47 1.78 (1.51, 2.09) 1.30 (0.72, 2.37)   
  48-50 1.77 (1.51, 2.08) 1.68 (0.95, 2.99)   
  51-53 1.70 (1.45, 1.99) 1.35 (0.75, 2.41)   
  54-56 1.53 (1.32, 1.79) 1.14 (0.65, 2.00)   
  57-59 1.22 (1.03, 1.44) 0.94 (0.51, 1.73)   
  60-62 1.19 (1.00, 1.41) 1.19 (0.64, 2.19)   
  63+ 1.0 1.0   
Sex   2.80  
(2.37, 3.31) 
0.0623 
  Female 2.29 (2.16, 2.43) 1.33 (1.07, 1.65)   
  Male 1.0 1.0   
CWP   2.74  
(2.32, 3.24) 
0.0840 
  Yes 2.88 (2.49, 3.34) 6.25 (4.30, 9.08)   
  No 1.0 1.0   
CF-like illness   2.66  
(2.25, 3.15) 
0.1136 
  Yes 3.86 (3.30, 4.51) 6.38 (4.23, 9.64)   
  No 1.0 1.0   
BMI   2.99  
(2.54, 3.52) 
0.0034 
  <18.5 1.24 (0.97, 1.57) 2.00 (0.93, 4.30)   
  18.5-24.9 
kg/m2
1.0 1.0   
  25-29.9 kg/m2 0.84 (0.79, 0.89) 0.94 (0.74, 1.19)   
  ≥30 kg/m2 1.03 (0.93, 1.14) 1.64 (1.16, 2.32)   
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Table 2.44 (Continued): Evaluation of confounding for the association between 
lifetime MDD and risk of lifetime IBS, SALT study, 2002. 
 Lifetime MDD and 
covariate 
relationship 
Relationship 
between 
covariate and 
lifetime IBS 
Adjusted 
OR 
Ln[CoRR] 
OR (95% CI) for 
lifetime MDD 
2.98 (2.53, 
3.51) 
OR, (95% CI)  OR, (95% CI)  OR, (95% 
CI)  
Ln(ORcrude
/ORadj) 
Total=29,616    29,005 (controls) 23,114 (no 
lifetime MDD) 
  
Health 
compared to 5 
years ago 
  2.73  
(2.31, 3.23) 
0.0876 
  Better 0.58 (0.55, 0.62) 0.37 (0.30, 0.46)   
  Worse 1.0 1.0   
Does health 
limit your 
activities? 
  2.53  
(2.14, 3.00) 
0.1637 
  Not limited 0.46 (0.44, 0.49) 0.32 (0.26, 0.40)   
  Limited 1.0 1.0   
Number of days 
health limited 
activities 
  2.76  
(2.34, 3.26) 
0.0767 
  > a week 1.0 1.0   
  < a week 0.46 (0.43, 0.50) 0.54 (0.40, 0.72)   
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Table 2.45: Assessing confounding and effect measure modification in the case-control study, using backward 
elimination for the model of lifetime MDD, SALT study, 2002. 
 Min Model 
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
Model 3/FINAL MODEL 
β (SE) 
N (cases/controls) 
 
Main Exposure: 
Lifetime MDD 
29,616 
(611/29,605) 
 
1.0052 (0.0847) 
29,616 
(611/29,605) 
 
0.7083 (0.6767) 
29,616 (611/29,605) 
 
1.0007 (0.0848) 
29,616 (611/29,605) 
 
 
1.0052 (0.0847) 
|ln(crude/adj)| of 
beta 
 0.35 0.35 0.004 
Compare to: 
-2log L 
df 
Chi-square p-value 
 
5755.3826 
3 
Min Model 
5748.2854 
6 
 
Full 
5748.6312 
4 
0.3458 (p>0.2) 
Full 
5755.3826 
3 
N/A 
OR (95% CI) for 
main effect:  
lifetime MDD 
 
 
2.73  
(2.31, 3.23) 
 
 
2.03  
(0.54, 7.65) 
 
 
2.72  
(2.30, 3.21) 
 
 
2.73  
(2.31, 3.23) 
Crude vs Adjusted 
|ln(crude/adj)| 
  
0.30 
 
0.29 
 
0.004 
Notes/Conclusions 
about current 
model: 
MDL, adjusted for 
twin relatedness, 
sex, and 3-year 
age group. 
First-order 
interactions with 
gender and BMI, 
and linear terms. 
All interaction terms 
excluded from model 
to assess effect 
modification.  Effect 
modification is 
present based on 
likelihood ratio test. 
OR for main effect did not 
change by >10%.  BMI is 
not a confounder.  OR for 
main effect is not 
confounded by any 
covariates, but it is  
adjusted for twin 
relatedness, 3-year age 
group, and sex. 
Variable to be 
dropped next (Wald 
p-value) 
 All interaction 
terms (chunk 
test) 
BMI (0.0126) None 
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Table 2.46: Assessing confounding and effect measure modification in the co-twin control study (MZ and DZ IBS 
discordant twin pairs), using backward elimination for the model of lifetime MDD, SALT study, 2002. 
 Min Model 
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
Model 3/FINAL 
MODEL 
β (SE) 
# IBS discordant pairs 
 
Main Exposure: 
Lifetime MDD 
288 
 
 
0.7985 (0.2007) 
 
288 
 
 
0.9679 (0.2491) 
288 
 
 
0.7975 (0.2010) 
288 
 
 
0.7985 (0.2007) 
|ln(crude/adj)| of beta  0.19 0.19 0.001 
Compare to: 
-2log L 
df 
Chi-square p-value 
 
382.138 
1 
Min Model 
379.776 
3 
 
Full 
381.220 
2 
1.444 (p>0.2) 
Full 
382.138 
1 
N/A 
OR (95% CI) for main 
effect:  
lifetime MDD 
 
 
2.22 (1.50, 
3.29) 
 
 
2.63 (1.62, 4.29) 
 
 
2.22 (1.50, 3.29) 
 
 
2.22 (1.50, 3.29) 
Crude vs Adjusted 
|ln(crude/adj)| 
  
0.17 
 
0.17 
 
0 
Notes/Conclusions about 
current model: 
MDL only. First-order 
interaction with 
BMI, and linear 
terms. 
All interaction terms 
excluded from 
model to assess 
effect modification.  
Effect modification 
is present based on 
likelihood ratio test. 
OR for main effect 
did not change by 
>10%.  BMI is not a 
confounder.  OR for 
main effect is not 
confounded by any 
covariates. 
Variable to be dropped 
next (Wald p-value) 
 All interaction 
terms (chunk test)
BMI (0.3404) None 
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Table 2.47: Assessing confounding and effect measure modification in the co-twin control study (MZ IBS discordant 
twin pairs), using backward elimination for the model of lifetime MDD, SALT study, 2002. 
 Min Model 
β (SE) 
Full Model 
β (SE) 
Model 2 
β (SE) 
Model 3/FINAL MODEL 
β (SE) 
# IBS discordant 
pairs 
Main Exposure: 
Lifetime MDD 
119 
 
 
1.1527 (0.3311) 
119 
 
 
1.1811 (0.4606) 
119 
 
 
1.1556 (0.3317) 
119 
 
 
1.1527 (0.3311) 
|ln(crude/adj)| of 
beta 
 0.02 0.02 0.003 
Compare to: 
-2log L 
df 
Chi-square p-value 
 
150.762 
1 
Min Model 
150.729 
3 
 
Full 
150.736 
2 
0.007 (p>0.2) 
Full 
150.762 
1 
N/A 
OR (95% CI) for 
main effect:  
lifetime MDD 
 
 
3.17 (1.66, 6.06) 
 
 
3.26 (1.32, 8.04) 
 
 
3.18 (1.66, 6.09) 
 
 
3.17 (1.66, 6.06) 
Crude vs Adjusted 
|ln(crude/adj)| 
  
0.03 
 
0.03 
 
0.003 
Notes/Conclusions 
about current 
model: 
MDL only. First-order 
interaction with 
BMI, and linear 
terms. 
All interaction terms 
excluded from model 
to assess effect 
modification.  Effect 
modification is 
present based on 
likelihood ratio test. 
OR for main effect did not 
change by >10%.  BMI is 
not a confounder.  OR for 
main effect is not 
confounded by any 
covariates. 
Variable to be 
dropped next (Wald 
p-value) 
 All interaction terms 
(chunk test) 
BMI (0.8703) None 
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Table 2.48: Co-twin control analysis explanation. 
Step 1: ‘Classic’ 
case-control 
study—assesses 
association between 
exposure and 
outcome 
Step 2: Healthy co-
twin used as control 
for diseased twin (MZ 
and DZ twin pairs)—
controls for early 
environmental 
confounding 
Step3: Only disease 
discordant MZ twins 
used—controls for 
unmeasured genetic 
background 
Results Interpretation 
Association 
demonstrated 
Association 
demonstrated 
Association 
demonstrated 
Exposure contributes to the 
causation of the disease 
(Causal model) 
Association 
demonstrated 
Association 
demonstrated 
No association 
demonstrated 
Genetic effects confounded 
the results (Non-causal 
genetic model) 
Association 
demonstrated 
No association 
demonstrated 
Association 
demonstrated 
Perversity 
 
Association 
demonstrated 
No association 
demonstrated 
No association 
demonstrated 
Non-causal Family 
Environment Model 
No association 
demonstrated 
Not applicable Not applicable No association 
 Table 2.49: Summary of Power Calculations using the AHP data. 
  Prevalence Odds Ratio Detected Using 203 IBS 
cases 
Exposure 
(MDD) 
Prevalence 
Outcome 
(IBS) 
Prevalence 
 
1.2 
 
1.3 
 
1.5 
 
1.6 
 
1.7 
5% 29% 47% 78% 88% 94% 20% 
10% 28% 45% 76% 86% 93% 
5% 26% 42% 72% 82% 89% 15% 
10% 25% 40% 69% 80% 88% 
5% 22% 34% 61% 72% 81% 10% 
10% 21% 33% 59% 70% 79% 
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2.5 FIGURES 
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Figure 2.1: Directed acyclic graph to assess associations between MDD and IBS in the AHP study, 1999.  Analysis 
of this graph implies that the sufficient adjustment set of covariates is age, gender, and BMI.  CFS-like illness is 
abbreviated as CFS in this graph. 
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Figure 2.2: Directed acyclic graph to assess associations between gender and IBS in the AHP study, 1999.  
Analysis of this graph implies that the sufficient adjustment set of covariates is the null set.  CFS-like illness is 
abbreviated as CFS in this graph. 
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Figure 2.3: Directed acyclic graph to assess associations between CWP and IBS in the AHP study, 1999.  Analysis 
of this graph implies that the sufficient adjustment set of covariates is age, gender, and BMI.  CFS-like illness is 
abbreviated as CFS in this graph. 
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Figure 2.4: Directed acyclic graph to assess associations between CFS-like illness and IBS in the AHP study, 
1999.  Analysis of this graph implies that the sufficient adjustment set of covariates is age, gender, and BMI.  CFS-
like illness is abbreviated as CFS in this graph. 
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Figure 2.5: Directed acyclic graph to assess associations between age and IBS in the AHP study, 1999.  Analysis 
of this graph implies that the sufficient adjustment set of covariates is the null set.  CFS-like illness is abbreviated 
as CFS in this graph. 
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Figure 2.6: Directed acyclic graph to assess associations between BMI and IBS in the AHP study, 1999.  Analysis 
of this graph implies that the sufficient adjustment set of covariates is age and gender.  CFS-like illness is 
abbreviated as CFS in this graph. 
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Figure 2.7: Directed acyclic graph to assess associations between IBS and MDD in the AHP study (sensitivity 
analysis), 1999.  Analysis of this graph implies that the sufficient adjustment set of covariates is age, gender, and 
BMI.  CFS-like illness is abbreviated as CFS in this graph. 
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Figure 2.8: Directed acyclic graph to assess associations between MDD and IBS in the SALT study, 2002.  
Analysis of this graph implies that the sufficient adjustment set of covariates is age, gender, and BMI.  CF-like 
illness is abbreviated as CFS in this graph.  The three self-rated health measures are included in as Health Status 
Variables in this graph. 
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3 RESULTS MANUSCRIPT 1.  ASSOCIATIONS WITH ROME II IBS IN 
A US TWIN REGISTRY 
3.1 ABSTRACT  
Objective.  To investigate the prevalence and associations of self-reported 
lifetime Rome II IBS in a U.S. twin registry.   
Methods.  We performed a nested case-control study on a subset of the 
population-based Mid-Atlantic Twin Registry (MATR).  Variables representing 
Rome II IBS, co-morbid disorders, self-rated quality of life (SF-12), and 
personal characteristics were obtained by mailed questionnaire.  Odds ratios 
(OR) and 95% confidence intervals (CI) were used as measures of 
association between IBS and each covariate, using generalized estimating 
equations to account for the non-independence of twin pairs.  
Results.  4,307 participants responded with complete covariate information.  
4.7% (95% CI: 4.1, 5.4) fulfilled the Rome II IBS symptom criteria.  Female 
gender and several co-morbid disorders were positively associated with IBS.  
Age, body mass index, and SF-12 scores demonstrated approximately null 
associations with IBS.   
Conclusion.  The lifetime prevalence of IBS in this study was similar to prior 
research using the Rome II criteria, but lower than in prior studies employing 
different symptom criteria for IBS, as expected due to the greater specificity of 
the Rome II criteria.  Rome II IBS criteria were associated with similar IBS risk 
factors as prior IBS criteria.  Additionally, in this general population, we noted 
that those with major depressive disorder are twice as likely to satisfy Rome II 
IBS symptom criteria.  More research into the possible common etiology of 
these two disorders is warranted. 
3.2 INTRODUCTION  
Irritable bowel syndrome (IBS) is a chronic disorder of the 
gastrointestinal (GI) tract.  It is characterized by exacerbations and remissions 
of abdominal pain and/or discomfort, leading to alterations in bowel habits (1-
5).  The diagnosis of IBS is based on symptom criteria and exclusion of 
structural disease (1, 3).  Community-based studies of IBS have estimated 
the prevalence to range from 9-22%, depending on the symptom criteria 
employed by the study, Table 3.1 (4, 6-13).  Upon closer inspection of these 
studies, the majority did not employ the most recent adaptation of the 
symptom criteria, the Rome II criteria (14), but either the Manning or Rome I 
criteria, from which the Rome II criteria evolved.  Additionally, most studies 
were not performed in the United States.  A subset of these studies also 
presented IBS prevalence by gender, Table 3.2 (13, 15-17).   
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The Rome II criteria for IBS are preferred over prior criteria because 
they are readily applied and identify a core group of individuals that exhibit the 
typical waxing and waning of IBS symptoms (4).  Moreover, the use of one 
standardized criteria across studies would allow for more accurate cross 
study comparisons and may, in the long term, lead to a better understanding 
of the pathogenesis of IBS.  
Although there has been little research regarding risk factors 
associated with Rome II IBS, the association between Manning and Rome I 
IBS and major depressive disorder (MDD) has been of great interest.  MDD 
and IBS have demonstrated a co-occurrence of about 50%, which is much 
higher than the expected co-occurrence of IBS and MDD.  Assuming that IBS 
and MDD are independent, and varying their prevalence rates between 5 and 
20% for IBS and 15-20% for MDD, one would expect a co-occurrence range 
between 1-4% in the community (18-24).  However the majority of studies 
noting a higher than expected co-occurrence were not performed in the 
community (18, 24-26) and used earlier symptom criteria for IBS.   
Notably, community-based studies had a co-occurrence of 25% (27).  
This difference between community and non-community studies could be 
explained by treatment seeking bias because those individuals that actively 
seek treatment have self-selected themselves to see a physician and thus 
may be different than those not seeking care.  Specifically, individuals 
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seeking care for IBS-related symptoms document a more depressed 
psychopathology than individuals not seeking care (18, 21).  Thus non-
community populations are a biased sample when examining the co-
occurrence of MDD and IBS.   
This study addresses some of the shortcomings of prior IBS research.  
It employs the most recent symptom criteria, Rome II, and is population-
based to eliminate any possible effects of treatment-seeking bias.  We aim to 
estimate the population prevalence of Rome II IBS, to assess Rome II-defined 
IBS associations with MDD, other co-morbid disorders, and other 
demographic variables in order to more fully understand the population of 
individuals that fulfill the Rome II IBS symptom criteria. 
3.3 METHODS  
3.3.1 Study Population  
We conducted a nested case-control study on a subset of the Mid-
Atlantic Twin Registry (MATR) (N=4,591).  The MATR cohort is a population-
based registry of twin pairs ascertained from birth and school system records 
in Virginia, North Carolina, and South Carolina (28).  The study was reviewed 
and approved by the Institutional Review Boards (IRB) at Virginia 
Commonwealth University, the for-profit Western IRB, the University of 
Washington at Seattle, and the University of North Carolina at Chapel Hill.  All 
subjects provided written informed consent. 
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3.3.2 Data Collection   
During the last quarter of 1999, a detailed survey was mailed to 
approximately 15,000 individual participants in the MATR.  Of these, 4,591 
returned completed surveys for a response rate of 31%.  After the initial 
mailing, the study was halted by the US Department of Health and Human 
Services Office for Human Research Protections (29, 30), as was all ongoing 
human subjects research at Virginia Commonwealth University.  This 
shutdown was for reasons not directly related to this study.  However the 
shutdown led to the early termination of this study, and the planned repeat 
mailings, non-responder telephone follow-up, and clinical evaluations that 
were planned were not conducted, see Furberg et al. for more discussion 
(31).  Additionally zygosity data were available on only a minority of the 
subjects. 
3.3.3 Irritable Bowel Syndrome (IBS) Assessment  
Subjects completed a questionnaire that captured lifetime history of 
IBS according to the Rome II criteria (14).  Briefly, these criteria were 
operationalized as the lifetime occurrence of pain or discomfort in their lower 
abdomen for ≥ 3 months in the past year, which need not be consecutive, 
along with at least two of the following for a duration of 3 months: bowel 
movement relieving the pain or discomfort; change in number of bowel 
movements (either more or less than usual); or a change in the consistency of 
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their stool (either harder or looser than usual).  Individuals who reported a 
personal history of ulcerative colitis (n=12), Crohn’s disease (n=9), or both 
(n=3) were excluded. 
3.3.4 Covariate Assessment  
The mailed survey also used previously validated instruments to 
assess symptomatology consistent with a lifetime history of major depressive 
disorder (MDD), chronic widespread pain (CWP), and chronic fatigue 
syndrome (CFS)-like illness.  Assessment of lifetime MDD was based on a 
questionnaire adaptation (31-33) of the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV), criteria (34).  The presence of lifetime 
CWP assessment used an adaptation of the American College of 
Rheumatology criteria for fibromyalgia (35, 36).  Lifetime presence of CFS-
like illness was assessed using a module similar to the US Center for Disease 
Control (CDC) consensus criteria (37) for chronic fatigue syndrome (38).  No 
clinical examinations were conducted.  
Participants also answered questions on self-rated health, and current 
height and weight at the time of the questionnaire.  The self-rated health 
questions comprised the SF-12 (39) and were divided into mental and 
physical health subscales for analysis.  The SF-12 assesses health-related 
quality of life with scores ranging from 0 to 100 where a higher score is 
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indicative of better health-related quality of life.  Current height and weight 
were used to calculate current body mass index (BMI, kg/m2). 
3.3.5 Statistical Analyses  
Odds ratios (OR) with 95% confidence intervals (CIs) were used as 
measures of association between IBS and each covariate.  To account for the 
inherent relatedness of twin pairs, we used generalized estimating equations 
(40).  All analyses were conducted using the SAS software (41).  Additionally, 
analyses were completed for both sexes combined and stratified by sex, due 
to the higher prevalence of IBS among women.  However, as gender stratified 
associations differed little from the overall pattern of associations in the 
combined data (data not shown), only the results from the complete sample 
will be reported. 
The distribution of covariates in the study population, stratified by IBS 
case-control status, was assessed to determine similarity between the case 
and control populations.  This allowed for an assessment of whether the 
demonstrated association may be due to differences in the distributions.  We 
used generalized estimating equations with linear and logistic regression 
models.  Continuous covariates were analyzed using appropriate categories 
for this part of the analysis.  For dichotomous and categorical covariates, 
frequencies are presented.  χ2 statistics were calculated to determine if 
missing covariate information varied by IBS status (results not shown), 
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thereby allowing us to assess if missing information was associated with IBS 
case status. 
Multivariable Models.   Eight multivariable models, one for the 
association between each covariate of interest and IBS, were constructed 
using a backward elimination procedure.  For each model, effect measure 
modification was assessed before confounding.  At the end of the 
confounding assessment, the final fully adjusted multivariable model 
assessing the association between the covariate of interest in that model and 
IBS in this population was obtained.  Thus a multivariable model was 
obtained using each covariate (age at interview, gender, BMI, MDD, CWP, 
CFS-like illness, SF-12 mental health score, and SF-12 physical health score) 
as the main exposure in one of the eight models. 
Covariate Selection.  For each model potential covariates and 
confounders were identified by analyzing directed acyclic graphs (42).  A 
directed acyclic graph was drawn and analyzed for each exposure based on a 
review of the literature to help establish potential covariates as confounders.  
Potential covariates that were affected by the exposure or affected by the 
outcome were not considered as potential confounders or included as 
covariates in any models.   
Effect Measure Modification.  In each model, we assessed effect 
modification of the association between the main exposure in that model and 
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IBS using logistic regression models (employing generalized estimating 
equations) in which first-order interaction terms between the exposure for that 
model and each of the potential confounders for that association were 
created.  To determine if any potential interactions were significant effect 
modifiers, we compared results from two logistic regression models, one with 
all the potential interactions and one without any interaction terms, both 
containing the main exposure and all linear terms of the interactions.  This 
allowed for a ‘chunk’ test using the likelihood ratio test and its associated χ2 
statistic to determine if the interaction terms as a whole could be eliminated 
from the model (43).  If the χ2 statistic associated with this test was not 
significant at p<0.20, the removed interaction terms were not significant to the 
exposure and IBS association and thus remained eliminated from the model 
(43).  However, if the χ2 statistic associated with this ‘chunk’ test for 
interaction was significant at p<0.20, at least some or all of the interaction 
terms were significant.  Thus all the interaction terms were returned to the 
model for further assessment using backward elimination to examine each 
interaction term one at a time in order to eliminate insignificant variables from 
the model (43).  Once all potential effect modifiers were assessed, covariates 
involved in significant effect modification terms were included as linear terms 
in all remaining logistic models.  
Confounding.  Once the assessment of effect measure modification 
was complete, we assessed confounding for each model.  To determine if a 
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potential confounder of the exposure and IBS association did confound the 
association in our population, logistic regression models (using generalized 
estimating equations) with and without the potential confounder were 
compared using the OR for the main exposure.  First, we obtained results for 
the model with the exposure, all potential confounders, and any significant 
interaction terms (full model).  Using these results, the potential confounder 
not involved in any interaction terms with the largest associated p-value was 
removed from the full model and we obtained modeling results for this 
adjusted model.  In order to determine if the inclusion of this term confounded 
the association, the OR from this adjusted model was compared to the OR 
from the full model.  If ln|(ORfull/ORadjusted)| > 0.10, then the variable was a 
confounder and was returned to the full model; otherwise the variable was not 
a confounder of this association and was eliminated from the model (43).  
This process was repeated for all potential confounders, where the full model 
changed based on the results of the prior confounder assessment (i.e. if the 
potential confounder did not confound the association, then that model 
became the full model), until all potential confounders were assessed. 
Sensitivity Analysis.  Since the order of onset of IBS and MDD is not 
known, we chose IBS as our dependent variable and assumed that MDD 
preceded IBS.  In an effort to determine if this assumption affected the 
association between IBS and MDD, we performed a sensitivity analysis in 
which MDD was the dependent variable and IBS was the primary exposure. 
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3.4 RESULTS 
3.4.1 Sample Description  
  Of all individual twins who responded (N=4,591), 4,307 individuals 
had complete covariate information and were used in this analysis.  Among 
this sample, 203 participants (4.7%, 95% CI: 4.1, 5.4; women 5.7%, 95% CI: 
4.9, 6.6; men 2.9%, 95% CI: 2.1, 3.8) fulfilled the Rome II IBS criteria.  Due to 
the higher prevalence among women of IBS, and also among most other 
covariates of interest, the associations between IBS and each covariate were 
examined by gender; however, no gender interactions were noted and thus all 
subsequent results are presented for males and females combined.  Based 
on the χ2 statistics (results not shown), missing data for the variables we 
examined did not differ by IBS status.   
3.4.2 Descriptive Statistics   
Irrespective of IBS case-control status, the gender distribution of the 
sample had a female predominance (67.9%).  Characteristics of the sample 
population, stratified by IBS case-control status are shown in Table 3.3.  No 
major differences in BMI or age between cases and controls were noted.  The 
co-morbid disorders, CWP, CFS-like illness, and MDD, were more common in 
cases than in controls.  Moreover, a higher percentage of controls had above 
average mental and physical health scores on the SF-12 than cases. 
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3.4.3 Multivariable Analyses   
Effect Measure Modification Assessment.  For each of the eight 
models, the results of the likelihood ratio test determined that no effect 
measure modification was identified when assessing the association between 
each exposure (MDD, gender, BMI, CFS-like illness, CWP, age, mental 
health score, and physical health score) and IBS.    
Confounding Assessment.  Since no effect modifiers were identified, 
each model assessed the a priori identified potential confounders (determined 
based on the directed acyclic graph analysis) as true confounders in our 
population.  The multivariable models for the associations between BMI and 
IBS, and CFS-like illness and IBS were adjusted for gender and familial 
clustering of twins.  The multivariable models for the other exposures were 
only adjusted for the familial clustering of twins.   
Summary of Multivariable Models.  For the multivariable models, 
female gender, MDD, CWP, and CFS-like illness were positively associated 
with IBS (Table 3.4).  Age at interview and BMI were not associated with IBS.  
The mental and physical self-rated health questions demonstrated inverse 
associations with IBS.   
Sensitivity Analysis.  To assess if the timing of onset between MDD 
and IBS had an effect on their association, we performed a sensitivity 
analysis.  In this analysis, we found little difference (2.5%) in the magnitude of 
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the association, with overlapping confidence intervals and good precision 
(Table 3.5).  Thus, the choice of dependent variable did not affect any 
association in this analysis, and we were unable to make any inferences 
about the timing of the onset of these disorders.  However, it should be noted 
that most individuals (54%) who fulfilled both the lifetime IBS and lifetime 
MDD (N=69) symptomatology also stated that the onset of MDD occurred 
before the onset of IBS (data not shown).    
3.5 DISCUSSION 
  In this subset of the Mid-Atlantic Twin Registry, the lifetime 
prevalence of Rome II IBS was 4.7%.  This finding is supported by previous 
research which reported a lower IBS prevalence when using Rome II 
symptom criteria in place of earlier symptom criteria (4, 8, 11, 12, 17, 44).  
Similar to previous studies, women were twice as likely to satisfy IBS criteria 
(13, 15-17).  In our study, a perception of good physical and mental health 
were associated with a decrease in the odds of lifetime IBS, whereas chronic 
fatigue syndrome-like illness and chronic widespread pain were associated 
with an increase in the odds of IBS.  BMI and age were not associated with 
IBS.  MDD and IBS were positively associated with IBS, where those with 
MDD were twice as likely to satisfy the Rome II IBS symptom criteria. 
Prior studies using Rome II IBS criteria (Table 3.1) have demonstrated 
1-year IBS prevalences between 3.3 and 7% (4, 8, 11, 12, 17, 44).  Earlier 
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IBS symptom criteria (Manning and Rome I, Table 3.1) have demonstrated a 
higher population prevalence of IBS, between 9-22% (4, 5, 45).  Thus while 
our lifetime prevalence of 4.7% is lower than that of prior studies which 
employed earlier symptom criteria, it is consistent with results of prior studies 
using the more recent Rome II symptom criteria. 
Women were twice as likely as men to satisfy the symptom criteria for 
IBS in our study.  This is consistent with other population-based studies in 
North America that demonstrated a 2:1 predominance of women meeting IBS 
symptom criteria (15, 46).  Additionally, studies performed in Bangladesh (13) 
and China (17) also reported a higher prevalence of IBS in women in 
comparison to men.  However, in studies performed since 2003 (Table 3.2), 
the 2:1 predominance of women satisfying IBS symptom criteria is not upheld.  
In these studies, the ratio of female:male IBS prevalence was clustered 
between 1.2 and 1.5, regardless of which IBS symptom criteria were used.  
When looking solely at the Rome II IBS symptom criteria, the ratio spans from 
1 to 2 in these studies.  Thus our finding of a female predominance of IBS 
using the Rome II criteria is consistent with earlier research, and with the 
results of Sperber et al. (47) which was performed in Israel and used the 
Rome II IBS symptom criteria.  However while the magnitude of this ratio 
conflicts with the more recent IBS studies in Table 3.2, women in general 
have a higher prevalence of IBS, regardless of which IBS criteria (Manning, 
Rome I, or Rome II) were applied.  Thus, our research supports the notion of 
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women satisfying IBS criteria more often than men, and further demonstrates 
the robustness of gender being associated with IBS, since its association with 
IBS is independent of the symptom criteria employed. 
This study demonstrated an association between MDD and IBS that 
was precise (OR 2.0, 95%CI 1.5, 2.7; p<0.0001).  Thus individuals with MDD 
were twice as likely to satisfy lifetime IBS criteria.  This estimate is similar to 
that of Talley et al. (11), where an OR of 2.0 (95% CI: 0.7, 5.6) was 
documented when comparing Rome criteria for IBS to controls.  Two other 
studies also demonstrated higher odds ratios: 3.5 (95% CI: 3.4, 3.6) (23) and 
14.3 (95% CI: 13.2, 15.4) (24) both using prior IBS criteria.  Additional 
research into the association between MDD and IBS has demonstrated that 
approximately half of individuals fulfilling criteria for one disorder also meet 
symptom criteria for the other disorder (20, 22, 24).  In our study, the overlap 
of the two disorders was slightly less, as 32% of individuals meeting Rome II 
IBS symptom criteria also fulfilled criteria for MDD.  This could be explained 
because our study was population-based, whereas most prior research 
examining IBS and MDD used individuals who were actively seeking care for 
either one or both disorders.  Use of such a treatment-seeking population can 
be biased, and thus may have a higher percent overlap between IBS and 
MDD due to individuals assessing doctors more often and thus having more 
opportunities for a diagnosis of one or both disorders.  Thus our results are 
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consistent with most prior research demonstrating an association between 
MDD and IBS.     
The timing of onset of IBS in comparison to MDD has been an issue in 
this study and in previous studies (7, 20, 21, 24, 48).  It is still not known 
whether the onset of IBS precedes that of MDD or if the onset of MDD 
precedes that of IBS.  Our study was cross-sectional, and as such, we chose 
which disorder to be the dependent variable for the analyses, thus assuming 
that the onset of the independent variable event (MDD) occurred before the 
onset of the dependent variable event (IBS).  Our sensitivity analysis 
attempted to determine if this choice of the timing of onset between these 
disorders affected any association.  The results demonstrated no difference in 
the association had MDD been the dependent variable among this sample.  
Additionally, the number of individuals in our study that suffered from both 
disorders was too small for a further examination of this question, and there is 
clearly more work to be done to establish the temporality question, ideally in 
the context of a prospective cohort study.  
Individuals satisfying the Rome II IBS symptom criteria had lower 
mean SF-12 scores for both the mental and physical health components than 
those not satisfying the IBS symptom criteria in our study.  This finding has 
also been documented in prior studies using both the longer SF-36 (49-52) as 
well as in the SF-12 (53). In population-based studies, individuals with IBS 
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also had lower SF-36 scores (54) in comparison to healthy population 
controls.  Our finding is consistent with prior studies, and suggests an 
association between IBS and worse health-related quality of life, regardless of 
the IBS definition used. 
In our study, chronic fatigue syndrome-like illness and chronic 
widespread pain (CWP) were associated with an increased odds of lifetime 
IBS.  Previous studies of CFS have demonstrated an association with IBS 
(55-57), where CFS patients were more likely to demonstrate symptoms of 
IBS than healthy controls or non-fatigued co-twins.  Moreover, the prevalence 
of IBS among those with CFS was between 50-92% (55, 57, 58), which is 
higher than in our study, where the prevalence of IBS was 18% among those 
with CFS-like illness.  Although the prevalence of IBS in these studies differs 
in magnitude, the effect estimates from our study are in the same direction 
and for at least one twin study which found fatigued twins 4-10 times more 
likely to be diagnosed with IBS compared to non-fatigued twins, our 95% 
confidence interval encompasses its lower bound (57). 
Previous studies have also documented a co-occurrence between 
CWP and IBS, at a rate of 32-66% (59-62).  Additionally, in a small study of 
33 women with CWP, 39% had a current diagnosis of IBS and 52% had a 
lifetime diagnosis of IBS (63).  Thus our findings of a higher prevalence of IBS 
among those with CFS-like illness or CWP are generally consistent with the 
 286
previous literature, although the actual magnitude of the association varies 
across studies. 
We found no evidence of age or BMI influencing the risk of IBS.  Prior 
studies of age and IBS have found that most individuals fulfilling symptom 
criteria for IBS have symptoms by age 35 (3), and that individuals younger 
than 45 were more likely to be diagnosed with IBS than those older than 45 
(15).  However, other studies have shown that the prevalence of IBS varies 
minimally with age (64).  Thus in prior studies age was not a risk factor for 
IBS, but aided in describing the population that fulfills the IBS criteria, which is 
consistent with our findings.  Prior research on the relationship between BMI 
and IBS has been conflicting.  Most studies have found no association 
between BMI and IBS (65-68).  However, a more recent community-based 
study in Croatia demonstrated that for every increase in BMI of 5 kg/m2 an 
increased risk of IBS of 36% was reported (69).  In contrast, our study found 
no association between BMI and IBS, which is consistent with the majority of 
studies. 
While this study increases the knowledge base of Rome II IBS, there 
are several limitations to consider.  First, the early termination of this study did 
not allow for the follow-up mailings, which may have substantially increased 
the response rate (see Furberg et al. for a more detailed discussion) (31).  
Thus the sample may be biased due to only obtaining information on those 
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who were early responders, those who did not move, and those with correct 
addresses.  Additionally, the information contained in this study is all self-
report.  No physical exams, psychiatric evaluation, or medical record reviews 
were performed, which could lead to misclassification for some disorders.  
Lastly, there was limited information on the timing of onset of MDD and IBS.  
As such, we made a choice as to which disorder preceded the onset of the 
other disorder, which could be incorrect.   
Despite these limitations, there are several strengths of this study.  
First, our study used data from a large population-based study.  Therefore, 
the effect of treatment-seeking bias should have been kept to a minimum.  
Additionally, the use of a population-based sample should include individuals 
of all levels of disease severity.  Second, the Rome II symptom criteria for IBS 
were employed, which are arguably superior to prior criteria (70).  Thus, this 
study allows for a better understanding of the Rome II criteria and its risk 
factors in comparison to prior studies which applied earlier symptom criteria.  
Lastly, we performed a sensitivity analysis in an attempt to address the timing 
of onset of IBS and MDD.  The results indicated that in our study, timing of 
onset did not mask any association, however much work remains to be done 
to establish the timing of onset of IBS and MDD. 
In conclusion, we used a population-based study to assess previously 
known IBS associations, using the most recent IBS criteria, the Rome II 
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criteria.  Results demonstrate that IBS associations using previous IBS 
criteria are similar to our results using the Rome II criteria.  Additionally, our 
study adds to the growing body of literature (7, 15, 18, 24) that demonstrates 
individuals with IBS being more likely to have MDD than those without IBS 
(Table 3.3: 32% versus 19%).  While these results support prior research, 
they are also unique due to the use of the most recent IBS criteria, Rome II, 
and the use of a population-based study.  Many prior studies examining 
disorders co-morbid with IBS have used populations of individuals seeking 
care (7, 15, 18, 20), and thus may suffer from treatment seeking bias and are 
not representative of all individuals with IBS.  Since an individual’s quality of 
life is associated with IBS and other co-morbid disorders, reasons for the 
large overlap among individuals with IBS and chronic widespread pain, 
chronic fatigue syndrome-like illness, and major depressive disorder should 
receive increased research in order to investigate the possibility of a common, 
as yet unknown, etiology in an effort to alleviate the burden of these disorders 
in the population and on health care resources.   
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Table 3.1. Prior community-based studies estimating IBS1 prevalence. 
Study Sample 
Size 
IBS criteria Prevalence (95% 
CI1) 
Country 
Boyce et al. (4) 3,235 Manning 
Rome I 
Rome II 
13.6 (12.2, 15.1) 
4.4 (3.6, 5.2) 
6.9 (5.9, 8.0) 
Australia 
Hu et al. (7) 1,649 Rome I 4.1 (3.2, 5.1) China 
Kwan et al. (12) 1,000 Rome II 6.6 (5.1, 8.2) Hong Kong 
Masud et al. (13) 2,632 Rome I 8.5 (7.5, 9.6) Bangladesh 
Mearin et al. (8) 1,932 Manning 
Rome I 
Rome II 
10.3 (9.0, 11.7) 
12.1 (10.7, 13.6) 
3.3 (2.5, 4.1) 
Spain 
Saito et al. (9) 892 Manning (≥ 2) 
Rome I 
Rome II 
20.4 (16.7, 24.2) 
12.1 (10.0, 16.2) 
8.5 (5.9, 11.1) 
US 
Talley et al. (10) 730 Manning 
Rome I 
13 (11, 16) 
12 (10, 15) 
Australia 
Talley et al. (6) 3,022 Manning 18 (16.7, 19.4) US 
Talley et al. (11) 890 Manning 
Rome II 
12.7 (10.6, 15) 
4.3 (3.1, 5.7) 
New Zealand 
Thompson et al. (46) 1,149 Rome I 
Rome II 
(modified) 
13.5 (11.6, 15.5) 
12.1 (10.3, 14.1) 
Canada 
Lau et al. (17) 1,278 Rome II 3.2 (2.3, 4.2) Hong Kong 
Hungin et al. (71) 5,009 All 
Rome II 
14.1 (11.6, 16.8) 
6.7 (4.3, 9.6) 
US 
Yilmaz et al. (72) 3,000 Rome II 10.2 (9.1, 11.3) Turkey 
Sperber et al. (47) 981 Rome II 2.9 (1.9, 4.1) Israel 
Dapoigny et al. (73) 15,106 Rome II 4.7 (4.4, 5.0) France 
Gwee et al. (74) 2,276 Manning ( >1) 
Rome I 
Rome II 
11.0 (9.7, 12.3) 
10.4 (9.1, 11.6) 
8.6 (7.5, 9.8) 
Singapore 
Xiong et al. (75) 4,178 Manning 
Rome II 
11.5 (10.6, 12.5) 
5.7 (4.9, 6.4) 
South China 
Kanazawa et al. (76) 417 Rome II 14.2 (11.0, 17.7) Japan 
Talley et al. (68) 923 Manning 18.2 (15.8, 20.7) New Zealand 
Celebi et al. (77) 1,766 Rome II 6.3 (5.2, 7.5) Turkey 
Hoseini-Asl et al. (78) 4,762 Rome II 5.8 (5.2, 6.5) Iran 
Hillila et al. (79) 3,631 Manning (>2) 
Manning (>3) 
Rome I 
Rome II 
16.2 (15.0, 17.4) 
9.7 (8.8, 10.7) 
5.5 (4.8, 6.3) 
5.1 (4.4, 5.8) 
Finland 
Saito et al. (80) 643 Rome II 4.7 (3.2, 6.5) US 
1 Abbreviations: IBS=irritable bowel syndrome in lifetime.  CI=confidence interval.  
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Table 3.2.  Gender stratified IBS1 prevalence from prior studies. 
 
Study IBS criteria Male 
sample 
size 
Male prevalence 
(95% CI1) 
Female 
sample 
size 
Female 
prevalence 
(95% CI) 
Saito et al. 
(80) 
Rome II 306 4.9 (2.7, 7.6) 337 4.5 (2.5, 7.0) 
Hillila et al. 
(79) 
Manning (>2) 
Manning (>3) 
Rome I 
Rome II 
1,980 13.1 (11.4, 14.8) 
8.3 (7.0, 9.7) 
5.1 (4.0, 6.2) 
5.1 (4.0, 6.2) 
1,668 19.2 (17.4, 20.9) 
11.2 (9.8, 12.6) 
6.1 (5.0, 7.2) 
5.3 (4.3, 6.3) 
Gwee et al. 
(74) 
Manning ( >1) 
Rome I 
Rome II 
1,143 9.5 (7.8, 11.3) 
9.0 (7.4, 10.8) 
7.8 (6.3, 9.5) 
1,133 12.6 (10.7, 14.6) 
11.7 (9.9, 13.6) 
9.4 (7.8, 11.3) 
Xiong et al. 
(75) 
Manning 
Rome II 
1,907 9.7 (8.5, 10.9) 
5.03 (4.2, 6.0) 
2,271 12.95 (11.5, 
14.5) 
6.3 (5.3, 7.4) 
Kanazawa 
et al. (76) 
Rome II 203 12.9 (8.7, 17.7) 214 15.5 (10.8, 20.8) 
Talley et al. 
(68) 
Manning 445 14.6 (11.6, 17.9) 484 22.3 (18.6, 26.3) 
Celebi et al. 
(77) 
Rome II 802 5.0 (3.6, 6.6) 964 7.4 (5.8, 9.1) 
Yilmaz et al. 
(72) 
Rome II 1,479 8.0 (6.7, 9.4) 1,521 12.4 (10.8, 14.1) 
Sperber et 
al. (47) 
Rome II 441 1.8  (0.7, 3.3) 540 3.7 (2.3, 5.5) 
 
1 Abbreviations: IBS=irritable bowel syndrome in lifetime.  CI=confidence interval.  
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Table 3.3.  Descriptive statistics of 203 IBS cases and 4,104 controls in the 
MATR Study1.  
 
Characteristic Cases, n (%)  
(n=203) 
Controls, n (%)  
(n=4,104) 
OR1 95% CI1
Gender     
    Males 44 (21.7) 1,478 (36.0) 1.0 Referent 
    Females  159 (78.3) 2,626 (64.0) 2.03 1.44, 2.85 
Major Depressive 
Disorder 64 (31.5) 762 (18.6) 
2.0
0 1.48, 2.71 
Chronic Widespread 
Pain 47 (23.2) 294 (7.2) 3.89 2.74, 5.53 
Chronic Fatigue 
Syndrome-like Illness 29 (14.3) 129 (3.1) 5.13 3.30, 7.97 
Body Mass Index     
    ≤ 24.9 kg/m2 75 (36.9) 1,744 (42.5) 1.0 Referent 
    25-29.9 kg/m2 70 (34.5) 1,393 (33.9) 1.17 0.83, 1.64 
    ≥30 kg/m2 58 (28.6) 967 (23.6) 1.40 0.98, 2.00 
Age at Interview   1.00 0.98, 1.01 
    < 36 49 (24.1) 1,016 (24.8)   
    36-43 57 (28.1) 1,080 (26.3)   
    44-51 54 (26.6) 1,091 (26.6)   
    > 51 43 (21.2) 917 (22.3)   
Mental Health Score   0.97 0.95, 0.98 
    < 50 98 (48.3) 1,266 (30.8)   
     ≥ 50 105 (51.7) 2,838 (69.2)   
Physical Health Score   0.95 0.94, 0.97 
    < 50 103 (50.7) 997 (24.3)   
     ≥ 50 100 (49.3) 3,107 (75.7)   
 
1 Abbreviations: IBS=irritable bowel syndrome in lifetime (past three months).  OR=odds 
ratio. CI=confidence interval.  
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Table 3.4. Assessment of effect modification and confounding.  Adjusted odds 
ratios (ORs) and 95% CIs for IBS in relation to descriptive characteristics, co-
morbid disorders, and self-rated health.  
Characteristic Cases, n (%)  
(n=203) 
Controls, n (%)  
(n=4,104) 
OR1,2 95% CI1
Gender     
     Males 44 (21.7) 1,478 (36.0) 1.0 Referent 
     Females 159 (78.3) 2,626 (64.0) 2.03 1.44, 2.85 
Major Depressive 
Disorder 
64 (31.5) 762 (18.6) 2.00 1.48, 2.71 
Chronic Widespread Pain 47 (23.2) 294 (7.2) 3.89 2.74, 5.53 
Chronic Fatigue 
Syndrome-like Illness 
29 (14.3) 129 (3.1) 4.67† 3.01, 7.26 
Body Mass Index     
     ≤ 24.9 kg/m2 75 (36.9) 1,744 (42.5) 1.0 Referent 
     25-29.9 kg/m2 70 (34.5) 1,393 (33.9) 1.34† 0.95, 1.90 
     ≥30 kg/m2 58 (28.6) 967 (23.6) 1.48† 1.04, 2.11 
Age at Interview   1.00 0.98, 1.01 
     < 36 49 (24.1) 1,016 (24.8)   
     36-43 57 (28.1) 1,080 (26.3)   
     44-51 54 (26.6) 1,091 (26.6)   
     > 51 43 (21.2) 917 (22.3)   
Mental Health Score   0.97 0.95, 0.98 
     < 50 98 (48.3) 1,266 (30.8)   
     ≥ 50 105 (51.7) 2,838 (69.2)   
Physical Health Score   0.95 0.94, 0.97 
     < 50 103 (50.7) 997 (24.3)   
     ≥ 50 100 (49.3) 3,107 (75.7)   
1 Abbreviations: IBS=irritable bowel syndrome in lifetime (past three months).  OR=odds 
ratio. CI=confidence interval.  
 
2 Odds ratio for the association of each variable in the first column on irritable bowel 
syndrome status. These analyses are adjusted for non-independence of twins within a 
pair via generalized estimating equations.  
 
† These models are additionally adjusted for gender as a confounder. 
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Table 3.5.  Sensitivity analysis of the magnitude of the association between 
IBS and MDD when changing the implied timing of onset between MDD and 
IBS1.   
Primary 
Exposure 
Outcome OR 1 95% CI 1 Precision % 
change 
Adjustment 
Variables2
IBS2 MDD 1.95 1.44, 2.64 1.8 2.6% None 
MDD2 IBS 2.00 1.48, 2.71 1.8 2.5% None 
1 Abbreviations: IBS=irritable bowel syndrome in lifetime (past three months). MDD=major 
depressive disorder (past six months).  OR=odds ratio. CI=confidence interval.  
2 Models are adjusted for the clustering of twin pairs via generalized estimating equations. 
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4 RESULTS MANUSCRIPT 2.  IRRITABLE BOWEL SYNDROME: A 
COTWIN-CONTROL ANALYSIS 
4.1 ABSTRACT  
Background.  Irritable bowel syndrome (IBS) and major depressive disorder 
(MDD) are common disorders with one-year prevalences ranging from 10-
20% in the population.  A large proportion of individuals who satisfy diagnostic 
criteria for one of these disorders also tend to satisfy criteria for the other.  
While MDD has a well-characterized familial tendency; this tendency is less 
substantiated among individuals meeting criteria for IBS.  Further, among 
individuals who satisfy diagnostic criteria for both disorders, even less is 
known about the role of familial tendency and environmental influences to 
disease susceptibility. 
Aim.  To examine the genetic and environmental architecture of the co-
occurrence of MDD and IBS in participants from the population-based 
Swedish Twin Registry.  
Methods.  We implemented a nested case-control study and a co-twin control 
study.  IBS cases were ascertained using an adapted version of the Rome 
criteria and MDD cases were assessed using a shortened version of the 
  
Computerized International Diagnostic Interview.  The case-control study 
included individuals with complete covariate information (N=29,616), and 
adjusted for twin pair, 3-year age band, and sex.  The co-twin control study 
employed 288 twin pairs discordant for IBS.  Odds ratios (OR) and 95% 
confidence intervals (CI) were estimated using generalized estimating 
equations for the case-control study and conditional logistic regression for the 
co-twin control study.  
Findings.  In both studies, co-morbid disorders of chronic widespread pain, 
chronic fatigue-like illness, and MDD were more common in IBS cases than 
controls.  In the case-control study, a positive association between MDD and 
IBS was noted, where individuals with MDD had an increased odds of IBS 
(OR =2.7; 95% CI 2.3, 3.2).  In the co-twin study, the association was similar 
(OR=2.2; 95% CI 1.5, 3.3).  
Interpretation.  Based on this analysis, genetic and environmental factors do 
not confound the association between MDD and IBS.  Rather it appears as 
though one of these disorders is part of the disease causing sequence of 
events for the other disorder.  However, the study design makes it impossible 
to evaluate the timing of onset between MDD and IBS. 
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4.2 INTRODUCTION  
Irritable bowel syndrome (IBS) affects 10-20% of the adult population 
(1, 2).  IBS is a complex trait with a demonstrated familial tendency (genetic 
or environmental); documented through family (3, 4) and twin studies (5-7).  
Similarly, major depressive disorder (MDD) affects 10-20% of the adult 
population (8-11).  MDD is also a complex trait influenced by both genes and 
environment.  Although no genes evaluated have been substantiated, further 
examination of the candidate genes (12-15) involved in MDD has been 
undertaken.  Additionally, family (16-20), adoption (16, 21, 22), twin (16, 23, 
24), and linkage (25, 26) studies support a familial predisposition to MDD.  
Research has also demonstrated that 50% of individuals with IBS also have a 
psychiatric disorder, with MDD being the most prevalent (27, 28). 
The co-occurrence of MDD and IBS has been understudied.  
Moreover, the research that has been conducted is limited by the use of 
patient populations (29, 30).  The use of a patient population could induce a 
bias as those that actively seek care may be different that those that do not 
seek care for their disorders.  In particular, individuals seeking treatment for 
IBS related symptoms document a more depressed psychopathology than 
individuals not seeking care (28, 30).  Thus, the results may be biased and 
reflective of those individuals that are actively seeking treatment for either or 
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both disorders.  In the few studies that have used population-based samples, 
the co-occurrence between the two disorders is smaller.  One study 
documented 13% of individuals with two gastrointestinal symptoms also had 
MDD (31).  Similarly, a second population-based study found that 13% of 
individuals with Rome II IBS had chronic depression, however the odds of IBS 
was not increased among those with MDD, thereby not substantiating any 
association between IBS and MDD (32).  However it is difficult to compare 
these study results because different symptom criteria for IBS and MDD were 
employed, different geographic populations were used, and different 
measurement tools were employed. 
Regardless of the discrepancy in the magnitude of the overlap in 
occurrence between IBS and MDD between patient and population samples, 
it is clear that their co-occurrence happens more often than would be 
expected.  Thus the question becomes why is this occurring, or more directly, 
what is causing this phenomenon.  This is an especially daunting task since 
the biologic mechanisms of occurrence of both IBS and MDD are not fully 
known.  However, since both disorders separately demonstrate familiality, an 
etiologic hypothesis of a possible common familiality to their co-occurrence is 
plausible.  Further, if these disorders do share a common biology, it may be 
possible to manage these disorders with medications specifically targeted to 
the common biology, or to obtain an additional indication for a medication 
already being used to treat one of these disorders.  This would not only aid in 
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the disease management of individuals, but also in improving our 
understanding of their disease etiology. 
In this study, we employ a co-twin control design.  This analysis 
exploits the natural biologic similarity and differing degrees of genetic 
relatedness among monozygotic (MZ) and dizygotic (DZ) twins to assess the 
importance of potential risk factors after controlling for genetic and familial 
environmental effects (33, 34).  Specifically, through the use of this study 
design in combination with a case-control study, it is possible to assess if 
familial environment or genetics are important to the etiology of co-occurring 
disorders or if there is a biologic causal mechanism between the co-occurring 
disorders.  This is performed by comparing results from the two study 
designs.  If an association is observed between MDD and IBS in the case 
control study and also when the non-diseased co-twin is used as a control for 
each case (diseased co-twin), the association is not fully explained by genetic 
or familial environmental factors and therefore the results support a causal 
link between MDD and IBS (33-35).  However if an association is found in the 
case control study but not in the co-twin control study, then the case control 
study findings reflect confounding by genetic and familial environmental 
factors (34, 35). 
Using this study design, we aim to examine the genetic and 
environmental architecture of the co-occurrence of MDD and IBS in 
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participants from the population-based Swedish Twin Registry.  To 
accomplish this goal we assessed the association between MDD and IBS 
using a case-control design.  We then compared these results to those of a 
co-twin control study. 
4.3 METHODS  
4.3.1 Study Population  
We conducted a nested case-control study on a subset of the Swedish 
Twin Registry (STR, http://www.mep.ki.se/twinreg/index_en.html).  The STR 
cohort is the largest population-based registry of twin births (33, 36).  Over a 
four-year period ending in December 2002, all living, contactable, 
interviewable, and consenting twins in the STR born between 1/1/1935 and 
12/31/1958 were screened for a range of disorders that included 
gastrointestinal and mental disorders as well as self-rated health, and 
comprised the Screening Across the Lifespan Twin (SALT) study of the STR.  
A second study is currently targeting younger adult twins.  
4.3.2 Data Collection   
During this time, approximately 1,000 pairs were randomly selected 
each month for interviews.  Prior to interviewing, a letter describing the study 
was sent to these twins, and then telephone contact and interviews with the 
twins commenced within two weeks of the initial letter.  Interviews were 
conducted by trained interviewers using a computer based data collection 
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system.  This process was repeated until all twins were interviewed or had 
actively or passively declined to participate.  The study was reviewed and 
approved by the Ethical Committee of the Karolinska Institutet, the Swedish 
Data Inspection Board, and the Institutional Review Board of the University of 
North Carolina at Chapel Hill.  
4.3.3 Irritable Bowel Syndrome (IBS) Cases  
Gastrointestinal disorders were assessed during the interview using an 
adapted version of the Rome criteria.  This Rome II IBS definition included a 
positive response to the following questions: recurrent abdominal discomfort, 
abdominal discomfort that lasted as least 7 days a month, if intestinal 
problems were more prominent when feces became looser and defecation 
more frequent, and reporting recurrent problems with pain in either the upper 
abdomen, lower abdomen, or another part of the abdomen.  Participants of 
the SALT study who reported a history of Crohn’s disease (n=34), ulcerative 
colitis (n=55), stomach ulcers (n=59), intestinal ulcers (n=46), or any 
combination of these (n=52) were excluded.  Together, the subset of 
questions combined with the exclusions was applied to the cohort to identify 
Rome II IBS cases in the SALT study.   
To assess the magnitude of agreement between our derived IBS 
definition and that of other studies, we compared our IBS definition with a 
Rome II IBS definition used in the Adult Health and Personality (AHP) Study 
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of the Mid-Atlantic Twin Registry (37).  This study was chosen because we 
had access to the questionnaire and raw data for the AHP study.  Briefly, the 
questions used in the SALT were matched to questions in the AHP 
questionnaire.  Then, using the AHP data, we determined those satisfying IBS 
symptom criteria using the Rome II definition of the AHP study and also those 
satisfying the subset of questions corresponding to the SALT IBS definition 
we described above.  Comparison of these definitions was done to determine 
concordance between the IBS definitions and reliability of the IBS definition.  
Results of the comparison in IBS definition yielded a good to excellent 
reliability (κ=0.92), and 99% concordance in IBS case status. 
4.3.4 Exposure Assessment  
During the interview, emphasis was placed on diagnostic items for 
determining whether a twin was likely to have a disease, rather than asking a 
twin directly about the disease.  The diagnostic items were presented in a 
branching format so that within a disease area, follow-up items were asked 
only if the participant responded positively to the key introductory items.  
These diagnostic items were compiled by experts in each of the disease 
areas.  Additionally, standardized instruments were used when available, for 
example a specific short version of the Computerized International Diagnostic 
Interview (CIDI) (38) was used for psychiatric disorders.   
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Irritable bowel syndrome (IBS) was assessed by an adapted version of 
the Rome criteria (7, 39).  Major depressive disorder (MDD) (40) and 
generalized anxiety disorder (GAD) (40) were assessed using the short 
Computerized International Diagnostic Interview (CIDI) through which 
Diagnostic and Statistical Manual of Mental Disorders, third edition revised 
(DSM-III-R) (41) diagnoses could be obtained.  Although no psychological 
evaluations were performed, the interview used a validated and appropriate 
instrument to assess MDD using a personal interview (38) which has been 
implemented in several population based studies of MDD (42-44).  An 
adaptation of the American College of Rheumatology criteria for fibromyalgia 
(45, 46) was used to assess chronic widespread pain (CWP).  Chronic 
fatigue-like illness was assessed using a module similar to the US Centers for 
Disease Control (CDC) consensus criteria (47) for chronic fatigue syndrome 
(48).    Questionnaire items developed for the Older Americans Resource 
Survey at Duke University (49) were used to assess self-rated health.   
To establish zygosity of the twin pairs, questions about childhood 
resemblance were used.  Validation studies have demonstrated this 
technique to accurately determine zygosity 98% of the time (33).  Additional 
confirmation of the zygosity determination was performed on a subset of this 
sample using 13 DNA markers.  Zygosity diagnosis using the questions 
agreed with the DNA marker zygosity determination in 99% of the pairs 
(n=199 twin pairs) (33). 
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4.3.5 Statistical Analyses  
   Odds ratios (OR) with 95% confidence intervals (CI) were used to 
estimate the association between MDD and IBS, and were obtained using 
regression models in the SAS software (50).  For the case-control study, ORs 
were calculated using generalized estimating equations in SAS (PROC 
GENMOD), adjusted for twin pair, sex, and age (3 year age band).  ORs were 
calculated for the co-twin control subjects using conditional logistic regression 
in SAS (PROC PHREG) where the unit of analysis was the twin pair.     
4.3.6 Case-control Analysis   
A nested case-control study was employed to assess the association 
between MDD and IBS in this population of twins.  Generalized estimating 
equations (GEE) were used to obtain odds ratios (OR) and 95% confidence 
intervals (CI) for the MDD-IBS association, thereby adjusting for the familial 
clustering of twin data.  Additionally we adjusted the analysis for gender and 
age (3-year age band). 
Multivariable Model.  In the case-control study, a multivariable model 
using both sexes was constructed using a backward elimination procedure 
(described below).  This model was subsequently used for the co-twin control 
study to be able to compare the study results.  To determine the appropriate 
model we first assessed effect measure modification and then confounding.  
At the end of the confounding assessment, the final fully adjusted 
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multivariable model assessing the association between MDD and IBS in this 
population was obtained.   
Effect Measure Modification.  To assess effect measure modification 
of the association between MDD and IBS, a logistic regression model (using 
GEE to control for twin relatedness) was constructed using all first-order 
product interactions between MDD and all other covariates deemed as 
potential confounders of the MDD-IBS association based on an evaluation of 
a directed acyclic graph (51).  To determine if any potential interactions were 
significant effect modifiers, we compared results from two logistic regression 
models, one with all the potential interactions and one without any interaction 
terms, both containing the main exposure and all linear terms of the 
interactions.  This allowed for a ‘chunk’ test using the likelihood ratio test and 
its associated χ2 statistic to determine if the interaction terms as a whole 
could be eliminated from the model (52).  If the χ2 statistic associated with this 
test was not significant at p<0.20, the removed interaction terms were not 
significant to the MDD-IBS association and thus remained eliminated from the 
model (52).  However, if the χ2 statistic associated with this ‘chunk’ test for 
interaction was significant at p<0.20, at least some or all of the interaction 
terms were significant.  Thus all the interaction terms were returned to the 
model for further assessment using backward elimination to examine each 
interaction term one at a time in order to eliminate insignificant variables from 
the model (52).  Once all potential effect modifiers were assessed, covariates 
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involved in significant effect modification terms were included as linear terms 
in all remaining logistic models.  
Confounding.  Once the assessment of effect measure modification 
was complete, we assessed confounding for covariates not involved in effect 
measure modification terms.  To determine if a potential confounder of the 
MDD-IBS association did confound the association in our population, logistic 
regression models (using generalized estimating equations) with and without 
the potential confounder were compared using the OR for MDD.  First, we 
obtained results for the model with the exposure, all potential confounders, 
and any significant effect measure modification terms (full model).  Using 
these results, the potential confounder not involved in any effect measure 
modification terms with the largest associated p-value was removed from the 
full model and we obtained modeling results for this adjusted model.  In order 
to determine if the inclusion of this term confounded the association, the OR 
from this adjusted model was compared to the OR from the full model.  If 
ln|(ORfull/ORadjusted)| > 0.10, then the variable was a confounder and was 
returned to the full model; otherwise the variable was not a confounder of the 
MDD-IBS association and was eliminated from the model (52).  This process 
was repeated for all potential confounders, where the full model changed 
based on the results of the prior confounder assessment (i.e. if the potential 
confounder did not confound the association, then that model became the full 
model), until all potential confounders were assessed. 
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4.3.7 Co-Twin Control Study, MZ and DZ Twin Pairs   
Upon completion of the case-control analysis, we performed a co-twin 
control analysis using both MZ and DZ twin pairs that were discordant for IBS 
(N=288 twin pairs).  Thus the healthy (no IBS) co-twins were used as the 
controls for the diseased (IBS) twins.  This allowed for an evaluation of 
potential confounding by the latent variable of unmeasured early familial 
environment.  To easily compare the results of the case-control and co-twin 
control analyses, the covariates from the final fully adjusted multivariable 
model from the case-control study were used. 
4.3.8 Co-Twin Control Study, MZ Twin Pairs   
This extension of the co-twin analysis restricted the sample to only MZ 
twin pairs that were discordant for IBS (N=119 twin pairs).  Rationale for this 
analysis was to control for confounding due to genetic effects when compared 
to the co-twin control results using both MZ and DZ twin pairs.  Adjustment 
variables were the same as those used in the case-control study. 
4.4 RESULTS 
4.4.1 Sample Description  
  Of all eligible twins (N=41,499), 31,406 individual twins responded, 
giving an individual response rate of 75.7%. This included data from 12,407 
complete pairs and 6,592 incomplete pairs.  Zygosity of the complete pairs 
was determined, and the sample consisted of 3,269 monozygotic pairs, 9,010 
 317
  
dizygotic pairs, and 128 pairs of unknown zygosity.  This analysis focused on 
the 29,616 individual twins who had complete covariate information.  Based 
on the χ2 statistics (results not shown), missing data for the variables we 
examined did not differ by IBS status.  These twins represented 119 
monozygotic twin pairs and 169 same-sex dizygotic twin pairs discordant for 
IBS.   
4.4.2 Descriptive Analyses   
Table 4.1 shows descriptive statistics of cases and controls 
irrespective of sex.  There were no differences in body mass index or age 
between cases and controls.  More women satisfied criteria for IBS than men.  
Co-morbid disorders of CWP, chronic fatigue-like illness, and MDD, were 
more common in cases than in controls, with positive associations and 
precise estimates (confidence limit ratio (CLR) <2.0 (53)).  Control responses 
to the health status questions demonstrated better self-rated health compared 
to cases.  Table 4.2 describes the descriptive statistics of IBS cases and 
controls for the co-twin control study.  In the twin pair analyses, covariates 
were distributed similarly to their distributions in the case control study. 
4.4.3 Case-Control Model Selection   
Effect Measure Modification.  When we assessed the first-order 
product interactions between MDD and the potential confounding covariates 
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as potential effect measure modifiers, no interactions significantly modified 
the association between MDD and IBS.   
Confounding.  Since we did not identify any effect measure modifiers, 
the covariates identified as potential confounders of the MDD-IBS association 
were assessed.  In this analysis none of the remaining covariates investigated 
confounded the association between MDD and IBS.   
4.4.4 Case-Control Results   
Multivariable Model.  The multivariable model investigating the 
association between MDD and IBS was adjusted for sex and age at interview 
(3-year age band) (Table 4.3).  The association between MDD and IBS was 
similar to the crude association, but slightly attenuated.     
4.4.5 Co-Twin Control Results  
MZ and DZ Twin Pairs.  When the healthy co-twin was used as the 
control for the IBS affected twin, the association between MDD and IBS was 
similar to the case control estimate (Table 4.3).   
MZ Twin Pairs.  When only IBS discordant MZ twin pairs were used, 
the association between MDD and IBS was larger in magnitude than either 
the case-control study or the co-twin study among MZ and DZ twins.  While it 
was less precise, the confidence interval encompassed all previous estimates 
of the MDD-IBS associations demonstrated in our analyses (Table 4.3).   
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4.5 DISCUSSION 
  We evaluated familial predisposition to co-occurring MDD and IBS in 
29,616 members of the population-based Swedish Twin Registry aged 42-64 
years, comprising part of the SALT study.  To accomplish this goal, we 
implemented a three-step analysis design.  The first study was a classic case-
control study examining the association between MDD and IBS in this general 
population sample.  This study confirmed that individuals who were female, or 
had co-morbid disorders of MDD, CWP, and chronic fatigue-like illness, were 
more likely to satisfy diagnostic criteria for IBS.  In the multivariable analysis 
of IBS, individuals with MDD had a higher likelihood of having IBS (OR 2.7; 
95% CI 2.3, 3.2).  In the co-twin study, using both MZ and DZ IBS discordant 
twin pairs, there was also an increased odds of IBS among those with MDD 
(OR 2.2; 95% CI 1.5, 3.3).  In the third study, when only MZ IBS discordant 
twin pairs were used, an imprecise increased odds of IBS among those with 
MDD was demonstrated (OR 3.2; 95% CI 1.7, 6.1).  
In our study, women had a higher prevalence of IBS compared to men.  
This difference in prevalence signifies that women are affected at a ratio of 
about 1.8:1 compared to men in this study.  Previous studies have 
demonstrated women to have IBS at a rate of 2:1 compared to men (1, 54, 
55).   Thus while our estimate is slightly smaller in magnitude, it is similar to 
the 2:1 ratio of female to male IBS affection seen in prior studies, further 
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evidence that our twin population is similar to singleton populations in terms 
of the IBS gender distribution. 
In this subset of the STR, 11% of individuals with IBS also reported 
symptoms consistent with chronic widespread pain.  Prior studies that 
employed the Rome I symptom criteria for IBS have documented higher rates 
of co-occurrence between IBS and CWP (56-58).  This discrepancy in the 
magnitude may be due to our use of an approximation of the Rome II criteria 
for IBS which may be more accurate (59) and has been associated with lower 
prevalence rates for IBS (60, 61) than earlier symptom criteria (32, 62-64).  
However, regardless of the lower magnitude demonstrated in our study, it is 
still larger than the background rate of CWP of 2.4% in this study and thus 
adds to the literature in support of a larger proportion of individuals fulfilling 
symptoms of both disorders than either disorder independently. 
Similarly, our study documented 12% of individuals with IBS also 
fulfilled the criteria for chronic fatigue-like illness, and conversely 11% of 
individuals with chronic fatigue-like illness also fulfilled IBS criteria.  Most prior 
studies examining this relationship have used the Manning criteria for IBS 
(58, 65).  In these studies, the rate of IBS among chronic fatigue syndrome 
patients was between 50 and 92% (58, 66).  Our rates, while higher than 
population prevalences for either disorder independently, are lower than 
those previously documented, which could be attributed to our use of a 
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general population as opposed to patient populations used in earlier studies.  
The use of patient populations is problematic as it involves individuals that are 
self-selecting to use healthcare and may not be representative of the general 
population.  As has been demonstrated for IBS, patient populations are not 
similar to non-patient populations (28, 30).  Therefore, in our general 
population, while the magnitude of the association is lower, it demonstrates 
that chronic fatigue-like illness and IBS occur more often together than as 
individual disorders amongst those that do and do not seek health care. 
In our study, 45% of individuals satisfying the Rome II IBS criteria also 
satisfied the symptom criteria for MDD.  Prior studies have documented IBS 
patients to be more depressed than inflammatory bowel disease patients or 
healthy controls using the Anxiety Disorders Interview Schedule—Revised 
(ADIS-R) (30).  IBS patients also had higher scores on the Zung Depression 
Self-Rating Scale compared to controls (67).  The study by Mayer et al., 
summarized studies of IBS patients seeking care at gastroenterology clinics 
and found that in studies with an adequate sample size and a standardized 
psychiatric interview, 50-60% of IBS patients also have psychiatric disorders 
(27).  Additionally among IBS patients seeking specialist care, 54-94% met 
DSM-III-R criteria for a primary psychological disorder (29), however in a 
population based study, only 13% of IBS patients met DSM-III criteria for a 
primary psychiatric disorder (31).  Thus among individuals with IBS that 
actively seek healthcare, the percentage of individuals satisfying some sort of 
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major depression criteria is large, but less is known about individuals in the 
community.  This study begins to address the co-morbidity of IBS and MDD in 
a population-based sample. 
In the prior population-based study examining the co-occurrence of 
IBS and MDD, the overlap between these two disorders was 13%, while ours 
was 45%.  Reasons for this discrepancy could be the use of different 
symptom criteria for IBS (Rome II versus Manning) and different MDD 
diagnostic criteria.  However one would think that the study using the 
Manning criteria would have a larger potential overlap of individuals suffering 
form MDD since the Manning criteria are less restrictive and identify a more 
heterogeneous group of IBS sufferers.  The overlap between IBS and MDD in 
our study was more similar to those reported using patient populations, and 
thus more research into the co-occurrence of IBS and MDD in the general 
population is warranted. 
This study supports an association between MDD and IBS.  Previous 
population-based studies of the association between MDD and IBS have 
been inconsistent (28, 32, 68).  The Masand et al. study supported an 
association between MDD and IBS among those seeking some sort of 
healthcare.  However this study was mainly descriptive and did not use 
acknowledged symptom criteria for IBS (68).  Similarly, the Lydiard et al. 
study supported an association between MDD and IBS in a population-based 
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sample, yet gastrointestinal symptoms were assessed in a structured 
psychiatric interview not designed to diagnose IBS (28).  Additionally, the IBS 
definition was an “IBS-like” cluster of gastrointestinal symptoms, not 
corresponding to any particular symptom criteria for IBS (28).  In the 
population-based study by Talley et al., both IBS and MDD were evaluated 
using validated questionnaires and appropriate symptom criteria for IBS 
(Manning and Rome II).  This study did not support an association between 
MDD and IBS, however it was limited to younger individuals, aged 26 years 
old, and thus did not include those that have gone through the ages where 
the prevalence of MDD increases (namely at ages 30 and 50) (32).  
Additionally, the stratified analysis based on Rome II criteria was 
underpowered. 
The results from the co-twin control study suggest that there is a 
common causal link between MDD and IBS.  Since both MDD and IBS have 
unknown etiologies, it is possible that one of these disorders may predispose 
individuals to the other disorder.  Additionally the use of serotonin derived 
drugs to treat both MDD and IBS (69, 70) supports a common biologic 
similarity between these disorders.  Our results support the notion that either 
IBS or MDD plays an etiologic role in the occurrence of the other disorder, 
and encourage future research into the etiology of the co-occurrence of IBS 
and MDD in a general population. 
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This study has several strengths.  First, the SALT population contains 
both patients seeking care for their IBS symptoms and those who do not.  
This is important because previous studies have shown that IBS patients who 
seek care are different from those who do not, specifically in their 
psychological profiles, with those seeking care having more mental illness 
(28, 30).  Second, this study was conducted in a large population-based 
sample of twins.  Because this study was population based, the potential for 
ascertainment bias was likely reduced because participants’ awareness of 
their disease status should have remained small since it could not be 
determined which disease was the main disease of interest based on the 
wide array of diseases contained in the interview.  Third, this study applied 
two analytical strategies in an attempt to disentangle the complex genetic and 
environmental influences on the co-occurrence of MDD and IBS. 
Despite these strengths there were some limitations.  The main 
limitation of this study was its cross-sectional nature.  All disorders were 
assessed through a telephone interview at the same time.  Thus it is not 
possible in this study to address the timing of onset between any of these 
associations.  As such, it is only able to compare associations and not imply 
anything about risk.  Another limitation was its reliance on self-report.  
Specifically, self-reported data may lead to disease misclassification in many 
ways.  Disease misclassification is possible as no psychological evaluations, 
clinical exams, or medical record reviews were performed to confirm the 
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disorders we obtained using the interview.  Therefore, individual participants 
could have responded hypervigilantly to questions during the interview, or 
they could have responded lackadaisically, either option leading to 
misclassification of disease and a possible bias to our results.  Additionally, it 
is possible that we may have underestimated the number of IBS cases, as we 
identified a prevalence of IBS of 2%, which is notably lower than that found in 
other population-based studies of IBS employing Rome II symptom criteria 
(32, 55, 60-64, 71, 72).  However we feel that the amount of misclassification 
of our data is small due to the use of previously validated research 
instruments. 
In conclusion, the demonstrated association between MDD and IBS in 
the case-control study was substantiated in the co-twin analysis.  This reflects 
that the association is not due to a general susceptibility factor (genetic or 
familial-environmental influences) which is shared by MDD and IBS but more 
likely one of these disorders predisposes individuals to the other disorder.  
Future studies should examine this relationship in more depth, as we were 
unable to assess the timing of onset between MDD and IBS, thereby only 
substantiating an association in a general population.   
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Table 4.1.  Descriptive statistics of IBS case-control population, from the Screening Across the Lifespan Twin Study of 
the Swedish Twin Registry1.  
 Case-Control Population (n=29,616) 
Variable Cases, n (%)  (n=611) 
Controls, n (%)  
(n=29,005) OR (95% CI)
1
Female Sex 390 (63.8) 15,039 (51.8) 1.64 (1.39, 1.93) 
Major Depressive Disorder  275 (45.0) 6,227 (21.5) 2.98 (2.53, 3.51) 
Chronic Widespread Pain 69 (11.3) 691 (2.4) 5.17 (3.97, 6.73) 
Chronic Fatigue-like illness 72 (11.8) 597 (2.1) 6.31 (4.87, 8.18) 
Body Mass Index2 25.2 (0.14) 25.0 (0.02) 1.02 (0.99, 1.04) 
Age at interview2 53.7 (0.04) 53.7 (0.04) 0.97 (0.95, 0.98) 
Health Status    
Better/same health as 5 years earlier 361 (59.1) 22,469 (77.5) 0.42 (0.36, 0.50) 
Health does not limit activities 306 (50.1) 21,667 (74.7) 0.43 (0.36, 0.52) 
Health limited usual activities, 0-7 days in prior six 
months 467 (76.4) 25,600 (88.3) 0.34 (0.29, 0.40) 
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1 Abbreviations: IBS=irritable bowel syndrome in lifetime; OR=odds ratio; CI=confidence interval. 
2 Least square mean and standard errors (LS mean (SE)) are presented for continuous characteristics.  These were obtained from 
mixed models that accounted for the relatedness of twin pairs. 
 
  
Table 4.2.  Descriptive statistics of IBS Discordant MZ and DZ twin pairs and IBS Discordant MZ twin pairs from the 
Screening Across the Lifespan Twin Study of the Swedish Twin Registry1. 
Variable MZ and DZ IBS Discordant Twins (n=576) MZ IBS Discordant Twins (n=238) 
 Cases, n (%)  (n=288) 
Controls, n 
(%)  (n=288) OR (95% CI)
1 Cases, n (%) 
(n=119) 
Controls, n 
(%) (n=119) OR (95% CI) 
Female Sex 191 (66.3) 191 (66.3)   1.0 83 (69.8) 83 (69.8) 1.0 
Major Depressive Disorder  130 (45.1) 86 (29.9) 2.22 (1.5, 3.29) 63 (52.9)  
        
37 (31.1) 3.17 (1.66, 6.06) 
Chronic Widespread Pain 28 (9.72) 15 (5.21) 2.08 (1.05, 4.15) 14 (11.8) 8 (6.7) 2.20 (0.76, 6.33) 
Chronic Fatigue-like illness 37 (12.85) 12 (4.17) 3.50 (1.73, 7.07) 18 (15.1) 9 (7.6) 2.29 (0.94, 5.55) 
Body Mass Index2 25.06 (0.21) 24.82 (0.21) 1.03 (0.97, 1.10) 25.36 (0.33) 25.34 (0.33) 1.0 (0.90, 1.12) 
Age at interview2 52.59 (0.35) 52.57 (0.35) 2.25 (0.65, 7.77) 52.94 (0.54) 52.93 (0.54) 1.54 (0.28, 8.57) 
Health Status
Better/same health as 5 years 
earlier 161 (55.9) 211 (73.3) 0.41 (0.27, 0.60) 64 (53.8) 82 (68.9) 0.40 (0.21, 0.78) 
Health does not limit activities 221 (76.7) 243 (84.4) 0.61 (0.40, 0.93) 93 (78.2) 97 (81.5) 0.79 (0.40, 1.55) 
Health limited usual activities, 0-7 
days in prior six months 147 (51.0) 198 (68.8) 0.45 (0.31, 0.65) 58 (48.7) 75 (63.0) 0.47 (0.25, 0.87) 
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1 Abbreviations: MZ=monozygotic; DZ=dizygotic; IBS=irritable bowel syndrome in lifetime; OR=odds ratio; CI=confidence interval. 
2 Least square mean and standard errors (LS Mean (SE)) are presented for continuous characteristics.  These were obtained from 
mixed models that accounted for the relatedness of twin pairs. 
 
  
Study Population IBS Cases, n (%) 
IBS Controls, 
n (%) 
OR for MDD1 95% CI1 Adjustment Variables 
Crude 611 (2.1) 29,005 (97.9) 2.98 2.53, 3.51 None 
IBS Case Control Study 611 (2.1) 29,005 (97.9) 2.73 2.31, 3.23 Gender and age 
MZ and DZ IBS Discordant Twin 
Pairs1 288 (50) 288 (50) 2.22 1.50, 3.29 None2
MZ IBS Discordant Twin Pairs1 119 (50) 119 (50) 3.17 1.66, 6.06 None2
1 Abbreviations: IBS=irritable bowel syndrome in lifetime; MDD=major depressive disorder; OR=odds ratio; 
CI=confidence interval; MZ=monozygotic; DZ=dizygotic. 
2 These analyses were adjusted for gender and age due to the matching of twin pairs. 
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Table 4.3.  Multivariable analysis of Major Depressive Disorder and its Relation to IBS1. 
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5 DISCUSSION 
5.1 FINDINGS AND AIMS  
 The first aim of this dissertation was to examine associations for Rome 
II defined IBS in a U.S. population-based twin registry.  The analysis 
supported previous studies performed in both population and clinic-based 
samples using earlier IBS symptom criteria.  That is, previously established 
risk factors for IBS remained associated with Rome II defined IBS in this 
population-based sample.  Women satisfied the Rome II IBS symptom criteria 
at a ratio of 2:1 compared to men.  Age, BMI, mental self-rated health, and 
physical self-rated health demonstrated approximately null associations with 
Rome II IBS.  Additionally, higher than expected rates of co-occurrence were 
obtained for IBS with MDD, CWP, and CFS-like illness.  Similar to the few 
studies completed using the Rome II IBS criteria, our IBS prevalence was 
4.7% (95% CI: 4.1, 5.4), which is lower than the prevalence of IBS 
documented in studies using earlier IBS symptom criteria. 
 The second aim of this work examined the co-occurrence of MDD and 
IBS, specifically investigating the possible genetic and environmental effects 
involved in their co-occurrence.  A subset of the population-based Swedish 
Twin Registry was used for this purpose.  Descriptive results of the IBS cases 
were similar to the associations demonstrated in the first part of this 
dissertation.  Novel to this work was the demonstration that neither 
environmental nor genetic influences confounded the association between 
MDD and IBS.  This led to the conclusion that either MDD plays a causal role 
in the etiology of IBS or IBS plays a causal role in the etiology of MDD.  
 While the timing of onset between these disorders is an unresolved 
issue, there is plausibility that these disorders are manifestations of a 
common underlying pathology (i.e. somatization disorder), or that one is part 
of an as yet defined causal pathway that produces the other disorder.  
Support for these hypotheses is the influence of serotonin to both MDD and 
IBS independently.   
In IBS, a dysfunction of the brain-gut axis has been implicated, as this 
dysfunction may trigger a number of inappropriate reflexes which alter 
gastrointestinal motility, secretion and absorption, thus causing the wide 
variety of symptoms associated with IBS (1).  Additionally, certain subclasses 
of the neurotransmitter serotonin have been shown to partially mediate the 
postprandial colonic motor response (2) that is often associated with 
cramping, urgency, and diarrhea in patients with IBS (3, 4), and there is also 
evidence that a different serotonin subclass mediates the excitatory effects of 
serotonin in the human colon (5).   
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In MDD, there is substantial evidence supporting a role for the 
dysfunction of brain serotonergic systems (6).  Specifically, the serotonin type 
2 receptor has a disturbed function in depressed patients (7).  Additionally, 
the serotonin type 3 receptor that is present in the brain is identical to the 
peripheral serotonin found in the gastrointestinal tract (7), further supporting a 
link between brain and gut serotonin abnormalities that may explain the 
higher than expected overlap of these two disorders in the population.  Thus 
the hypotheses of either a common underlying pathology or an undetermined 
causal pathway between these disorders arise from the critical role that 
serotonin plays in the normal gut function and also in the brain-gut 
communication. 
Both aims of this study support an association between MDD and IBS 
in population-based studies.  Previous population-based studies of the 
association between MDD and IBS have been inconsistent (8-10).  The 
Masand et al. study supported an association between MDD and IBS among 
those seeking some sort of healthcare.  However this study was mainly 
descriptive and did not use acknowledged symptom criteria for IBS (9).  
Similarly, the Lydiard et al. study supported an association between MDD and 
IBS in a population-based sample, yet gastrointestinal symptoms were 
assessed in a structured psychiatric interview not designed to diagnose IBS 
(8).  Additionally, the IBS definition was an “IBS-like” cluster of gastrointestinal 
symptoms, not corresponding to any particular symptom criteria for IBS (8).  
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In the population-based study by Talley et al., both IBS and MDD were 
evaluated using validated questionnaires and appropriate symptom criteria for 
IBS (Manning and Rome II).  This study did not support an association 
between MDD and IBS, however it was limited to younger individuals, aged 
26 years old, and thus only a subset of subjects had traversed the period of 
risk for MDD (10).  Additionally, the stratified analysis based on Rome II 
criteria was underpowered.  Our results fill a void in the literature through the 
use of accepted symptom-based criteria for both disorders, analyzing 
population-based samples, and having adequate sample sizes to be 
appropriately powered. 
Similarly, both study populations demonstrated IBS prevalence rates 
between 2 and 5%.  These estimates are lower than estimates of IBS 
prevalence using earlier symptom criteria, however prior studies using the 
Rome II IBS symptom criteria have documented similar lower prevalence 
rates.  This discrepancy is most likely attributable to the ability of the Rome II 
criteria to identify a core group of individuals that exhibit the waxing and 
waning of symptoms associated with IBS (11, 12). 
5.2 STRENGTHS  
The largest strength of this study was the use of two population-based 
samples of twins.  Since prior studies on the co-occurrence of IBS and MDD 
had been studied mainly in clinical populations, multiple biases were possible.  
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For example, health-care seeking bias as well as Berkson’s bias has plagued 
these studies.  The use of patient populations could induce a bias as those 
that actively seek care may be different than those that do not seek care for 
their disorders.  In particular, individuals seeking treatment for IBS related 
symptoms evidence greater depressive symptoms than individuals with IBS 
who do not seek care (8, 13).  Thus, the results may be biased and reflective 
of those individuals that are actively seeking treatment for either or both 
disorders.  Additionally, hospital-based case-control studies have suffered 
from Berkson’s bias as hospitalized individuals were more likely to be 
selected into the study as either cases or controls, and therefore do not 
represent a random sample from the general population.  This study was not 
influenced by either of these biases, and included individuals with all levels of 
disease severity.  Therefore, it provides a new viewpoint on the co-
occurrence of IBS and MDD. 
Both of our studies also employed the Rome II IBS symptom criteria.  
These are the most recent symptom criteria, and are more specific than prior 
criteria (12).  Thus these studies allow for a better understanding of the Rome 
II criteria in a general population. 
The analytic methods employed in these studies were additional 
strengths.  These methods included a built-in sensitivity analysis in an attempt 
to address the timing of onset between IBS and MDD, a correlation between 
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the diagnostic algorithm for IBS used in the SALT study and the Rome II IBS 
definition in the AHP study in order to use similar IBS definitions in both 
studies, and a co-twin control study to disentangle the complex genetic and 
environmental influences on the co-occurrence of MDD and IBS.   
5.3 LIMITATIONS  
One of the main concerns of this study was its cross-sectional nature.  
In both studies, disorders were assessed at the same time, whether in the 
questionnaire or over the telephone.  Thus, it was not possible in either of 
these studies to address the timing of onset, or causality between any of the 
disorders studied.  In the first study, the AHP study, we attempted to address 
the issue of timing of onset between IBS and MDD through a sensitivity 
analysis.  This had limited applicability, since there were only 69 participants 
that satisfied the criteria for both Rome II IBS and MDD.  While this number 
was too small to fully address which disorder occurred first, the magnitude of 
the association was similar when the dependent and independent variables 
were switched.  Thus while the timing of onset is still undetermined, the 
association between MDD and IBS is robust among individuals that fulfill IBS 
and MDD symptom criteria. 
Additionally, there were limitations to the AHP survey that were beyond 
our control.  Shortly after the initial mailing of the survey, all human subjects 
research at Virginia Commonwealth University was stopped by the U.S. 
 346
Department of Health and Human Services Office for Human Research 
Protections.  The reason why research was halted at VCU was due to 
concerns of ‘secondary subjects’, which is relatives of the participant who are 
not directly participating in the study, but the participant is answering 
questions about their family history of disorders for close relatives (14, 15).  
Thus the issue became, should informed consent be obtained from the 
relatives as well as the study participant, thus causing the shut-down of all 
human studies until this ethical question was resolved.  The ethicality of this 
study was not questioned during the shut-down, but as a result of the shut-
down, our study was terminated earlier than anticipated.   
Due to these events, our study was limited to early responders since 
only the initial mailing was sent and no follow-up mailings were completed.  
Additionally, it also included only those who had a correct address on file with 
the Mid-Atlantic Twin Registry.  Another consequence of the early termination 
was that no telephone follow-up of non-responders was completed, nor was 
the planned reliability sub-study performed.  Finally, no telephone diagnostic 
interviews or clinical evaluations were conducted to confirm the disorders.   
Another limitation with the AHP data was that zygosity data were only 
available on a minority of subjects.  This limited the usefulness of this twin 
dataset, as zygosity determination is a cornerstone of a twin analysis.  In 
response to this, no twin analysis was performed on this data, but rather it 
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was used to obtain a better understanding of Rome II IBS, and to validate the 
IBS algorithm used in the SALT study.   
The sampling and response to the AHP survey was another limitation.  
The response rate was about 30%, again related to the study being halted 
and due to uncertain mailing practices of the company hired to distribute the 
survey.  The issue was that we did not know how many twins actually 
received the survey, and thus a response rate cannot be calculated due to the 
missing denominator.  The estimated response rate is around 30%, and that 
estimate is likely the minimum response rate. 
A limitation specific to the SALT study was the definition of IBS.  This 
study included no Rome criteria, but rather applied a diagnostic algorithm to 
participant responses.  Thus, it was not certain if the individuals identified with 
IBS would have been classified as having IBS based on Rome II criteria.  To 
address this issue, a concordance of the SALT study IBS questions to the 
Rome II IBS questions in the AHP survey was completed.  The results 
demonstrated that by using a subset of the SALT study IBS questions, an 
excellent agreement to Rome II IBS was made.  This allowed for more 
confidence in the IBS definition from the SALT study. 
Both studies had the limitation of being self-reported and not having 
psychiatric evaluations, clinical exams, or medical record reviews to confirm 
the disorders reported.  Thus, all of these disorders would be subject to 
 348
misclassification.  It is possible that individuals with a disorder were willing 
participants and thus very diligently responded to the questions, possibly 
leading to an overestimate.  However it is also possible that individuals with a 
disorder were less likely to participate, which would lead to an underestimate 
of the number of individuals satisfying symptom criteria for these disorders.  If 
either of these scenarios occurs, our results would likely be biased.  However 
both studies used previously validated instruments, and the prevalence of all 
disorders we examined were similar to prevalences previously reported in the 
literature.  Thus the amount of bias was probably minimal.  
5.4 PUBLIC HEALTH SIGNIFICANCE  
This study examined characteristics of co-occurring disorders with IBS 
and whether a common familial biologic or environmental mechanism 
underlies the co-occurrence of IBS and MDD.  This study corroborates 
previous research demonstrating associations between IBS and MDD, CWP, 
and CFS.  Thus more research into the etiology of these associations and 
overlapping co-occurrences should aid in our understanding of these 
disorders that affect considerable portions of the population.   
Additionally, our results demonstrated that a common familial biologic 
or environmental mechanism was not important to the co-occurrence of IBS 
and MDD.  Rather using the results, we can conclude that one of these 
disorders is causally affecting the other.  Thus future research should look 
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further into the etiology of both disorders independently, and specifically into 
the timing of onset between IBS and MDD.  Once the order of onset between 
these disorders is discovered, then future advances to the treatment of the 
co-occurrence of these disorders can be made. 
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